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Abstract 
 
 Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that can cause 
explosive outbreaks of a febrile, arthritic/arthralgic disease usually lasting weeks to 
months, and in rare cases, more than a year.  In 2004, the largest ever CHIKV outbreak 
began in Kenya, spreading to islands of the Indian Ocean, India, South East Asia and 
major outbreaks have recently occurred in the South Pacific Islands and the Caribbean.  
The host type I interferon (IFN) response is crucial for effective control of CHIKV infection.  
Herein, the dynamics, source and responses generated by the type I IFNs following 
CHIKV infection were investigated. 
 
 Interferon regulatory factors 3 (IRF3) and IRF7 are key transcription factors for the 
type I IFN response.  While CHIKV infection of wild-type mice is non-lethal, infection of 
mice deficient in both IRF3 and IRF7 (IRF3/7-/-) resulted in mortality, illustrating that these 
factors are essential for protection.  Using knockout mice for the adaptor molecules 
upstream of IRF3 and 7, IPS1 was  found to be the most important for type I IFN 
production, with TRIF and MyD88 also contributing to the response.  Mortality in IRF3/7-/- 
mice was also associated with type I IFN suppression of pathological levels of IFNγ and 
haemorrhagic shock. 
 
 Heterozygous reporter mice, in which eGFP was expressed under the control of 
either the IFNβ or the IFNα6 promoter on one chromosome, were employed to try and 
identify the cellular source of type I IFN production following CHIVK infection.  However, 
eGFP production was found to be insufficient for detection, limiting the utility of this 
approach.  Investigations of type I IFN production in tissues using RT-PCR revealed a 
strong correlation between type I IFN induction and viral tissue titres, with feet and lymph 
nodes producing the most robust type I IFN responses. 
 
 RNASeq was undertaken to examine, in detail, the nature of the type I IFN 
responses generated in the feet and inguinal lymph nodes of mice following CHIKV 
infection at days 2 and 7 post-infection.  High quality sequencing data was generated from 
 III 
host and viral poly-adenylated RNA, permitting investigation of low level gene transcription 
from both sources, and the identification of novel genes/transcripts, in addition to analysis 
of differential gene expression.  
 Investigation of host transcriptional activity revealed a type I IFN dominated immune 
response, in spite of a low induction of type I IFN mRNA transcripts at day 2 and an 
absence of type I IFN mRNA induction on day 7.  Many type I IFN-regulated genes, 
including IRF7, remained up-regulated in the feet at day 7, suggesting type I IFN-
independent mechanisms for maintenance of type I IFN-regulated gene expression.  Six 
novel IRF3 isoforms and a potentially novel protein coding gene were also identified. 
 RNA-Seq analysis of CHIKV transcriptional activity reflected the known CHIKV 
replication kinetics, in which virus replicates in the joints, and spreads to the draining 
lymph nodes, with viral titres peaking at day 2 and largely resolving at day 7.  Assessment 
of mutations within the CHIKV genome showed an accumulation with time, with error 
accumulation higher in the lymph nodes than in the feet.  These studies represent the first 
deep sequencing analysis of CHIKV genomes in tissues.  
 
 The findings in this thesis substantially add to our knowledge of the role and 
function of the immune response after CHIKV, illustrating for the first time that type I IFNs 
protect against haemorrhagic shock and that expression of type I IFN inducible genes is 
maintained well after type I IFN induction has waned. 
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1. Introduction 
1.1 Alphaviruses 
 Alphaviruses are enveloped, positive sense, single strand ribonucleic acid (RNA) 
viruses (Strauss and Strauss 1994, Zuckerman, Banatvala et al. 2009).  The alphavirus 
genus, along with genus rubivirus, comprise the Togaviridae family (Fauquet, Mayo et al. 
2005).   The 29 known viruses within the alphavirus genus are divided into eight antigenic 
complexes according to serological cross-reactivity with a species prototype – Trocara, 
Middleburg, Ndumu, Semliki Forest, Barmah Forest, Eastern, Western and Venezuelan 
Equine Encephalitis Virus complexes (Fauquet, Mayo et al. 2005).   Alphaviruses are 
arboviruses (arthropod-borne), maintained in a zoonotic transmission cycle between an 
hematophagous arthropod vector (generally mosquitoes) and a vertebrate, reservoir host 
(Fauquet, Mayo et al. 2005, Zuckerman, Banatvala et al. 2009).  Occasionally, the virus 
may infect an epizootic vector or incidental host, resulting in outbreaks of disease in both 
human and animal (particularly equine) populations (Strauss and Strauss 1994, 
Zuckerman, Banatvala et al. 2009). 
 
 Based on geographical distribution, alphaviruses are commonly referred to as ‘Old 
World’ and ‘New World’ viruses (Strauss and Strauss 1994).  New World viruses, such as 
Venezuelan and Eastern Equine Encephalitis viruses are found in the Americas and target 
the nervous system, resulting in encephalitic disease, which can be fatal.  Old World 
viruses are native to the African, Australian, European and Asian continents, and are more 
commonly associated with arthralgia/myalgia, rash and fever, and only rarely associated 
with mortality (Suhrbier and La Linn 2004, Zuckerman, Banatvala et al. 2009).  Table 1 
lists the alphaviruses associated with arthritis/arthralgia.  Mayaro virus is a new world 
virus, associated with the febrile, rheumatic disease characteristic of the old world viruses 
(Tesh, Watts et al. 1999). 
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Table 1.1  Febrile, rheumatic alphaviral disease in humans. 
Virus & Local 
Nomenclature 
Distribution Disease outbreaks Disease Symptoms 
Chikungunya virus 1 Africa, Asia, Indian Ocean 
Islands, Central America 
Large recurrent epidemics Fever, arthralgia,  myalgia, rash, 
vomiting 
Barmah Forest virus2 Australia 500 – 1900 cases per annum Fever, arthralgia, myalgia, rash 
Ross River virus2  Australia 
Oceania 
1500 – 8000 cases per annum 
1979/80 epidemic >60 000 cases 
Fever, arthralgia, myalgia, rash  
O'nyong-nyong virus3 
Igbo Ora virus3 
Africa, Asia 
Uganda/Nigeria 
Sporadic epidemics, 30-50 yr 
intervals 
400-2 million cases   
Fever, arthralgia, myalgia,  rash 
Semiliki Forest virus4 Southern Africa Rare Often asymptomatic or very mild. 
Fever, arthralgia, headaches. 
Sindbis virus1,5 
 
Karelian Fever1, 5 
Ockelbo virus1,5 
Pogosta virus1,5 
Africa, Asia, Australia, & 
Europe 
Russia 
Sweden 
Finland 
Small seasonal outbreaks, larger 
outbreaks  every 7 years 
Rare 
31 cases annual average 
136 (1-1282) cases annual 
average 
Fever (mild), arthralgia, itching rash, 
nausea 
 
Mayaro virus 6 Northern South America Small recurrent outbreaks (30-50 
cases) 
Fever (mild), headache, eye pain, 
arthralgia, myalgia, rash, vomiting 
1Suhrbier, Jaffar-Bandjee et al. (2012); 2Suhrbier and La Linn (2004); 3Powers, Brault et al. (2000), Lanciotti, Ludwig et al. (1998); 4Mathiot, Grimaud et al. (1990) 
5Hubálek (2008)  6(Tesh, Watts et al. (1999), Powers, Aguilar et al. (2006) 
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1.1.1 Virion and genome 
 Alphaviruses are approximately 60-70 nm in diameter, spherical and comprised of 
three layers (Figure 1.1) (Strauss and Strauss 1994, Smith, Cheng et al. 1995, Mancini, 
Clarke et al. 2000).  Envelope proteins E1 and E2 form 240 heterodimers that form 80 
trimeric spikes and cover the virion surface.  A third envelope protein (E3), is present in the 
virion of Semliki Forest Virus, but is not a structural component of most mature alphavirus 
virions (Mancini, Clarke et al. 2000, Jose, Snyder et al. 2009).  Each trimeric spike is 
embedded in a host-derived lipid bilayer and attached, in a one to one ratio via the E2 
subunits, to capsid protein monomers underneath.  The capsid protein monomers form an 
icosahedral, shell which directs the spherical shape of the virion and encases the viral 
genome (Jose, Snyder et al. 2009, Leung, Ng et al. 2011).  Together, the capsid protein 
shell and enclosed genome form the viral nucleocapsid (Strauss and Strauss 1994, 
Zuckerman, Banatvala et al. 2009).  The 6K protein may play a role in genome release 
and virion assembly (Liljestrom, Lusa et al. 1991, Melton, Ewart et al. 2002, McInerney, 
Smit et al. 2004). However, the location or presence of the 6K protein in the virion is yet to 
be detected by cryo-electron microscopy (Jose, Snyder et al. 2009).  
 
Figure 1.1  Sketch diagram of the cryoelectron microscopy image reconstruction of 
the CHIKV virion.  A) Trimeric protein spikes of the virion surface, which are embedded in 
the underlying host-derived lipid bilayer.  Underneath the lipid bilayer is the icosahedral 
nucleocapsid.  B) Cross-sectional view of the virion displaying the embedded 
heterodimers, and the E2 subunit associating with the icosahedral monomer of the 
nucleocapsid underneath the lipid bilayer (adapted from Smith, Cheng et al. 1995). 
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 The alphavirus genome is a positive sense, single strand RNA, approximately 11.8 
kbp in length and resembles eukaryotic mRNA with a 7-methylguanylate cap at the 5’ end 
and a 3’ polyadenylated tail () (Strauss and Strauss 1994, Fauquet, Mayo et al. 2005).  
The genome has two open reading frames (ORFs), separated by a promoter for 
subgenomic RNA.  The five structural proteins, E1-E3, capsid protein C and 6K protein are 
translated from 26S subgenomic RNA encoded by the 3’ ORF.  The non-structural proteins 
1-4 (nsp 1-4) are translated from genomic RNA encoded by the 5’ ORF and are involved in 
viral transcription and translation (Fauquet, Mayo et al. 2005, Leung, Ng et al. 2011).  
 
Figure 1.2  Schematic Diagram of the CHIKV genome.  The 7.6 kbp 5’ end encodes 
the four non-structural proteins involved in RNA synthesis and replication.  The 4.2 kbp 
3’ end encodes structural proteins that make up the CHIKV virion (adapted from 
Faragher, Meek et al. 1998). 
 
1.1.2 Non-structural proteins 
 The four nsps coalesce to form membrane-associated replication complexes (RCs) 
but function as individual enzymes with distinct roles in viral transcription and translation 
(Gould, Coutard et al. 2010, Schwartz and Albert 2010).  
 
 Nsp1 contains active guanine-7-methyltransferase and guanylyltransferase 
domains involved in RNA methylation and capping, are required for translation initiation 
(Mi and Stollar 1991, Wang, Sawicki et al. 1991, Ahola and Kääriäinen 1995).  An 
amphiphatic helix in the nsp1 structure interacts with cytoplasmic membranes, which 
triggers the enzymatic activity of nsp1 and also serves to anchor RCs to the cytoplasmic 
membranes (Ahola, Lampio et al. 1999, Spuul, Salonen et al. 2007). 
 
 The nsp2 N-terminus has nucleoside triphosphate activity thought to generate ATP 
required for nsp2 dsRNA helicase activity (Rikkonen, Peranen et al. 1994, Gomez de 
Cedrón, Ehsani et al. 1999, Gould, Coutard et al. 2010).  At the C-terminus, two domains 
function together as the nsp2 protease, which is involved in posttranslational modification 
of the nsps (Russo, White et al. 2006, Pastorino, Peyrefitte et al. 2008). 
Nsp1 Nsp2 Nsp3 Nsp4 C E3 E2 E16K
3’ 
UTR
5’
UTR
Sub-genomic 
promoter
11.8 kbp
 5 
 
 The function of nsp3 is less well understood.  While the macro domain within the N-
terminal domain of nsp3 is known to have an affinity for ADP-ribose, poly-ADP-ribose and 
RNA, the functional significance is unclear (Malet, Coutard et al. 2009, Gould, Coutard et 
al. 2010). The C-terminal domain of nsp3 contains a phosphorylation site, which appears 
to act in association with nsp2 in the synthesis of negative strand RNA in the early stages 
of viral replication (Wang, Sawicki et al. 1994, De, Fata-Hartley et al. 2003). 
 
 nsp4 functions as the viral RNA-dependant RNA polymerase that is able to switch 
from anti-sense to sense production of genomic RNA (Lemm, Rümenapf et al. 1994, 
Rubach, Wasik et al. 2009).  Additionally, nsp4 has been found to possess 
adenylyltransferase activity.  Thus, nsp4 may play a role in maintenance of the poly(A) tail 
of the genome, which is  required for initiation of viral replication (Hardy and Rice 2005, 
Tomar, Hardy et al. 2006). 
 
1.1.3 Infection and replication 
 Virus particles enter the host cell by receptor mediated endocytosis following 
interaction between host cell receptor/s and the E2 subunits of the viral envelope (Jose, 
Snyder et al. 2009, Leung, Ng et al. 2011).  The cellular receptor/s that facilitate 
endocytosis are yet to be clearly defined, although major histocompatibility complex, major 
laminin receptor (Wang, Kuhn et al. 1992), DC-SIGN and L-SIGN (Klimstra, Nangle et al. 
2003), heparin sulphate (Zhang, Heil et al. 2005) and α1β1 integrin collagen receptor (La 
Linn, Eble et al. 2005) have been listed as potential components of such a receptor.  
Within the endosome, the acidic pH destabilises the E1/E2 heterodimers, causing E1 
homotrimers to form (Leung, Ng et al. 2011).  E1 homotrimers then insert into the 
endosomal membrane allowing the endosomal and viral membranes to fuse (Justman, 
Klimjack et al. 1993, Spyr, Käsermann et al. 1995).  
 
 Fusion of the viral and endosomal membranes releases the nucleocapsid in to the 
cytoplasm where it is disassembled to expose the viral genome (Figure 1.1) (Jose, Snyder 
et al. 2009, Leung, Ng et al. 2011).  The 6K protein may facilitate membrane fusion and 
endosomal acidification by forming a cation-selective ion channel that allows an influx of 
protons into the endosome (Melton, Ewart et al. 2002).  SINV has been shown to infect 
 6 
cells without endocytosis and acidification (Paredes, Ferreira et al. 2004) and Kononchik et 
al., (2011) have proposed an alternative mechanism of alphavirus entry that involves direct 
entry at the plasma membrane.  In this model, a proteinaceous pore composed of virus 
and host proteins allows the viral nucleocapsid to be released directly into the host cell 
cytoplasm (Kononchik, Hernandez et al. 2011, Kononchik, Vancini et al. 2011).  Once in 
the cytoplasm, interaction between 60S ribosomal RNA and viral capsid proteins is thought 
to induce nucleocapsid disassembly (Wengler and Würkner 1992, Leung, Ng et al. 2011).  
Exposure to low pH following viral-endosomal membrane fusion may also assist in 
deconstruction of the nucleocapsid (Wengler and Gros 1996, Melton, Ewart et al. 2002).   
 
 Following nucleocapsid disassembly, two polypeptide precursors, p123 and p1234, 
are translated directly from the single strand genomic RNA (Jose, Snyder et al. 2009, 
Leung, Ng et al. 2011). Translation of the smaller p123 precursor predominates due to an 
opal stop codon (UAG) located after nsp3 that limits read-through translation (Jose, 
Snyder et al. 2009, Gould, Coutard et al. 2010).  p1234 is cleaved by nsp2 to generate 
p123 and nsp4 (Fauquet, Mayo et al. 2005, Leung, Ng et al. 2011), which form a negative 
strand replication complex (-RC-).  -RC synthesises a full length, negative strand RNA 
intermediate (Fauquet, Mayo et al. 2005, Schwartz and Albert 2010).  The p123 precursor 
is processed to produce individual nsp1, nsp2 and nsp3.   Nsps1-4 then assemble to form 
the positive strand RC (RC+)(Fauquet, Mayo et al. 2005, Schwartz and Albert 2010).  The 
RC+ uses the negative strand RNA intermediate as a template for the full length 49S 
genome to be packaged in mature virions, and 26S subgenomic RNA that is used for 
translation of the structural protein polypeptide precursor (Figure 1.1) (Fauquet, Mayo et 
al. 2005, Schwartz and Albert 2010). 
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Figure 1.3 Schematic diagram of alphavirus entry, replication and release from host 
cells. Adapted from (Jose, Snyder et al. 2009). 
1.1.4 Structural proteins 
 Translation of the 26S subgenomic RNA produces a polypeptide precursor 
containing the structural proteins in the sequence C-pE2-6K-E1, where C is the capsid 
protein and pE2 is an E2/E3 precursor (Strauss and Strauss 1994, Fauquet, Mayo et al. 
2005).  The C-protein is cleaved and exposes an N-terminal signal sequence on the 
remaining structural polypeptide precursor for translocation to the endoplasmic reticulum 
(ER) (Jose, Snyder et al. 2009).  In the ER, pE2 and E1 undergo a series of modifications 
that facilitate correct formation of a pE2/E1 heterodimer (Gaedigk-Nitschko and 
Schlesinger 1990, Jose, Snyder et al. 2009).  The 6K protein is believed to play a role in 
pE2/E1 formation via interaction with E2 subunit of pE2 (Gaedigk-Nitschko and 
Schlesinger 1990, Jose, Snyder et al. 2009). The E3 subunit of pE2 is cleaved by furin to 
form the E1/E2 heterodimer, which translocates to the plasma membrane via the Golgi 
apparatus secretory pathway (Jose, Snyder et al. 2009, Gould, Coutard et al. 2010). 
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 The cleaved C-proteins form C-protein dimers (Perera, Owen et al. 2001, Solignat, 
Gay et al. 2009), which interact with a packaging signal present on viral RNA causing 
encapsidation of 49S genomic RNA within the cytoplasm and formation of the viral 
nucleocapsid (Tellinghuisen, Hamburger et al. 1999, Gould, Coutard et al. 2010). The 
newly assembled nucleocapsids then translocate to the plasma membrane where they 
bind the cytoplasmic domain of E2 (Strauss, Lenches et al. 2002, Jose, Snyder et al. 
2009).  This interaction drives the nucleocapsid across the host cell membrane where it 
acquires the 80 E1/E2 heterodimer trimeric spikes that form the glycoprotein envelope and 
the host-derived lipid bi-layer as it exits the cell as a mature virion (Figure 1.3) (Jose, 
Snyder et al. 2009, Gould, Coutard et al. 2010). 
 
1.2 Chikungunya virus 
1.2.1 Natural history 
 Chikungunya virus (CHIKV) is an alphavirus known to cause large outbreaks of 
febrile, rheumatic disease and is re-emerging as a potential threat to global human health 
(Suhrbier and Mahalingam 2009, Powers 2010, Suhrbier, Jaffar-Bandjee et al. 2012).  
CHIKV was first isolated from patients and mosquitoes during an outbreak of dengue-like 
disease in Newala, Tanzania during 1952-3 (Robinson 1955, Ross 1956).  This was the 
first documented incidence of CHIKV and tribal elders in the region reported no knowledge 
of the same disease ever having occurred previously (Lumsden 1955).  The name 
‘chikungunya’ is derived from this initial outbreak; ‘chikungunya’ roughly translates to ‘that 
which bends up’ in the Makonde language and portrays the bowed posture of people 
suffering from joint pain that results from CHIKV infection (Robinson 1955, Ross 1956).   
  
 Outbreaks of CHIKV disease have occurred at intermittent intervals of 2-50 years 
and are attributed to two distinct variants that diverged from a common ancestor in the late 
19th century – the Asian genotype, first isolated during a 1958 outbreak in Bangkok, and 
the East/Central African genotype found in Africa and India (ECSA) (Ching and 
Hapuarachchi 2010, Schwartz and Albert 2010).  In Africa, CHIKV is naturally maintained 
in a zoonotic transmission cycle between non-human primate hosts and forest-dwelling 
Aedes furcifer or Aedes africanus mosquito vectors (Powers and Logue 2007, Zuckerman, 
Banatvala et al. 2009).  Virus transmission by the urban dwelling Aedes aegypti mosquito 
is thought to allow divergence from a sylvatic, or forest dwelling, transmission cycle to an 
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urban setting, resulting in sporadic outbreaks of disease (Powers 2010, Simon, Javelle et 
al. 2011). Within Asia, CHIKV is predominantly transmitted by Aedes aegypti and appears 
to exist in an urban transmission cycle only, with no known reservoir host (Simon, Javelle 
et al. 2011).  More recently, a new CHIKV variant, derived from the ECSA genotype has 
evolved to be efficiently transmitted by the Aedes albopictus mosquito (Schuffenecker, 
Iteman et al. 2006, Tsetsarkin, Vanlandingham et al. 2007). 
 
1.2.2 The A226V mutation and the global dissemination of CHIKV 
 The largest CHIKV outbreak ever recorded began late 2004 in Kenya before 
spreading to over 40 countries, including Islands of the Indian Ocean, India, Sri Lanka, 
South East Asia (Burt, Rolph et al. 2012), the South Pacific (Dupont-Rouzeyrol, Caro et al. 
2012) and the Caribbean (Van Bortel, Dorleans et al. 2014).  Much of this outbreak has 
been attributed to the new viral variant within the ECSA strain, which is found to contain an 
alanine to valine mutation (A226V) within the viral E1 glycoprotein (Schuffenecker, Iteman 
et al. 2006, Tsetsarkin, Vanlandingham et al. 2007).  The A226V mutation allowed efficient 
replication, dissemination and transmission of CHIKV by Aedes albopictus, previously only 
a minor vector for CHIKV (Tsetsarkin, Vanlandingham et al. 2007, Simon, Javelle et al. 
2011).  The Aedes albopictus mosquito is an aggressive mosquito with a widespread 
global dissemination that has been increasing over the past thirty years (Benedict, Levine 
et al. 2007).  The increased vector competence of Aedes albopictus for the A226V-CHIKV 
strain has enabled CHIKV to establish autochthonous outbreaks in regions where it has 
not been seen before, including 205 cases in Italy during 2007, two cases in southern 
France in 2010 and in March 2011, New Caledonia a total of 24 cases have been 
confirmed (Rezza, Nicoletti et al. 2007, Gould, Gallian et al. 2010).   
 
 The most notable endogenous outbreak in CHIKV-naive regions was a particularly 
aggressive outbreak in the French overseas department, Reunion Island.  During March 
2005 and April 2006, an estimated 270 000 people, or one third of the Reunion Island 
population were infected with CHIKV (Schwartz and Albert 2010).  A combination of an 
immunologically naive population and the adaptation of the A226V-CHIKV strain to the 
Aedes albopictus vector is thought to have contributed to the intensity of this outbreak, in 
which 46 000 cases of CHIKV were recorded in one week alone (Pialoux, Gaüzère et al. 
2007, Renault, Solet et al. 2007, Taubitz, Cramer et al. 2007, Gould and Higgs 2009).  In 
addition to the explosive incidence of infection, the Reunion Island epidemic was 
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associated with atypical disease manifestations and for the first time, some mortality 
(Pialoux, Gaüzère et al. 2007).  The unusual clinical features observed in Reunion Island 
were subsequently observed, during the CHIKV outbreak in India.  Indian government 
reports document 1.4 million confirmed cases of CHIKV infection, and no deaths.   
However, Mavalankar et al., (2007) estimate up to 6.5 million cases to have occurred and 
as many as 19000 deaths as a result of CHIKV disease. 
 
While the CHIKV Indian Ocean Lineage containing the A226V mutation has 
facilitated increased spread of CHIKV in some parts of the globe, not all outbreaks of 
CHIKV are attributable to this recent strain.  The recent epidemics in the Caribbean derive 
from Asian genotypes, while outbreaks in South America derive from the ECSA strain, 
prior to the A226V mutation.  Additionally, outbreaks in East Asia and the subcontinent 
derive from both the Asian isolate and the A226V mutated Indian Ocean Lineage 
(Champion, Weaver et al. 2015). 
  
1.2.3 Disease presentation 
 The classic indicators of CHIKV infection are fever, arthralgia/myalgia and rash.  
Few cases (less than 5%) are asymptomatic, and symptoms appear after a 3 -12 day 
incubation period (Jaffar-Bandjee, Ramful et al. 2010, Singh and Unni 2011).  CHIKV 
disease can be divided into an acute and chronic phase. 
1.2.3.1 Acute phase 
 The acute phase comprises fever and sudden, incapacitating polyarthritis, and may 
also include a non-itchy rash, asthenia and headache (Sam and AbuBakar 2006, Jaffar-
Bandjee, Ramful et al. 2010).  Fever is severe (39-40˚C), lasting 24 -48 hours (Jaffar-
Bandjee, Ramful et al. 2010).  Arthralgia, like fever, has an abrupt onset and manifests 
largely in the hands, wrists, feet and ankles, but may also affect larger joints such as the 
knees and shoulders, generally in a symmetrical distribution (Sam and AbuBakar 2006, 
Singh and Unni 2011).  Three to five days after disease onset, 40-50% of CHIKV patients 
develop a non-itchy, maculopapular, rash that occurs largely on the trunk and limbs and 
lasts no more than two days in most cases (Sam and AbuBakar 2006, Simon, Javelle et al. 
2011).  Manimunda et al (2010) describe the acute phase as the first month of disease.  
However, in uncomplicated cases, acute symptoms generally resolve within 10 days (Sam 
and AbuBakar 2006, Simon, Javelle et al. 2011). 
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1.2.3.2 Chronic phase 
 Chronic disease, often marked by a second bout of fever and arthralgia, is more 
prevalent in adults over 40 years of age (Das, Jaffar-Bandjee et al. 2010, Singh and 
Unni 2011).  A high viral load during the acute phase can be associated with persistent 
symptoms (Das, Jaffar-Bandjee et al. 2010).  However, Chow, Her et al. (2011) found 
elevated levels of IL-6 and GM-CSF were more likely to be associated with persistent 
arthralgia than viral load.  Chronic symptoms are fatigue and joint pain lasting several 
months (Manimunda, Vijayachari et al. 2010).  However,  arthralgia and joint effusions 
have been reported at 18 months (Jaffar-Bandjee, Ramful et al. 2010, Simon, Javelle 
et al. 2011) and long term sequale such as depression and insomnia are common (De 
Andrade, Jean et al. 2010, Gérardin, Fianu et al. 2011, Couturier, Guillemin et al. 
2012).  Manimunda (2010) reported 36% of chronic CHIKV patients met the 1987 
American College of Rheumatology criteria for rheumatoid arthritis (RA) and there is 
some evidence that CHIKV induces RA-like illness (Bouquillard and Combe 2009).  
Imaging studies provide evidence of erosive arthritic lesions consistent with RA in 
CHIKV patients (Malvy, Ezzedine et al. 2009, Manimunda, Vijayachari et al. 2010, 
Mizuno, Kato et al. 2011), and some CHIKV patients respond to disease modifying 
anti-rheumatic drugs, such a methotrexate and sulfasalazine (Pandya 2008, 
Bouquillard and Combe 2009, Ganu and Ganu 2011).  However, further studies are 
required before it can be determined whether CHIKV results in an RA-like illness, 
causes RA or simply brings to light an underlying condition. 
1.2.3.3 Atypical disease and mortality 
 The most recent CHIKV epidemic was associated with particularly aggressive 
disease in terms of the infectivity, and the nature and severity of clinical manifestations. 
Vertical transmission of CHIKV infection was observed (Ramful, Carbonnier et al. 2007, 
Jaffar-Bandjee, Ramful et al. 2010, Mangalgi, Shenoy et al. 2011) when CHIKV infection 
coincided with the perinatal period, prior to maternal antibody production  and could not be 
prevented by caesarean section (Couderc and Lecuit 2009, Jaffar-Bandjee, Ramful et al. 
2010).  Neonatal manifestations of CHIKV infection included febrile convulsions, severe 
anorexia and a characteristic perioral hyperpigmentation (Gérardin, Barau et al. 2008, 
Valamparampil, Chirakkarot et al. 2009, Mangalgi, Shenoy et al. 2011).  In older children, 
in whom CHIKV infection is generally mild,  febrile seizures, retro-orbital pain and skin 
blistering that required dressing changes under general anaesthesia (Robin, Ramful et al. 
2008, Sebastian, Lodha et al. 2009, Valamparampil, Chirakkarot et al. 2009).  Death in 
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neonates and children was rare (Couderc and Lecuit 2009, Jaffar-Bandjee, Ramful et al. 
2010). 
 
 In adults, atypical symptoms and mortality were associated with increasing age and 
underlying prior health conditions (Economopoulou, Dominguez et al. 2009, Das, Jaffar-
Bandjee et al. 2010).  A total of 254 deaths in Reunion Island and an estimated 19000 
deaths in India were reported during 2005-7 (Mavalankar, Shastri et al. 2007, Pialoux, 
Gaüzère et al. 2007).  Severe atypical manifestations included encephalitis, organ failure 
(Economopoulou, Dominguez et al. 2009) and transient blindness was also observed in 
the recent epidemic (Mahendradas, Ranganna et al. 2008).  Mouth and genital ulcers, 
stomatitis and exfoliative dermatitis were frequent atypical manifestations (Inamadar, Palit 
et al. 2008).  Atypical symptoms generally resolved completely, although some patients 
retained skin hyperpigmentation (Jaffar-Bandjee, Ramful et al. 2010). 
 
1.2.4 Diagnosis of CHIKV infection 
 Clinical diagnosis of CHIKV infection is based on the ‘classic triad’ of presenting 
signs and symptoms: fever, arthralgia and rash, and during an epidemic, a clinical 
diagnosis may be adequate (Kalantri, Joshi et al. 2006).  However, the recent increase in 
the endemicity of CHIKV, particularly to regions that harbour other pathogens that result in 
similar symptoms, such as malaria and dengue, or closely related viruses like Ross River 
virus, and in travellers returning from such regions, laboratory confirmation is required to 
exclude differential diagnoses and direct the appropriate treatment regime. 
 
 Enzyme–linked immunosorbance assay (ELISA) or immunofluorescence is used to 
detect IgM antibodies or demonstrate an increase in IgG antibodies (Kalantri, Joshi et al. 
2006).  IgM appears 4-5 days after disease onset and may not be present at detectable 
levels within the first week of disease (Taubitz, Cramer et al. 2007, Panning, Grywna et al. 
2008).  Demonstration of rising IgG titres requires collection of paired serum samples, 
taken at acute and convalescent stages of disease (Kalantri, Joshi et al. 2006).  In 
populations where other alphaviruses are prevalent and may provide cross reactive false 
positives, detection of CHIKV by PCR may be more suitable (Kalantri, Joshi et al. 2006, 
Taubitz, Cramer et al. 2007).  Recently however, an epitope-blocking ELISA, which uses a 
monoclonal antibody targeting an eptiope in the CHIKV E2 protein, has been developed 
and is not cross-reactive with the closely related Ross River virus and Barmah Forest virus 
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(Goh, Kam et al. 2015).  CHIKV can be detected in patient blood from disease onset 
(Taubitz, Cramer et al. 2007, Panning, Grywna et al. 2008) and from tissues in patients 
(Simon, Javelle et al. 2011) and non-human primates (Labadie, Larcher et al. 2010) well 
after viraemia has passed, providing a wide timeframe in which to confirm CHIKV 
infection.  Real time PCR is a highly sensitive technique for detection of viral RNA, with 
Edwards et al., (2007) reporting effective detection from as few as 20 RNA 
transcripts.  Virus culture from tissue samples can be used to provide reference standards, 
but is time consuming, and within Australia,  can only be performed in Biosafety Level 3 
laboratories and is thus not appropriate for a clinical setting (Kalantri, Joshi et al. 2006).   
1.2.5 Treatment of CHIKV disease 
 The treatment strategy for CHIKV is symptomatic; paracetamol or other non-
salicylate analgesia and non-steroidal anti-inflammatory drugs (NSAIDs) are generally 
used in the acute phase of the disease (Pialoux, Gaüzère et al. 2007, W.H.O 2009).  
Aspirin is avoided due the potential for haemorrhage, and steroidal anti-inflammatory 
drugs are avoided due to their immunosuppressive effects and the potential exacerbation 
of symptoms (W.H.O 2009, Singh and Unni 2011).  However, Padmakumar (2009) found 
that a treatment regimen of NSAIDs and low doses of prednisone (a corticosteroid) 
produced the most favourable pain relief outcomes in acute CHIKV disease patients.  
Chronic arthralgia is treated in the same manner as the acute phase of the disease.  
However, long term use of NSAIDs is not recommended (W.H.O 2009). 
 
Several drugs have been explored for use as prophylactics, or disease modification.  
The antimalarial, chloroquine provided promising results in an early clinical trial (Brighton 
1984).  However, later studies indicated chloroquine may enhance viral replication and 
acute disease (Maheshwari, Srikantan et al. 1991) and was associated with a greater 
incidence of chronic arthritic symptoms (Lamballerie, Boisson et al. 2008).  Disease 
modifying anti-rheumatic drugs (DMARDs) have been used in the treatment of CHIKV 
arthritis with varying success (Pandya, 2008, Bouquillard and Combe 2009, Ganu and 
Ganu, 2009, Javelle, Ribera et al., 2015) and with methotrexate treatment found to be 
effective in treating patients with a specific  RA-like illness (Pandya 2008, Bouquillard and 
Combe 2009, Ganu and Ganu 2011, Javelle, Ribera et al., 2015).  The antiviral drug 
Ribavirin works synergistically with IFNα to effectively inhibit CHIKV replication (Scheidel 
and Stollar 1991).  However, this therapy is expensive, requires parenteral injection and is 
therefore not suitable for large scale use (Gould, Coutard et al. 2010).  Furthermore, 
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Ribavirin treatment only provided a mild improvement in symptoms (Ravichandran and 
Manian 2008).  Bindarit, a macrophage chemoattractant protein-1 (MCP-1) inhibitor, 
ameliorates inflammatory disease in mouse models of RRV and CHIKV, and may be a 
candidate for treatment of acute disease in humans (Rulli, Guglielmotti et al. 2009, Rulli, 
Rolph et al. 2011).  Studies of neutralising monoclonal anti-CHIKV antibodies have 
demonstrated effective attenuation of viraemia and disease in knockout and neonatal 
mouse models of CHIKV (Couderc, Khandoudi et al. 2009, Fric, Bertin-Maghit et al. 2013, 
Pal, Dowd et al. 2013).  This therapy may prove useful for prevention of peri-natal 
maternal transfer (Gould, Coutard et al. 2010, (Warter, Lee et al. 2011, Fric, Bertin-Maghit 
et al. 2013). 
 
1.2.6 Vaccine development 
 No licensed vaccine currently exists for any alphaviruses.  Early, formalin-
inactivated and tween-ether treated live-attenuated vaccines, while highly immunogenic 
and easily prepared, were not developed further due to safety issues (Harrison, Binn et al. 
1967, Eckels, Harrison et al. 1970).  Later investigation of two live attenuated strains 
produced by serial, plaque to plaque passaging in MRC5 cells yielded the TSI-GSD-218 
vaccine candidate, which progressed to a Phase II clinical trail in humans.  However, this 
approach was abandoned after 5 of 59 trial participants developed a transient arthralgia 
(Edelman, Tacket et al. 2000).  Muthumani et al., (2008) developed a synthetic DNA 
vaccine incorporating antigenic regions of the CHIKV genome, which has demonstrated 
protection against CHIKV disease in mice and induced protective neutralising antibody 
titres in non-human primates (Mallilankaraman, Shedlock et al. 2011).  However, it must 
be delivered by concurrent intramuscular injection and electroporation. 
 
In 2008, Wang et al. (2008) developed three chimeric vaccines comprising the 
CHIKV structural proteins antigens and a genetic backbone from an attenuated EEEV 
strain, Sindbis virus or the attenutated VEEV strain, TC-83.  The TC-83 chimera produced 
robust antibody responses, were non-pathogenic and protective against CHIKV in type I 
IFN-deficient mice (Wang, Kim et al. 2011), and displayed low transmission potential in 
Aedes mosquitoes (Darwin, Kenney et al. 2011).  However, the propensity of alphaviruses 
to reform into replication competent viruses hindered the development these chimeric 
vaccines for use in humans.  Similarly, a recombinant adenovirus vector vaccine encoding 
the CHIKV structural proteins, has also been shown to induce protective antibody 
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responses in wild type mice (Wang, Suhrbier et al. 2011).  Replacement of the 
subgenomic promotor of a CHIKV clone with the internal ribosomal entry site (IRES) of 
encephalomyocarditis virus has produced a highly attenuated vaccine that confers 
immunogenicity in WT and IFN-deficient mice after a single dose. The IRES-attenuated 
vaccine is also unable to infect or replicate in mosquito cells and is currently being tested 
in non-human primates as a precedent for human trials (Plante, Wang et al. 2011, Roy, 
Adams et al. 2014). 
 
A virus-like particle (VLP) vaccine that elicited protective humoral immune responses 
in non-human primates developed in 2010 by Akahata, Yang et al. (2010) has recently 
been used in a Phase I clinical trial involving 25 participants.  The vaccine, VRC-
CHKVLP059-00-VP, was immunogenic and well tolerated with neutralising antibody titres 
detectable 6 months after the third and final vaccination in all dosage groups (Chang, 
Dowd et al. 2014).  A live recombinant measles virus-based vaccine has also been found 
to be well tolerated in a Phase I clinical trial involving 42 participants, with neutralising 
antibodies detectable at day 28 post vaccination and immunogenicity unaffected by anti-
measles vector immunity (Ramsauer, Schwameis et al. 2015).   
  
1.3 Immunobiology of chikungunya virus 
1.3.1 Disease models 
 Non-human primates provide insight in to the pathogenesis of CHIKV that is more 
comparable to humans, but are limited in their utility due to cost, housing and training 
requirements.  Early studies of CHIKV pathology used cercopithecus, Rhesus (macaca 
mulatta) and Bonnet (macaca radiata) monkeys and also baboons (Kam, Ong et al. 2009).  
A rhesus model was also used to investigate the efficacy of a formalin-inactivated CHIKV 
vaccine against different CHIKV strains (Harrison, Binn et al. 1967).  More recently, 
intradermal inoculation of cynomologous monkeys (macaca fascicularis), has produced a 
CHIKV disease model that closely resembles the viremic, clinical and pathogenic pattern 
of CHIKV infection in humans, including chronic disease (Labadie, Larcher et al. 2010).  
Tree shrews, a non-rodent primate like squirrel, have been used as a small animal 
alternative to non-human primates.  However, these animals are susceptible to 
psychosocial stress and depression unless they are maintained in specialised housing  
that negates the cost and space benefit of their smaller size (Cao, Yang et al. 2003, Kam, 
Ong et al. 2009).  
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 The first animal of model of CHIKV disease was used to isolate virus from Albino 
Swiss mice inoculated with sera from an infected human (Ross 1956).  Older mice were 
resistant, while neonatal mice succumbed by day 4-6 post infection (Ross 1956).  
Subsequent models have used neonatal and young mice, to demonstrated tissue tropism 
similar to that seen in human infection, with CHIKV detected in muscle, joints, skin and 
brain (Couderc, Chrétien et al. 2008, Ziegler, Lu et al. 2008).  Using type I IFN receptor α 
chain (IFNAR1) knock out mice, Couderc et al., (2008) produced an adult model of CHIKV 
disease that resembled the timing and tropism of CHIKV infection in humans.  However, in 
all of these models, CHIKV infection is these mice was either very severe, or lethal.  The 
application of a lethal knockout model, or the use of very young mice for investigation of a 
chronic arthralgia not normally present in children, has limited application.  In 2010, 
Gardner, Anraku et al. (2010) developed an adult, wild type, immunologically intact, non-
lethal mouse model of CHIKV disease.  This model mirrors the pathogenesis and arthritic 
symptoms of acute CHIKV disease (Gardner, Anraku et al., 2010) and the gene 
expression profile of acute and chronic disease seen in humans (Wilson, Poo et al. in 
prep).  However, this model requires virus injection into the foot, which does not mimic 
mosquito transmission, and is not known to induce the polyarthritis or recurrent arthritis 
typical of human CHIKV disease (Teo, Lum et al. 2012). 
1.3.2 CHIKV cell and tissue tropism 
 CHIKV has been detected in skin, joints, muscle, brain, lymphoid organs and the 
liver where it appears to infect the connective tissues and epithelium (Couderc and Lecuit 
2009).  In muscle, CHIKV infects satellite cells in the basement membrane and the fascia 
that converges to form tendons, but not myocytes themselves (Ozden, Huerre et al. 2007, 
Couderc, Chrétien et al. 2008, Labadie, Larcher et al. 2010).   In contrast to the 
neurotropic alphaviruses that infect neurons and vasculature of the brain, CHIKV infects 
the epithelial cells of the choroid plexus and the ependymal walls (Couderc, Chrétien et al. 
2008, Couderc and Lecuit 2009, Labadie, Larcher et al. 2010).  In skin, dermal fibroblasts 
and possibly keratinocytes are infected and in joints, CHIKV infects the joint capsule and 
periosteum (Couderc, Chrétien et al. 2008, Couderc and Lecuit 2009, Labadie, Larcher et 
al. 2010). In vitro analysis of human primary and immortalised cell lines, CHIKV was found 
to infect and replicate primarily fibroblasts, epithelium, endothelium (Sourisseau, Schilte et 
al. 2007).  Haematopoietic cells, except monocyte derived-macrophages, have been 
reported not to be permissive to CHIKV infection (Sourisseau, Schilte et al. 2007, Solignat, 
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Gay et al. 2009).  However, Her, Malleret et al. (2010) found that human peripheral blood 
monocytes (PBMCs) were a major target of CHIKV during the acute phase of infection, 
and in macaques, CHIKV was found predominantly in splenic macrophages, and the 
resident hepatic macrophages, Kupffer cells (Labadie, Larcher et al. 2010). 
 
1.3.3 CHIKV pathogenesis  
 CHIKV enters the body following via the bite of an infected mosquito (Sourisseau, 
Schilte et al. 2007, Her, Malleret et al. 2010, Pakran, George et al. 2011).  The virus 
undergoes local replication at the site of infection, then migrates to the draining lymph 
nodes, enters the lymph circulation and is released into the blood stream (Kam, Ong et al. 
2009, Schwartz and Albert 2010).  CHIKV disseminates through the blood to the liver, 
muscle, joints and in some cases the central nervous system, with serum titres peaking 
around day 6 post infection (Kam, Ong et al. 2009, Schwartz and Albert 2010).  Viraemia 
lasts 5-7 days, but reaches very high levels, frequently over 109 virus particles/ml (Jaffar-
Bandjee, Das et al. 2009).  The peak viraemia at day 2-4 post infection precedes a peak in 
serum type I interferon (IFN) that ranges between 0.5-2 ng/ml (Ng, Chow et al. 2009, 
Schwartz and Albert 2010).   
 
 Acute CHIKV induces a pro-inflammatory cytokine response, predominantly 
involving type I IFNs, IFNγ, IL-6, IL-12, TNF-α and MCP-1 (Jaffar-Bandjee, Das et al. 
2009, Ng, Chow et al. 2009, Chaaitanya, Muruganandam et al. 2011).  Many of these 
inflammatory responses remain present in chronic disease, with elevated MCP-1, IL-6 and 
IL-8 detected in synovial tissues at 18 months (Hoarau, Jaffar Bandjee et al. 2010), and 
MCP-1, IL-6 and IL-8 and MIP-1 at 10 months post disease onset (Chaaitanya, 
Muruganandam et al. 2011)  in synovial samples.  Kelvin et al., (2011) also found 
increased serum IL-8 expression in patients at 12 months post disease onset, and 
elevated CXCL9 and IP-10 levels in these patients was correlated with raised IgG and 
increased severity of symptoms (Kelvin, Banner et al. 2011). 
1.3.4  Persistence 
 CHIKV chronic arthritis/arthralgia is thought to be the result of persistent virus or 
viral products within joint tissues that maintain a protracted inflammatory response 
(Suhrbier and Mahalingam 2009, Suhrbier, Jaffar-Bandjee et al. 2012).  At 18 months post 
disease onset, human synovial fluid was found to contain monocytes/macrophages with 
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inclusion bodies indicating viral replication (Hoarau, Jaffar Bandjee et al. 2010).  In WT 
mice, infectious virus can be recovered up to day 14, and viral RNA can be isolated up to 
day 100 (Poo, Rudd et al. 2014).  In macaques, infectious virus could be isolated from 
tissues up to 44 days post infection, while CHIKV RNA was detected up to 55 days post 
CHIKV infection (Labadie, Larcher et al. 2010).  Macrophages have been identified as a 
major reservoir for this persistent virus, with CHIKV RNA detected in splenic macrophages 
up to 90 days post infection (Labadie, Larcher et al. 2010), and macrophage cultures have 
been found to harbour RRV over a period of 148 days, (Soden, Vasudevan et al. 2000, 
Way, Lidbury et al. 2002).  Viral mRNA in these cultures was seen to subside and re-
emerge to detectable levels, sporadically and via stress induction, resulting in cytopathic 
effect and suggesting that alphaviruses may be able to persist latently and reinfect at times 
when the host immune system is compromised (Way, Lidbury et al. 2002).  
 
1.3.5 Immune control of chikungunya virus 
 Antibody responses and type I IFNs act to clear CHIKV viraemia usually within 5-7 
days (Schwartz and Albert 2010).  Type I IFN levels peak shortly after the peak in 
viraemia, and subside before the appearance of neutralising antibodies (Jaffar-Bandjee, 
Ramful et al. 2010).  Virus specific IgM and IgG antibodies can be detected at 3-5 days 
and 5-7 days post infection, respectively (Couderc, Chrétien et al. 2008, Panning, Grywna 
et al. 2008, Schwartz and Albert 2010).  While CHIKV infection of mice lacking the type I 
IFN  receptor, is lethal (Couderc, Chrétien et al. 2008), these mice are capable of 
producing antibodies and can be protected by vaccination (Wang, Kim et al. 2011).  
Administration of anti-CHIKV immunoglobulins within the first 24 hours of infection is also 
able to protect these mice (Couderc, Khandoudi et al. 2009).  However, type I IFNs have 
been shown to enhance humoral antiviral responses, and may be required for optimal 
antibody responses (Fink, Lang et al. 2006, Thompson, Whitmore et al. 2008).  
 
 CHIKV induces a profound, predominantly monocyte/macrophage infiltrate within 
the joints in both human patients and animal models of CHIKV disease (Couderc, Chrétien 
et al. 2008, Gardner, Anraku et al. 2010, Rulli, Rolph et al. 2011).  Severe joint swelling in 
CHIKV-infected TLR3-/- (Her, Teng et al. 2014) and CCR2-/- (Poo, Nakaya et al. 2014) 
mice has been associated with increased neutrophil infiltrates.  CD8+ T-cells have not 
previously been thought to have a major role in alphaviral infection (La Linn, Mateo et al. 
1998, Smith-Norowitz, Sobel et al. 2000).  However, recently, CD8+ T-cells have been 
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found to have a role in the control of RRV in musculoskeletal tissues (Burrack, 
Montgomery et al. 2015), and CHIKV in humans has been shown to activate a strong 
CD8+ T-cell response early in CHIKV infection (Wauquier, Becquart et al. 2011).  CD4+ T-
cell responses predominate later in disease (Wauquier, Becquart et al. 2011), and have 
been shown to contribute to CHIKV immunopathology (Nakaya, Gardner et al. 2012, Teo, 
Lum et al. 2013), independent of IFNγ, and have a minor role in control of CHIKV infection 
(Poo, Rudd et al. 2014).  Neutrophils do not appear to play a major role in CHIKV disease 
(Alsharifi, Lobigs et al. 2006, Petitdemange, Becquart et al. 2011, Poo, Rudd et al. 2014), 
although severe joint swelling in CHIKV-infected TLR3-/- (Her et al. 2014) and CCR2-/- 
(Poo, Nakaya et al. 2014) mice has been associated with increased neutrophil infiltrates.  
Recently, NK cell activity during the early-acute phase of CHIKV (day 1-3 post infection) 
has been shown to mediate more severe CHIKV oedema and arthritis seen in the late 
acute phase (day 6-8 post infection; (Teo, Her et al. 2015). 
1.4 The type I IFN response and RNA viruses 
 
 Type I IFNs include IFNβ, IFN-δ, IFN-ε, IFN-κ, IFN-τ and IFN-ω and the thirteen 
IFNα subtypes (Platanias 2005, Trinchieri 2010).  IFN-δ and IFN-τ are only found in pigs 
and cattle/sheep, respectively (Perry, Gang et al. 2005, Platanias 2005).  As the name 
suggests, IFNs act to ‘interfere’ with viral replication, but are secreted in response to most 
pathogen infections, providing one of the first lines of defence in the innate immune 
response, as well as activating adaptive immunity (Perry, Gang et al. 2005, Sadler and 
Williams 2008).  The IFNα and IFNβ subtypes, are the most widely expressed and studied 
of the type I IFNs (Trinchieri 2010).  All type I IFNs signal through a common receptor 
known as the type I IFN receptor (IFNAR).  (Perry, Gang et al. 2005, Trinchieri 2010).  
IFNAR signalling promotes further production of type I IFNs, as well as IFN regulated 
genes (IRGs) (detailed in section 1.4.1). 
  
 Initiation of the type I IFN response to infection relies on the recognition of 
molecular structures, collectively termed pathogen-specific molecular patterns (PAMPs), 
that are not presented on healthy host cells (Kumagai, Takeuchi et al. 2008, Yoneyama 
and Fujita 2010).  Detection of PAMPs is achieved by pattern recognition receptors 
(PRRs), either membrane bound toll-like receptors (TLRs), or non-TLR receptors, located 
within the cytoplasm (Perry, Gang et al. 2005, Kumagai, Takeuchi et al. 2008).  Binding of 
PRRs to their respective ligands recruits adaptor molecules present within the cytoplasm, 
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and activates signalling cascades leading to transcription of type I IFNs and inflammatory 
mediators (Perry, Gang et al. 2005, Kumagai, Takeuchi et al. 2008). 
 
1.4.1 Toll-like receptors 
 TLRs are highly conserved transmembrane glycoproteins that recognise specific 
PAMPs (Kawai and Akira 2010).  TLRs have an extracellular leucine-rich repeat (LRR) 
motif involved in ligand binding, a transmembrane region and the Toll/Interleukin-1 
receptor homology (TIR) domain in the cytoplasm involved in signalling (Kawai and Akira 
2010).    
  
 The TLRs involved in detection of RNA viruses are TLR3, 7 and 8.  TLR3 is 
expressed both intra- and extra-cellularly where it detects dsRNA viruses and the dsRNA 
replication intermediates of ssRNA viruses (Kumagai, Takeuchi et al. 2008, Jensen and 
Thomsen 2012).  TLR7 and 8 sense ssRNA viruses, as well as small interfering RNA 
(siRNA) and are phylogenetically and functionally related (Bauer, Pigisch et al. 2008).  
However, TLR7 is expressed within pDCs and B cells, while TLR8 is expressed 
predominantly in conventional DCs (cDCs) and monocytes (Heil, Hemmi et al. 2004, 
Bauer, Pigisch et al. 2008).  Both reside within the ER and translocate to endosomes or 
lysosomes where they detect ssRNA (Diebold, Kaisho et al. 2004, Kato, Sato et al. 2005, 
Wang, Liu et al. 2006, Mandl, Akondy et al. 2011, Jensen and Thomsen 2012).  TLR2 and 
4 are generally implicated in sensing bacterial pathogens by recognition of lipoproteins and 
lipopolysaccharide (LPS), respectively (Yoneyama and Fujita 2010, Kawasaki, Kawai et al. 
2011).  However, they have been shown to play a role in virus recognition by sensing 
certain viral proteins (Kurt-Jones, Popova et al. 2000, Bieback, Lien et al. 2002, Finberg 
and Kurt-Jones 2004, Triantafilou and Triantafilou 2004, Zhou, Halle et al. 2008).   
 
 Alphaviruses are ssRNA viruses that produce dsRNA during replication, thus TLR3, 
7 and 8 are implicated in alphavirus detection (Schwartz and Albert 2010).  Mice deficient 
in TLR3 are more susceptible to Semliki Forest virus (Schulz, Diebold et al. 2005) and 
CHIKV (Her, Teng et al. 2014) compared to WT mice.  RRV is known to cause more 
severe disease in TLR7-/- mice (Neighbours, Long et al. 2012), and Sindbis virus has 
been shown to engage TLR7 signalling in mice and microglia with disrupted TLR7 
signalling (Esen, Blakely et al. 2012).   However, the absence of either TLR3 or 7 does not 
render the host wholly susceptible to alphavirus infection, and it is has been suggested 
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that the different TLRs may compensate for each other, and may also work in conjunction 
with PRRs in the cytoplasm (Martinon and Tschopp 2005, Esen, Blakely et al. 2012). 
1.4.2 Cytoplasmic PRRs 
 In addition to TLRs, RNA viruses can be detected by PRRs in the cytoplasm.  
Cytoplasmic PRRs include the retinoic acid inducible gene-1 (RIG-1)-like helicases (RLRs) 
and NOD-Like receptors (NLRs) (Kawasaki, Kawai et al. 2011, Jensen and Thomsen 
2012).   NLRs cover a broad array of receptors within the cytoplasm that respond to 
PAMPs, non-PAMP structures and cellular stress (Wilkins and Gale Jr 2010, Jensen and 
Thomsen 2012).  RLRs are RNA helicases and include RIG-1, Melanoma Differentiation 
Associated Protein 5 (MDA5) and Laboratory of Genetics and Physiology 2 (LGP2) 
(Yoneyama, Kikuchi et al. 2005, Wilkins and Gale Jr 2010, Jensen and Thomsen 2012).  
RLRs are found in the cytoplasm of most cells where they sense viral RNA and viral 
replication products (Yoneyama and Fujita 2010, Jensen and Thomsen 2012).  All RLRs 
posses a C-terminal regulatory domain involved in ligand binding and a central DexD/H 
box helicase domain with an ATP-binding motif.  However, only RIG-1 and MDA5 posses 
two N-terminal caspase recruitment domain (CARD)-like domains involved in signal 
transmission (Yoneyama, Kikuchi et al. 2005, Jensen and Thomsen 2012).   
 
 Both MDA5 and RIG-1 have also been implicated in the detection of alphaviruses; 
Basler and Garcia-Sastre (2007) suggest MDA5 is the primary RLR involved in alphavirus 
detection by sensing dsRNA replication intermediates, rather than the ssRNA genome.  
MDA5 has been shown to be important in the host response to salmon alphavirus in 
studies of rainbow trout (Chang, Collet et al. 2011).  Experimentally-induced over-
expression of RIG-1 was also found to prevent viral replication of VEEV in the human 
embryonic kidney (HEK293) cell line (Wu, Huang et al. 2008).  MDA5 and RIG-1 signal 
through the adaptor molecule IPS-1 (see section 1.4.3.3), which has been found to play an 
important role in initiation of the type I IFN response to CHIKV (Schilte, Couderc et al. 
2010, Schilte, Buckwalter et al. 2012, Rudd, Wilson et al. 2012), and is discussed further 
Chapter 2. 
1.4.3 Signal transduction by PRRs 
 Ligand binding causes the cytoplasmic regions of PRRs to associate with adaptor 
molecules within the cytoplasm, which subsequently direct signalling cascades that result 
in production of type I IFNs and pro-inflammatory mediators (Slack, Schooley et al. 2000, 
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Kawai and Akira 2010).  Four adaptor molecules play a major role in directing TLR 
signalling: myeloid differentiation factor-88 (MyD88), TIR-associated protein/MyD88 
adaptor like (TIRAP/MAL), TIR-domain containing adaptor inducing IFNβ (TRIF/TICAM-1) 
and TRIF-related adaptor molecule (TRAM) (Perry, Gang et al. 2005, Kumagai, Takeuchi 
et al. 2008).  IFNβ-promoter stimulator (IPS-1) and TNF receptor-associated death domain 
(TRADD) serve as adaptor molecules for MDA5/RIG-1 signalling (Kawasaki, Kawai et al. 
2011, Jensen and Thomsen 2012).  MyD88, TRIF, and IPS-1 are pivotal members of three 
major signalling pathways (Kawai and Akira 2010, Kawasaki, Kawai et al. 2011, Jensen 
and Thomsen 2012).  Details of the three major signalling pathways, and major 
components involved are introduced below. 
 
1.4.3.1 MyD88-dependant signalling pathway 
 The MyD88 signalling pathway is used by all TLRs with the exception of TLR3, 
which signals exclusively through TRIF (Yamamoto, Sato et al. 2003, Kawai and Akira 
2010).  Activated MyD88 recruits IL-1 receptor associated kinase 4 (IRAK4), IRAK1, 
IRAK2 and IRAK-M (Kawai and Akira 2010).  IRAK activation allows interaction with TNF-
receptor associated factor 6 (TRAF6) allowing it to become ubiquinated (Kawai and Akira 
2010).  Ubiquinated TRAF6 then phosphorylates transforming growth factor-β-activated 
kinase (TAK-1)  (Kawai and Akira 2010).  TAK-1 activates the mitogen activated protein 
kinase (MAPK) pathway resulting in activation of the transcription factor activator protein-1 
(AP-1)  (Kawai and Akira 2010, Kawasaki, Kawai et al. 2011).  Activated TAK-1 can also 
activate the canonical NFκB signalling pathway by recruiting NFκB essential modulator 
(NEMO) of the IκB kinase (IKK) complex (Doyle and O’Neill 2006, Yoneyama and Fujita 
2010).  This results in phosphorylation of the IκB inhibitor by the proteasome and 
subsequent release and translocation of NFκB to the nucleus (Doyle and O’Neill 2006, 
Boyd 2012).  Activation of NFκB and AP-1 through the MyD88 pathway induces the 
production of various inflammatory mediators (Kawai and Akira 2010, Boyd 2012).  In 
plasmacytoid dendritic cells (pDCs), MyD88 activation of TRAF6, through TLR 7, leads to 
recruitment of TRAF3, which activates the transcription factor IRF7 to induce production of 
IFNαs, specifically (Kawai, Sato et al. 2004, Ning, Pagano et al. 2011). 
 
1.4.3.2 TRIF-dependant signalling pathway 
 Upon TLR3 binding, TRIF is activated to employ TRADD, TRAF6 and TRAF3 
(Perry, Gang et al. 2005, Kawasaki, Kawai et al. 2011).  TRIF possess a C-terminal 
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receptor interacting protein (RIP) homotypic interacting domain, a TRAF6 binding domain 
and a toll/interleukin-1 receptor (TIR) domain that interacts with the TIR domain of TLR3/4 
(Perry, Gang et al. 2005).  Recruitment of TRADD allows interaction between RIP-1 and 
the RIP domain of TRIF, via interaction with pellino-1, an E3 ubiquitin ligase (Perry, Gang 
et al. 2005, Kawai and Akira 2010).  Activation of RIP-1, and direct recruitment of TRAF6 
by TRIF, both result in phosphorylation and activation of TAK-1 (Kawai and Akira 2010, 
Yoneyama and Fujita 2010).  As described for MyD88 signalling, TAK-1 activation leads to 
either NFκB or MAPK signalling and downstream transcription of pro-inflammatory 
mediators by NFκB and AP-1, respectively (Yoneyama and Fujita 2010, Kawasaki, Kawai 
et al. 2011).  TRAF3 recruitment by TRIF activates TBK1 and IKKε, which act as kinases 
for IRF3 and IRF7, leading to production of type I IFNs (Paz, Sun et al. 2006, Yoneyama 
and Fujita 2010). 
 
1.4.3.3 IPS-1-dependant signalling pathway 
 Both RIG-1 and MDA5 signal through the adaptor protein IPS-1, also known as 
mitochondrial antiviral signalling protein (MAVS), caspase activation and recruitment 
domain-containing adapter protein (CARDIF) and virus-induced signalling adaptor (VISA) 
(Wilkins and Gale Jr 2010, Jensen and Thomsen 2012).  IPS-1 is a mitochondrial 
membrane bound protein that recruits RIG-1 and MDA5, following ligand binding, as well 
as recruiting the adaptor molecule, TRADD (Seth, Sun et al. 2005, Wilkins and Gale Jr 
2010).  IPS-1 is therefore believed to act by facilitating the interaction between RIG-
1/MDA5 and TRADD at the mitochondrial membrane (Jensen and Thomsen 2012).  This 
interaction activates TRAF3 and consequently TBK1-IKKε, resulting in phosphorylation of 
IRF3 and IRF7 in the same manner described for the TRAF3 arm of the TRIF-signalling 
pathway (Paz, Sun et al. 2006, Kawai and Akira 2010, Yoneyama and Fujita 2010).  IPS-
1/TRADD can also recruit Fas-receptor activated death domain (FADD) in a complex with 
RIP-1 (Yoneyama and Fujita 2010, Jensen and Thomsen 2012).  This activates TRAF6 
and NFκB, in the same manner described for described for TRIF signalling, leading to 
transcription of IFNα/β (Yoneyama and Fujita 2010, Kawasaki, Kawai et al. 2011, Jensen 
and Thomsen 2012). 
 
1.4.4 Activation of the IFNβ promoter 
 Transcription factors, activated by PRR signalling, translocate to the nucleus 
(Kawasaki, Kawai et al. 2011).  Here, they form transcription complexes with co-activators, 
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which then bind the virus response elements of the IFNα and IFNβ promoters to initiate 
IFNα/β production (Balachandran and Beg 2011, Ning, Pagano et al. 2011).  IRF3, IRF7, 
NFκB, AP-1 and p300/CREB-binding protein form a complex – the “enhancesome” – and 
cooperatively bind the enhancer region upstream of the IFNβ promoter to promote the 
transcription of IFNβ (Balachandran and Beg 2011, Ning, Pagano et al. 2011).  IRF3 and 7 
can also form a ternary complex, virus activated factor (VAF), which has a weak affinity for 
the IFNβ and IFNα4 promoters (Ning, Pagano et al. 2011). 
 
1.4.5  Type I IFN signalling and amplification. 
 Following activation of the IFNβ promoter, the resulting secreted IFNβ binds the 
IFNAR in an autocrine and/or paracrine manner (Platanias 2005, Yoneyama and Fujita 
2010).  The IFNAR is made up of two subunits, IFNAR1 and IFNAR2, the cytoplasmic 
domains of which are associated with Janus activated kinase1 (JAK1) and tyrosine kinase 
2 (TYK2), respectively (Platanias 2005).  Binding of the IFNAR1 induces auto-
phosphorylation of JAKs in the cytoplasmic domains and subsequent phosphorylation of 
signal transducer and activator of transcription 1 (STAT1) and STAT2.  STAT1/2 then 
forms a complex with IRF9, called IFN-stimulated gene factor 3 (ISGF3).  ISGF3 
translocates to the nucleus where it binds IFN-sensitive response elements (ISRE) in DNA 
to induce IFN regulated genes (IRG) transcription (Figure 1.2) (Platanias 2005, Yoneyama 
and Fujita 2010).  
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 Figure 1.4 Schematic diagram of the type I IFN signalling pathway and positive feedback loop. 
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 In addition to antiviral effectors (described in 1.4.6), IFNβ induced transcription 
TLRs, RIG-1 and MDA5 as well as IRF7 and the IFNαs.  This serves to generate a positive 
feedback loop that greatly amplifies the type I IFN response to pathogen infection (Brierley 
and Fish 2002, Trinchieri 2010).  The increased expression of PRRs enhances host cell 
capacity to detect viral infection, while secreted IFNαs signal back through the IFNAR1 to 
further promote ISG production (Sadler and Williams 2008, Yoneyama and Fujita 2010).  
Vital to the amplification of the type I IFN response is the up-regulation of IRF7 expression 
(Honda, Yanai et al. 2005, Ning, Pagano et al. 2011).  In unstimulated cells, IRF7 is 
expressed only at low levels (with the exception of pDCs), and only in lymphoid cells 
(Ning, Pagano et al. 2011).  During viral infection, increased IRF7 levels activate the IFNα 
promoter to vastly increase the production of IFNαs and subsequently, production of IRGs 
(Figure 1.2) (Honda, Yanai et al. 2005, Ning, Pagano et al. 2011).  
 
1.4.6 Interferon regulated genes 
 The more well characterised IRGs include myxovirus resistance proteins (Mx), 
which form oligomers around viral nucleocapsids and other viral components, before 
degrading them (Gao, von der Malsburg et al. 2011, Haller and Kochs 2011); the 2’5’ 
oligoadenylate synthetases (2’5’OAS), which activate RNAseL to degrade mRNA within 
the cell making it detectable by RIG-1 and MDA (Malathi, Dong et al. 2007, Silverman 
2007); interferon stimulated gene of 15kDa (ISG15), which is an ubiquitin homologue that 
exerts pleiotropic effects, including prevention of viral replication and viral degradation of 
IRF3, when conjugated to viral/host proteins (Minakawa, Sone et al. 2008) and double 
stranded RNA-activated protein kinase R (PKR), which induces host translational 
shutdown and thereby, cessation of viral protein synthesis (Garcia, Gil et al. 2006, Sadler 
and Williams 2008). PKR is also involved in stabilising type I IFN mRNA (Barry, Breakwell 
et al. 2009, Schulz, Pichlmair et al. 2010).   
 
 Many IRGs work cooperatively to target specific stages of viral replication and 
specific viruses/viral families (Zhang, Burke et al. 2007, Schoggins and Rice 2011, Karki, 
Li et al. 2012).  The interferon-induced transmembrane proteins 1/2/3 (IFITM1/2/3) restrict 
viral entry by sequestering 5’-triphosphate RNA produced by enveloped ssRNA viruses, 
(Liu, Sanchez et al. 2011, Pichlmair, Lassnig et al. 2011). Zinc antiviral protein (ZAP), 
which disrupts viral RNA translation, has been shown to work synergistically with ISG20, 
an ssRNA-specific RNAse that disrupts RNA synthesis, to inhibit yellow fever virus more 
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effectively than if expressed alone (Zhang, Burke et al. 2007, Karki, Li et al. 2012).  
Schoggins and Rice (2011) suggest that expression of multiple, functionally redundant, 
moderately effective IRGs may serve to prevent host cytotoxicity. 
 
1.5 Alphaviruses and the type I IFN response 
1.5.1 Sensitivity to the antiviral effects of IFNα/β 
 Alphavirus infection efficiently induces type I IFN responses, with high 
concentrations detected in both animal models of disease (Gardner, Anraku et al. 2010, 
Rudd, Wilson et al. 2012) and CHIKV patients (Jaffar-Bandjee, Ramful et al. 2010, 
Schwartz and Albert 2010).   In vitro, pre-treatment in an epithelial cell line with doses as 
low as 10 IU/ml of IFNα is known to effectively inhibit CHIKV infection (Sourisseau, Schilte 
et al. 2007).  Pre-treatment of Swiss 3T3 fibroblasts with only 5 IU/ml murine IFNα reduced 
EEEV-induced cyptopathic effect by 50% with higher doses (20 - 50 IU/ ml) required in  
SINV and VEEV infection (Ryman and Klimstra 2008).  In vivo, alphavirus infection is 
known to be controlled by type I IFNs.  Mice lacking IFNAR1 rapidly succumb to infection 
with these alphaviruses, indicating that type I IFNs are a predominant contributor to 
protection against alphavirus infection.  Similarly, IFNAR1-/- mice infected with VEEV die 
within 2-3 days post-infection, compared to 7-9 days in WT mice (Schoneboom, Lee et al. 
2000).  A live-attenuated CHIKV-strain that had displayed promising results in  vaccine 
trials and was avirulent in adult, WT mice was found to be pathogenic in type I IFN 
deficient mice, again demonstrating the importance of type I IFN responses in alphavirus 
pathogenesis (Partidos, Weger et al. 2011).  
 
1.5.2 IRGs in alphavirus infection. 
 IRGs known to be involved in alphaviral infection include PKR, which effectively 
limits viral replication and enhances type I IFN responses to SFV and SINV infection 
(Ryman, Meier et al. 2005, Ventoso, Sanz et al. 2006, Barry, Breakwell et al. 2009), the 
2’5’OAS isoform, OAS3, found to exert antiviral effects against CHIKV in an RNAseL-
independent manner (Bréhin, Casadémont et al. 2009), ISG15, found to be critical for 
survival against CHIKV in neonatal mice (Werneke, Schilte et al. 2011) …and viperin, 
shown to inhibit SINV replication (Wang, Hinson et al. 2007, Zhang, Burke et al. 2007, 
Chan, Chang et al. 2008) and limit CHIKV replication and pathology (Teng, Foo et al. 
2012).  ZAP has been also found to inhibit replication of several alphaviruses including 
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RRV, SFV, SINV and VEEV (Bick, Carroll et al. 2003, Zhang, Burke et al. 2007, Karki, Li et 
al. 2012) and over expression studies have identified C6orf150, heparanase, SLC15A3 
and SLC25A28 that exert anti-alphaviral effects.   However the mechanism of action of 
these, and many other IRGs is not well understood.  
1.5.3 Evasion of the type I IFN response 
 Type I IFN induction by different alphaviruses in vivo has been shown to correlate 
with the level of viral replication, in vitro (Ryman and Klimstra 2008).  While alphaviruses 
are shown to be highly sensitive to the antiviral effects of type I IFNs, they have also 
evolved to evade or impede the type I IFN response.  CHIKV nsp2 has been shown to 
block type I IFN signalling by blocking STAT1 phosphorylation and translocation of 
STAT1/STAT2 to the nucleus (Fros, Liu et al. 2010).  Alphavirus have also recently been 
found to contain secondary structures in the 5’UTR that allow alphaviruses to evade 
inhibition by the IFN-inducible proteins with tetratricopeptide (IFIT) family of IRGs (Hyde, 
Gardner et al. 2014).  Alphaviruses also induce widespread host translational and 
transcriptional shut down in favour viral protein synthesis (Aguilar, Weaver et al. 2007, 
Frolov, Akhrymuk et al. 2012).  The capsid protein of  the encephalitic VEEV and EEEV 
has been found to form a complex that inhibits host gene transcription by blocking the 
trafficking of cellular proteins through the nuclear membrane (Garmashova, Atasheva et al. 
2007, Atasheva, Fish et al. 2010).  SFV and SINV have been found to inhibit host 
transcription via nsp2, which translocates to the nucleus and acts to degrade RNA 
polymerase II (Akhrymuk, Kulemzin et al. 2012).  Production of dsRNA during alphavirus 
replication also activates PKR, and subsequently, eukaryotic initiation factor 2 α (eIF2α) 
leading to widespread host translational shutdown.  
 
1.6  Project aims 
 The overall aim of this thesis was to examine the role of the type I IFN response to 
CHIKV infection in a mouse model of CHIKV infection and disease.  Specifically, the thesis 
sought to understand the signalling pathways engaged in the induction of type I IFN 
responses, the primary sources of the type I IFNs during CHIKV infection, and the global 
gene expression profile induced following CHIKV infection, as well as gaining insights into 
the CHIKV genome within the tissues.  The findings from these studies will further our 
understanding of the immunopathological inflammatory processes induced by CHIKV, 
which may further the development of therapeutic interventions.  
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2. The role of interferon regulatory factors 3 and 7 during CHIKV 
infection 
 
2.1 Introduction 
CHIKV infection is primarily controlled by type I IFNs and antibodies (Gérardin, Barau 
et al. 2008, Suhrbier, Jaffar-Bandjee et al. 2012).  The host sensor pathways implicated in 
detection of CHIKV include: (i) the cytoplasmic receptors, retinoic acid-inducible gene I 
(RIG-I) and melanoma differentiation-associated gene 5 (MDA5), which signal through the 
adaptor molecule interferon β promoter stimulator 1 (IPS-1), and (ii) the membrane bound 
toll like receptors (TLR); TLR3 via TIR domain-containing adaptor inducing interferon-β 
(TRIF) and TLR7 via myeloid differentiation primary response gene 88 (MyD88) (Schilte, 
Couderc et al. 2010, Schwartz and Albert 2010, White, Sali et al. 2011).  Signalling 
through these pathways results in activation of IRF3 and IRF7, the key transcription factors 
involved in type I IFN induction (Blasius and Beutler 2010, Kawai and Akira 2011, Levy, 
Marié et al. 2011). The relative importance of these transcription factors in CHIKV 
pathogenesis and protection is unknown. 
 
IRF3 is expressed constitutively, in an inactive state, in most cells, and its activation 
results in transcription of IFNβ and IFNα4 (Yoneyama and Fujita 2010, Vitour, Doceul et al. 
2014).  IRF7 is the primary transcription factor for the IFNαs (Honda, Yanai et al. 2005), 
and is only expressed constitutively in plasmacytoid dendritic cells (pDCs), also known as 
professional IFN producing cells (Ning, Pagano et al. 2011).  Following the initial induction 
of IRF7 expression, subsequent rounds of pattern recognition receptor (PRRs) signalling 
further activate IRF3 and IRF7, resulting in transcription of the full spectrum of IFNαs and 
an effective type I IFN response (Yoneyama and Fujita 2010, Levy, Marié et al. 2011, 
Vitour, Doceul et al. 2014).   
 
Studies of IRF3 and IRF7, including the use of IRF3 and/or IRF7 deficient mice, have 
revealed the importance of these transcription factors during viral infection.  West Nile 
Virus NS1 protein, for example, interacts with IRF3 to prevent its translocation to the 
nucleus (Wilson, de Sessions et al. 2008).  Severe fever with thrombocytopenia syndrome 
virus forms inclusion bodies that sequester IRF3 in the cytoplasm, again preventing IRF3 
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translocation and induction of IFNβ (Qu, Qi et al. 2012, Wu, Qi et al. 2013).  IRF7 was 
initially discovered in studies of Epstein Barr virus infection, in which IRF7 bound a 
promoter region in the viral genome, thus facilitating viral latency (Ning, Pagano et al. 
2011).  The 3C viral protease of picornavirus enterovirus 71 effectively inhibits activity of 
both transcription factors, initially via cleavage of IRF7, rendering IRF7 functionally 
redundant.  The cleaved N-terminus of IRF7 then binds IRF3, which inhibits nuclear 
translocation of IRF3 and subsequent induction of type I IFNs, and thereby facilitating viral 
replication (Lei, Xiao et al. 2013). 
 
Given the roles of IRF3 and IRF7 in the generation of antiviral responses and the 
scope for their inactivation by viruses, these transcription factors were investigated in the 
context of CHIKV infection.  Mice deficient in IRF3, IRF7 and both IRF3 and IRF7, were 
infected with CHIKV using the mouse model of CHIKV infection and arthritis (Gardner, 
Anraku et al. 2010).  The relative importance of the adaptor molecules upstream of IRF3 
and IRF7 was also investigated using this infection model, in MyD88-/-, TRIF-/- and IPS-1-/- 
mice. 
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2.2 Materials and Methods 
2.2.1 Physical Containment Level 3 Procedures 
CHIKV is listed as a PC3 organism under Australian Standard 2243.3-2010. 
Chikungunya virus causes severe fever and arthritis, the National Institute for Allergy and 
Infectious Diseases lists CHIKV as a Category C priority pathogen due to the potential for 
“mass dissemination…high mortality, high morbidity and major health impact” and the virus 
is listed by the Australia Group (2014)  as a biological agent for export control.  
Accordingly, all work with this virus was carried out in a PC3 facility, certified by the Office 
of the Gene Technology Regulator. 
 
PC3 facilities are contained within a PC2 facility, ventilated independently, with an 
exhaust to the outside of the building via an absolute HEPA filter system and maintained at 
a negative pressure.  Personal protective equipment was worn (double gloves, gown, face 
mask and safety glasses) before entering the facility via an antechamber.  Access to PC3 
facilities was restricted to registered users who had undertaken appropriate training. 
 
2.2.2 Cells 
All cell lines were maintained in a 5% CO2 humidified atmosphere.  Vero cells 
(African green monkey kidney epithelial cells, ATCC CRL-1586) and L929 cells (murine 
connective tissue, ATCC CCL-1) were maintained at 37˚C.  C6/36 cells (Aedes albopictus 
mosquito clone, ATCC CRL-1660) were maintained at 28˚C.  Low endotoxin trypsin-EDTA 
(Gibco-Invitrogen, Carlsbad, USA) was used to passage cells at 1 in 10 dilution, twice a 
week, to maintain logarithmic growth.  Cells were cultured in Roswell Park Memorial 
Institute 1640 (RPMI1640) media containing L-glutamine (Gibco-Invitrogen) and 
supplemented with 25 mM HEPES (Sigma-Aldrich,) Pen-Strep antibiotic (penicillin, 
50U/ml; streptomycin sulphate 50 µg/ml) (Gibco-Invitrogen) and 5% (v/v) foetal calf serum 
(FCS) (Gibco-Invitrogen).  L929 cells were also supplemented with 1% 2-mercaptoethanol 
(2ME) (Gibco-Invitrogen). 
 
Primary murine embryonic fibroblasts (MEFs) derived from IRF3-/-, IRF7-/- and 
IRF3/7-/- transgenic C57BL/6J mice (section 2.2.3), were provided by Prof A Khryomkh 
(University of Queensland) and cultured in  Dubelco Minimum Essential Medium (DMEM) 
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containing L-glutamine (Gibco-Invitrogen) and supplemented with 25 mM HEPES (Sigma-
Aldrich), 1% 2-ME (Gibco-Invitrogen), Pen-Strep antibiotic (Gibco-Invitrogen) and 10% 
(v/v) FCS (Gibco-Invitrogen).  Low endotoxin trypsin-EDTA (Gibco-Invitrogen) was used to 
passage cells at 1 in 5 dilution, twice a week to maintain logarithmic growth. MEFs were 
maintained at 37˚C in a 5% CO2 humidified atmosphere. 
 
2.2.3 Mice 
IRF3-/- and IRF7-/- transgenic mice were generated by Dr. T. Taniguchi of Osaka 
University (Honda, Yanai et al. 2005).  IRF3-/-, IRF7-/- and IRF3/7-/- mice (Sato, Suemori et 
al. 2000, Daffis, Suthar et al. 2009) were provided by Dr MS Diamond (Washington 
University School of Medicine, St Louis). TRIF-/- and MyD88-/- transgenic mice were 
generated by Dr. M. Yamamoto of Osaka University (Yamamoto, Sato et al. 2003).  IPS1-/- 
mice (Kumar, Kawai et al. 2006) were generated by Dr. YM Loo and provided by Dr M 
Gale (Washington University School of Medicine, St Loius).  IFNAR-/- mice (Swann, 
Hayakawa et al. 2007) were supplied by Dr P Hertzog (Monash University, Victoria, 
Australia). C57BL/6J mice (Animal Resource Centre, Canning Vale, Western Australia) 
were used as aged matched controls.  Mice were housed in individual ventilated cages 
and allowed to feed ad libitum.  Experiments were conducted using female, mice aged 10-
18 weeks.  All animal experiments were approved by the QIMR Animal Ethics Committee 
and were conducted in accordance with the Australian code for the care and use of 
animals for scientific purposes. 
 
2.2.4 Blood and tissue preparation 
Whole blood was collected by tail bleed or heart puncture, and serum was 
separated by centrifugation (7500 rpm, 2.5 min) using 0.8 ml MiniCollect serum tubes 
(Greiner Bio-One GmbH, Kremsmünster, Germany).  Sera for viraemia measurement or 
neutralisation assays were added to the first row of a 96-well flat bottom plate in 10 µl 
replicates, and the plates stored at -20˚C.  Sera for bioassay or cytokine quantitation were 
added to the first row of a 96-V-well plate and the plate stored at -80˚C. 
 
 Tissues excised for virus titration were weighed, placed in 1 ml tube containing 
RPMI1640 media supplemented with 10% FCS, snap frozen using dry ice and ethanol, 
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and stored at -80 ˚C.  Excised tissues for PCR were placed in 1 ml of RNAlater (Invitrogen) 
overnight at 4˚C, then stored at -80˚C. 
 
2.2.5 Virus and viral preparations 
The CHIKV isolate used (LR2006-OPY1) is a primary isolate from the 2005 
Reunion Island outbreak (Parola et al., 2006).  Viral stocks were prepared as per 
(Gardner, Anraku et al. 2010).  Briefly, virus at multiplicity of infection (moi) 0.04-0.06 was 
passaged once in C6/36 cells.  Supernatants were collected at 48 hr post infection, 
centrifuged (2000 rpm, 5 min) to remove cell debris then aliquoted and stored at -80˚C.  
Cell culture infectious dose 50% (CCID50/ml) for each batch was determined as described 
for viraemia measurement, (section 2.2.8).  Inactivated purified CHIKV antigen was a kind 
gift from Inverness Medical Innovations Australia Pty. Ltd., (Brisbane, Australia) and was 
used as an ELISA antigen and as a vaccine antigen.  CHIKV was inactivated using binary 
ethylenimine and purified by polyethylene glycol precipitation as described in Gardner, 
Anraku et al. (2010). 
 
2.2.6 Mouse vaccination, infection and monitoring 
Vaccinated mice received 10 µg inactivated CHIKV antigen, (see above) in 40 µl 
RPMI1640 media supplemented with 2% FCS via subcutaneous injection at the base of 
the tail, 6 weeks prior to CHIKV infection. 
 
Mouse infection involved injection of 104 CCID50 CHIKV in 40 µl RPMI1640 
supplemented with 2% FCS via subcutaneous injection into the dorso-lateral metatarsal 
region of each hind limb, injecting toward the ankle as described (Gardner, Anraku et al. 
2010).  Mock infected mice received 40 µl RPMI1640 supplemented with 2% FCS via the 
same route.  Following infection, mice were monitored daily for signs of clinical disease.  
Euthanasia was performed by CO2 asphyxiation in accordance with animal ethics 
guidelines. 
 
2.2.7 Prophylactic IFN treatment and adoptive transfer 
IFNαA (Chemicon International, #GF023) and/or IFNγ (Chemicon International, 
#IF005) were administered via intravenous injection into the tail vein.  CD45+/CD11b+ cells 
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for adoptive transfer were derived from the spleen of an uninfected C57BL/6J mouse by 
fluorescence activated cell sorting (FACS) as described in Gardener et al., (2010).  Briefly, 
the excised spleen was passed through a fine metal mesh and resuspended in phenol red-
free RMPI 1640 supplemented with 2% FCS (Gibco-Invitrogen).  Red blood cells were 
lysed using ammonium choloride potassium (ACK) lysis buffer (Sigma) and remaining 
splenocytes were washed, then stained with anti-CD45-phycoerythrin (PE) (BioLegend, 
CA, USA) and anti-CD11b (BioLegend) labelled with fluorescein isothiocyanate (FITC).  
Cells were sorted using a FACSCalibur™ (Becton Dickinson, NSW, Australia) and 
counted.  CD45+/CD11b+ cells (2.7 x 105 cells) in 100 µl RPMI supplemented with 2% FCS 
were adoptively transferred by intravenous injection into the tail vein 24 hours prior to 
CHIKV infection. 
 
2.2.8 Viraemia measurement 
Serum samples were serially diluted, 10-fold, in duplicate, using RPMI1640 
supplemented with 2% FCS in 96-well, flat-bottom plates.  C6/36 cells (104 cells/well) in 
100 µl RPMI1640 media, supplemented with 5% FCS, were then added to each well and 
the plates cultured for three days.  A 25 µl sample of supernatant from each well was then 
transferred into a new parallel 96-well plate containing Vero cells (104 cells/well) in 100 µl 
RPMI1640 media supplemented with 5% FCS.  The plates were incubated at 37˚ C in a 5 
% CO2 atmosphere for four days.  On day four, the highest dilution at which cytopathic 
effect (CPE) occurred was recorded and used to calculate viral titres.  CPE, observed by 
light microscopy (Olympus CK2, Japan) was characterised by widespread cell death, 
rather than plaque formation.  Dead/dying cells remained adherent, but diminished in size 
and were clearly distinct from cell debris or detached viable cells.  Viraemia was 
expressed as log10 CCID50/ml of serum using the Spearman-Karber method (Hamilton, 
Russo et al. 1977). 
 
2.2.9 Viral titres in tissues 
Viral titres were determined by 5-fold serial dilutions of supernatants from disrupted 
tissue samples.  Frozen tissue samples were thawed and soft tissues passed through a 
fine metal mesh using the plunger of a 5 ml syringe.  Hard tissues were pulverised using 
individual mortar and pestles for each sample.  Tissue homogenates were then centrifuged 
(16 000 rpm, 1 min) and 125 µl of the supernatant were diluted in triplicate, by 5-fold serial 
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dilution, in a 96-well flat bottom plate and assayed as for viraemia (section 2.2.8).  Viral 
titres were expressed as log10 CCID50 per gram of tissue. 
 
2.2.10 Foot measurements 
Area measurements of height multiplied by width of the metatarsal region were 
taken using digital Vernier callipers (Kincrome Pty. Ltd., Victoria, Australia).  An initial, day 
0 measurement was made prior to infection, followed by subsequent measurements at the 
indicated times post infection.  Hind limb swelling was expressed as a mean percentage 
increase of the metatarsal area of each foot compared with pre-infection measurements. 
 
2.2.11 Interferon bioassay 
Sera were thawed, placed on ice and UV inactivated (1.5 hours) using biological 
safety cabinet UV lamps, to inactivate live virus.  Serum samples were then serially diluted 
(3-fold dilutions) in duplicate in RPMI supplemented with 2ME, Pen-Strep and HEPES 
buffer in 96-V-well plates.  A 50 µl sample of diluted serum or IFNαA standard dilutions 
from each well were then transferred into the equivalent well of a 96-well flat bottom plate 
containing L929 cells (104 cells/well) in 50 µl RPMI1640 supplemented with 10% FCS.  
L929 cells were cultured with the serum for 24 hours prior to the addition 400 CCID50/ml of 
Semliki Forest virus in 100 µl RPMI supplemented with 10% FCS).  Cells and virus were 
cultured for 4 days, or until complete CPE was observed in the positive control wells (i.e. 
no interferon treatment, virus only).  Supernatants were aspirated, and cells were stained 
with 0.01% crystal violet/10% formaldehyde.  Cells were then washed twice with PBS (200 
µl/well) before the addition of methanol (100 µl/well) to solubilise the crystal violet stain.  
The optical density of the solubilised stain was read at 595 nm on a Synergy 4 plate reader 
(BioTek, VT, USA).  A standard curve was generated from serial dilutions of recombinant 
IFNαA (Chemicon International, #GF023) and used to calculate the serum IFNα 
concentration of each sample. 
 
2.2.12 Cytokine concentration by cytometric bead array 
Serum concentrations of cytokines and chemokines was determined using a BD 
Biosciences Cytometric Bead Array (CBA) kit according to the manufacturer’s instructions 
(BD Biosciences, San Jose, USA).  Briefly, 10 µl serum samples in duplicate, or cytokine 
standards were incubated with 1.5 µl of capture antibody bead reagent and 1.5 µl detector 
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antibody PE conjugate reagent for 2 hours in the dark, at room temperature.  Samples 
were washed once with 100 µl wash buffer to remove unbound detector PE conjugate 
reagent (1000 rpm, 3 min), and a second time with formalin to inactivate CHIKV.  Samples 
were then resuspended in 120 µl wash buffer per well.  Sample data were acquired by flow 
cytometry using a BD FACS Array™ Bioanalyser (BD Biosciences) and analysed using 
FCAP Array™ v2 Software (BD Biosciences). 
 
2.2.13 Anti-CHIKV antibody ELISA 
Each well of a 96-flat well microtitre ELISA plate (MaxiSorb, Nunc, Rochester, USA) 
was coated overnight at 4˚C with 2 µg/ml inactivated CHIKV antigen (Inverness Medical 
Innovations) in carbonate-bicarbonate buffer (pH 9.5).  Plates were blocked with 5% skim 
milk powder in PBS for 1 hour at room temperature.  The blocking buffer was removed and 
the antigen-coated wells were incubated with 3-fold serial dilutions of mouse sera for 90 
min at room temperature.  Plates were washed (3 x 2 min) with 0.01% Tween 20 in PBS 
(PBS/T) and biotin-labelled rat anti-mouse IgG1 (BD Biosciences, USA, #553441) diluted 
1/3000 (~0.15 µg/ml) in PBST or rat anti-mouse IgG2c detection antibody (BD 
Biosciences, #553388) diluted 1/1500 (~0.30 µg/ml) in PBST, were added to each well and 
incubated for 90 min at room temperature.  Plates were washed as above and incubated 
for 1 hour with streptavidin-horseradish peroxidase (HRP) (BD Biosciences, #554066) 
diluted 1/1000 in PBST.  Plates were washed as above then developed with 100 µl 2,2’-
azino-bis (3 ethylbenzthaizoline-6-sulphonic acid) (ABTS) (Sigma-Aldrich) in H2O2 for 30 
min.  When fully developed, the OD was read at 405 nm on a Synergy 4 plate reader 
(BioTek, VT, USA). 
 
2.2.14 Neutralisation assay 
Serum samples were heat inactivated (60˚C, 30 min) to inactivate the virus and host 
complement proteins.  Inactivated sera were diluted 1 in 10 in RPMI1640 before being 
serially diluted in RPMI1640, 3-fold down a 96-well flat-bottom plate.  CHIKV (400 
CCID50/ml) in 50 µl of RPMI1640 supplemented with 2% FCS was added to each well.  
Sera and CHIKV were incubated at 37˚ C in a 5% CO 2 atmosphere for 1 hour before the 
addition of Vero cells (104 cells/well) in a 100 µl volume of RPMI1640 media supplemented 
with 5% FCS.  Cells were cultured for three days and monitored for CPE.  No CPE was 
considered indicative of complete antibody neutralisation of the virus.  The lowest dilution 
providing complete neutralisation was used to calculate neutralising antibody titres. 
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2.2.15 Analysis of clinical parameters 
2.2.15.1 Haematocrit determination.  
 Tail vein blood was collected, in duplicate, using heparinised haematocrit tubes 
(Beckton Dickinson, North Ryde, Australia).  Wax-sealed tubes were centrifuged (10, 000 
rpm, 10 min) and the total blood volume and haematocrit measured using digital Vernier 
callipers (Kincrome Pty. Ltd., Victoria, Australia).   Haematocrit was expressed as the 
percentage of red blood cells in the total blood volume (serum plus haematocrit).  The 
average percentage increase in haematocrit of infected mice compared to mock-infected 
control mice was presented. 
2.2.15.2 Platelet counts 
Platelets numbers per microliter of whole blood were determined in blood collected 
by tail bleed.  Approximately 10 µl blood was collected in 1.5 ml tubes, and a 5 µl sample 
was immediately diluted 1:20 in phosphate buffered 1% ammonium oxalate solution to lyse 
red blood cells and prevent clotting.  Lysed blood was loaded into a haemocytometer and 
platelets were left to settle in a humidified chamber for 20 mins before counting using a 
light microscope (Olympus CK2, Japan). 
2.2.15.3 Urine output 
Urine excreted by each mouse within 1 minute of scruff restraint was collected and 
weighed.  Sample collection was carried out at the same time each day to minimise the 
impact of natural, diurnal fluctuations in urine output. 
2.2.15.4 Temperature measurement 
Body temperature was measured at least 1 hour after urine collection, and prior to 
blood collection.  Temperatures were taken using a 2 mm thermocouple bead and a digital 
thermometer (Digitech, Electus Distributions Pty Ltd, Rhydalmere, Australia).  The probe 
was positioned in the inguinal region of the mouse, immediately after restraint, for 
approximately 30 s, until the temperature reading stabilised. 
 
2.2.16 RNA extraction 
RNA isolation was carried out using TRIzol reagent (Invitrogen) according to the 
manufacturer’s instructions.  Briefly, excised feet stored at -80ºC in RNAlater were thawed 
and added to a 2 ml microcentrifuge tube containing 1.5ml TRIzol reagent and 2 x 5 mm 
stainless steel beads (Qiagen Pty. Ltd., Doncaster, Australia).  The tubes were 
homogenised (3 x 2 min, 25 Htz) in a Qiagen TissueLyser II (Qiagen).  Homogenates were 
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centrifuged (12 000 x g, 10 mins), 800 µl supernatant transferred to a fresh tube and 200 
µl of chloroform (Sigma-Aldrich) added to each sample.  The samples were shaken by 
hand, incubated for 2-3 mins, then centrifuged (12,000 x g, 12 min) at 4° C and 400-600 µl 
of the resulting RNA-containing aqueous phase transferred to a fresh tube.  Samples were 
incubated with 500 µl isopropanol for 10 min at room temperature before centrifugation 
(12,000g x 10 min) at 4˚C.  The resulting precipitate was pelleted and the supernatant 
carefully aspirated and discarded.  The RNA pellet was washed in 1 ml cold 75% ethanol, 
and resuspended in 20 μl RNAse/DNAase free water (Sigma).  The RNA concentration of 
each sample was quantified using a Nanodrop ND 1000 (Nanodrop Technologies Inc.).  
RNA was treated for DNA contamination using RNAse-Free DNAse 1 (New England 
BioLabs, Ipswich, US).  Briefly, 10 µg of resuspended RNA was incubated in a 100 µl final 
volume of 1x DNAse 1 reaction buffer and 2 units (1 µl) of DNAse 1 at 37˚C for 10mins, 
before heat inactivation at 75˚C for 10 mins. 
 
2.2.17 cDNA synthesis 
Synthesis of first strand total cDNA was performed in a 12 µl final volume reaction 
containing 0.5-2 µg RNA, 200 ng of random hexamer oligonucleotides (Sigma-Aldrich), 2.5 
mM each dTTP, dCTP, dGTP, dATP (Promega) and DNAse/RNAse-free water (Sigma-
Aldrich).  The reaction mixture was incubated at 65˚ C for 5 mins, then placed on ice and 4 
µl of 5x Superscript 1st Strand Buffer (Invitrogen), 1 µl of 0.1 M dithiothreitol (DTT) 
(Invitrogen) and 1 µl DNAse/RNAse-free water (Sigma-Aldrich) added to each reaction.  
The reaction mixture was incubated at 25˚C for 1 min before the addition of 200 U of 
Superscript II (Invitrogen) and further incubation for 11 min at 25˚C, 50 min at 50˚C then 
15 min at 70˚C. 
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2.2.18 Real time RT-PCR 
Quantitative real time PCR (qRT-PCR) reactions contained 1 µl of cDNA (section 
0), 10 µl of Platinum SYBR Green Super mix-UDG (Invitrogen), 1x BSA, 1 µl of each 10 
µM primer and DNAse/RNAse-free water (Sigma-Aldrich) to 20 µl final volume.  
Thermocycling and data acquisition was carried out using a Rotor-Gene Q (Qiagen).  
Cycling conditions were 50˚C, 2 min; 95˚C, 2 min; 35 cycles of 94˚C, 5 s; 60˚C, 10 s; 72˚C, 
15 s.  Expression values are calculated from a standard curve and normalised to RPL13a.  
Primers were (5’3’): RPL13A gag gtc ggg tgg aag tac ca (forward),  tgc atc ttg gcc ttt tcc 
tt  (reverse); IRF7 ccg aga act gga gga gtt tcg forward), gct cca gct tca cca gga tca gg 
(reverse); IRF3 gcc tca ctc cca gga aaa cct ac (forward), aac tcc cat tgt tcc tca gct agc 
(reverse);  IFNβ1 ctc cag ctc caa gaa agg acg (forward), gca tct tct ccg tca tct cca 
(reverse);  IFNα4 tca ttc tgc aat gac ctc ca (forward), tat gtc ctc aca gcc agc ag (reverse).  
 
2.2.19 Histology 
Tissues were excised and placed in ≥10x volume of 10% neutral buffered formalin.  
Feet were fixed for 48-72 hours, and then decalcified using 15% EDTA in 0.1% phosphate 
buffer over ten days.  Tissues were embedded in paraffin wax before being cut into ~6 µm 
sections and stained with haematoxylin and eosin.  Stained slides were scanned using the 
Aperio Scan Scope XT digital slide scanner (Aperio, Vista, USA). 
 
2.2.20 In situ hybridisation 
Excised tissues were fixed as for histology (section 2.2.19).  In situ hybridisation 
using fixed tissues was carried out by C. Babarit under the supervision of T. Larcher 
(Ecole Nationale Vétérinaire, France).  Briefly, paraffin embedded tissues were sectioned 
to 4 µm, deparaffinised in xylene, and rehydrated through descending graded alcohols to 
nuclease-free water. Tissues were permeabilised with protein kinase K (DAKO, Glostrup, 
Denmark) and postfixed in 4% paraformaldehyde.  Sections were hybridised with a 450 bp 
digoxigenin-labelled CHIKV probe sequence (GenBank No.: DQ4435442) then incubated 
with alkaline phosphatase-conjugated anti-digoxigenin antibody (Roche).  Slides were 
treated with nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-indolyl phosphate alkaline 
phosphatase substrate and imaged by bright field microscopy (Nikon Eclipse 80i, 
Badhoevedo, Netherlands). 
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2.2.21 Statistical analysis 
Analyses were performed using IBM SPSS Statistics (version 19).  The t test was 
used if the difference in the variances was <4, skewness was > -2, and kurtosis was < 2.  
Where the data was non-parametric and difference in variances was < 4, the Mann 
Whitney U test was used, if > 4 the Kolmogorov-Smirnov test was used. 
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2.3 Results 
2.3.1 IRF3 and IRF7 protect against CHIKV-induced high viral burden and mortality. 
 
IRF3 and IRF7 are key transcription factors involved in the production of type I 
IFNs, cytokines well known to be critical for control of CHIKV (Honda, Takaoka et al. 2006, 
Gérardin, Barau et al. 2008, Suhrbier, Jaffar-Bandjee et al. 2012).  To assess the 
contribution of IRF3 and IRF7 during CHIKV infection, IRF3-/-, IRF7-/- and IRF3/7-/- mice 
were infected with CHIKV.  Clinical signs of disease, viral burden in blood and tissues, and 
arthritic disease following CHIKV infection were investigated. 
 
All WT, IRF3-/- and IRF7-/- mice survived CHIKV infection, whereas IRF3/7-/- mice 
became moribund, showing signs of severe clinical disease (ruffled fur, hunched posture, 
reduced activity), and required euthanasia, between day 4 and day 6 post infection (Figure 
2.1A).  Peripheral blood viraemia in all strains peaked at day 2 post infection, except in 
IRF3/7-/- mice, in which titres continued to increase until day 3 post infection.  Viraemia in 
IRF3/7-/- mice was significantly higher from day 3 onwards, reaching as high as four logs 
greater than WT mice by day five post infection.  Viraemia in IRF7-/- mice was also higher 
(~1 log) than WT mice from day 2 to day 4 post infection, however, this difference was only 
statistically significant at day 3 post infection.  Viraemia in IRF3-/- mice did not differ 
significantly from WT mice (Figure 2.1B).   
 
In the tissues, viral titres in muscle, spleen, liver and brain were again significantly 
higher in IRF3/7-/- mice compared to WT animals as early as day 2 post infection, and from 
day 3 onwards in the inguinal lymph nodes.  As with serum viraemia, viral titres in the 
tissues of IRF3/7-/- mice peaked at day three post infection, 24 hours after titres peaked in 
WT mice.  However, viral tires in the foot tissues of IRF3/7-/- mice peaked 24 hours earlier 
than WT mice, and remained elevated until time of death (up to day 6 post infection) 
(Figure 2.1C). 
 
These results demonstrate that IRF3 and IRF7 are involved in protection against 
CHIKV high viral burden and absence of both transcription factors results in death. 
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Figure 2.1 CHIKV infection in WT, IRF3-/-, IRF7-/-, and IRF3/7-/- mice.  Mice were 
infected with 104 CCID50 via subcutaneous injection of the dorsolateral metatarsal region 
of the hind limb.  A) Kaplan-Meier survival plot.  Data were recorded when an animal was 
euthanased in accordance with animal ethics guidelines (n=12-20 per group).  B) Virus 
titres in serum (n=7-12 per group).  Differences in viral titres between WT and IRF3/7-/- 
mice reached significance at days 3, 4 and 5 (p<0.05; Mann-Whitney U).  C) Virus titres in 
tissues (n=3-4 per group).  Titres in all tissues at day 3 and 4 were significantly higher in 
IRF3/7-/- mice compared to WT controls (p<0.05 Mann-Whitney U). 
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2.3.2 IRF3 and IRF7 protect against severe foot swelling post CHIKV infection. 
 
 Foot swelling is an indicator of arthritic disease in CHIKV-infected WT mice, with a 
peak increase in foot swelling of ~60%, at day 6-7 post infection and resolution occurring 
by day 12-14 post infection (Gardner, Anraku et al. 2010).  Infection of IRF3-/-, IRF7-/- and 
IRF3/7-/- mice also resulted in foot swelling.  However, foot swelling in the knockout mice 
was earlier (day 3-5) and more pronounced than that seen in WT mice.  Peak foot swelling 
(day 6) was slightly increased in IRF3-/- mice (~70% increase from pre-infection) more 
severe in IRF7-/- mice (~100% increase) and most severe in IRF3/7-/- mice (~140% 
increase) (Figure 2.2). 
 
To ascertain whether foot swelling was an artefact of the virus delivery method (i.e. 
subcutaneous injection of the foot), WT and IRF3/7-/- mice were inoculated with heat 
inactivated CHIKV, sterile RPMI1640 media only, or via a different route.  Injection of 
either heat inactivated virus or media alone did not result in foot swelling in either strain of 
mice (data not shown).  Administration of the standard dose of CHIKV via a different route 
(subcutaneous injection at the base of the tail) did not induce foot swelling in WT mice.  
However, in IRF3/7-/- mice, subcutaneous injection at the base of the tail caused mild foot 
swelling and still resulted in mortality (data not shown).  Together, these results confirm 
that foot swelling in mice following CHIKV infection is the result of replicating virus, rather 
than mechanical injury or local reaction to the inoculum. 
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Figure 2.2 Foot swelling in WT, IRF3-/-, IRF7-/-, and IRF3/7-/- mice following CHIKV 
infection.  Mice were infected with 104 CCID50 via subcutaneous injection of the 
dorsolateral metatarsal region of the hind limb.  Data presented is the percentage increase 
in the metatarsal region from day 0 post infection (n=30 per group except IRF3/7-/- day 6 
post infection, where n=6).  (ns not significant, * p<0.05, ** p<0.01; Mann-Whitney U, day 4 
and day 5: Kolmogov-Smirnov test).
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2.3.3 Prophylactic treatment with recombinant IFNα, IFNγ or adoptive transfer of 
CD45+/CD11b+ did not prevent mortality in IRF3/7-/- mice. 
 
IFNα is used in the treatment of a number of viral infections, namely hepatitis C 
(López, Molina et al. 2011, Ning, Pagano et al. 2011), and has also been shown to reduce 
viraemia and disease in WT mice if given prior to CHIKV infection (Gardner, Anraku et al. 
2010).  To asses whether prophylactic treatments could prevent the viraemia and disease 
observed in IRF3/7-/- mice, administration of IFNα and/or IFNγ, as well as adoptive transfer 
of WT cells was undertaken. 
 
IFNα (104 IU/ml) administered 6 hours prior to CHIKV infection was only able to 
delay death by 24 hours in IRF3/7-/- mice.  IFNγ is induced independently of IRF3 and IRF7 
(Platanias 2005, Levy, Marié et al. 2011), and was shown to induce an antiviral state faster 
than type I IFN treatment in response to RNA viruses  (Gomi, Morimoto et al. 1985, Saito 
1989).  Treatment of IRF3/7-/- mice with IFNγ (104 IU/ml) 24 hours post CHIKV infection 
was also able to delay death by 24 hours.  A combined treatment of 5x103 IU/ml IFNα at 6 
hours prior, and 5x103 IU/ml IFNγ 24 hours post CHIKV infection delayed death by 36 
hours (Figure 2.3).  Monocyte/macrophages play an important role in the pathobiology of 
alphaviral arthritis and can produce type I IFNs (Mateo, La Linn et al. 1999, Kumagai, 
Takeuchi et al. 2007, Her, Malleret et al. 2010).  FACS sorted CD45+/CD11b+ cells 
(2.7x105) (primarily comprised of monocytes and macrophages).derived from spleens of 
naive WT mice were adoptively transferred to IRF3/7-/- mice, 24 hours prior to infection.  
Again, mortality was only delayed by 24 hours, but not prevented (Figure 2.3).  This is 
consistent with findings by Schilte, Couderc et al. (2010) that haematopoietic cells do not 
produce protective levels of type IFNs during CHIKV infection. 
 
These results demonstrate that delivery of IFNs alone is not sufficient to induce an 
effective antiviral response or protect IRF3/7-/- mice against CHIKV mortality. 
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Figure 2.3  Prophylactic treatment of IRF3/7-/- mice and IRF7 induction.  IRF3/7-/- mice 
aged 8-12 weeks received either 104 IU/ml IFNα or IFNγ, 5x103 IU/ml each IFNα and IFNγ 
combined or 2.7x105 FACS sorted CD45+/CD11b+ splenocytes in 100 µl RPMI1640 
media by intravenous injection at the base of the tail.  Mice were challenged with CHIKV 6 
hours post treatment.  Mice treated with IFNγ were challenged 24 hours post treatment.  A 
death event was recorded when mice were euthanased in accordance with animal ethics 
guidelines (n=3-4 per group).  
 47 
2.3.4 IRF7 is induced > 150-fold in response to CHIKV infection in WT mice.  
 
In the previous section, contrary to results seen in WT mice (Gardner, Anraku et al. 
2010), administration of type I IFNs was not an effective prophylactic treatment in IRF3/7-/- 
mice.  IRF7 is the primary transcription factor for induction of IFNαs (Honda, Yanai et al. 
2005).  IRF7 induction, but not IRF3 induction is known to be essential to the positive 
feedback loop that results in effective type I IFN responses (Marie, Durbin et al. 1998, 
Sato, Suemori et al. 2000). 
 
IRF3 and IRF7 mRNA expression was analysed in the feet of WT mice infected with 
CHIKV.  IRF3 was only up-regulated on day 1 post infection and only by ~2.5 fold.  IRF7 
was induced to a much greater extent, with up-regulation >100 fold by day 1 post infection, 
≈150 fold increase at day 3 post infection, and expression values at day 7 still ≈50 fold 
higher than mock infected samples (Figure 2.4).  This is consistent with the positive 
feedback model of type I IFN induction, in which activation of constitutively expressed 
IRF3 precedes the induction of IRF7 and antiviral effectors (Levy, Marié et al. 2011).  IRF7 
itself is induced by type I IFNs; the high level of IRF7 induction seen here, indicates that 
the dose of IFNα used in section 2.3.3 was not sufficient to compensate for the level of 
IFNαs that would ordinarily be produced in the presence of IRF7 induction.  Furthermore, 
these results suggest that the protective role of prophylactic IFN treatment is mediated by 
up-regulation of IRF7, rather than induction of antiviral effectors. 
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Figure 2.4  IRF3 and IRF7 mRNA induction in WT mice.  IRF3 and IRF7 mRNA 
expression by quantitative real-time PCR in WT mouse feet at days 0, 1, 3 and 7 post 
CHIKV infection.  Normalised to RPL13a mRNA levels (n=6; all time points significantly 
greater than day 0, except IRF3 day 7, p ≤ 0.05; t-test). 
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2.3.5 An absence of IRF3 and IRF7 does not affect antibody responses to CHIKV infection 
 
Alphaviruses, including CHIKV, are known to be controlled by host antibody 
responses (Gardner, Anraku et al. 2010, Holzer, Coulibaly et al. 2011, Suhrbier, Jaffar-
Bandjee et al. 2012).  To determine whether protective antibody responses are 
compromised in the absence of IRF3 and/or IRF7, IRF3-/-, IRF7-/-, IRF3/7-/- and WT mice 
were vaccinated with 10 µg inactivated CHIKV antigen.  After four weeks, vaccinated mice 
were challenged with CHIKV. 
 
At 3 weeks post vaccination, serum was collected and assayed for anti-CHIKV 
antibody titres by ELISA.  All mouse strains were capable of mounting a robust antibody 
response to vaccination (Figure 2.5A).  Slightly more IgG1 and less IgG2c CHIKV-specific 
antibody was induced in IRF3/7-/- mice compared to WT mice, indicative of a slight shift 
toward Th2 responses, and consistent with the role of type I IFNs in promoting Th1 
responses (Bracci, La Sorsa et al. 2008, Farkas and Kemény 2011).  Neutralisation assay 
on serum showed that all mice had produced, comparable levels of neutralising antibody 
titres (Figure 2.5B). 
 
At 4 weeks post vaccination, mice were challenged with CHIKV.  All strains of mice 
were protected against CHIKV viraemia and disease (Figure 2.5 C).  Without vaccination, 
both IRF3/7-/- and WT mice were still able to mount neutralising antibody titres by day 4 
post infection (data not shown).  Nevertheless, antibody production was unable to provide 
protection for IRF3/7-/- mice against CHIKV infection, with mice requiring euthanasia 
between days 4-6.   
 
These results indicate that antibody responses are not hindered by the absence of 
IRF3 and/or IRF7.  However, antibody responses were either too late, or insufficient to 
protect IRF3/7-/- mice against cytokine dysregulation and subsequent haemorrhagic shock 
(see sections 2.3.6 - 2.3.11). 
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Figure 2.5  Antibody production and protection in WT, IRF3-/-, IRF7-/-, and IRF3/7-/- 
mice following vaccination.  Mice were vaccinated with inactivated CHIKV antigen.  
Naïve mice received RPMI1640 instead of CHIKV antigen.  At 3 weeks post vaccination, 
blood was collected and assayed for anti-CHIKV antibody titres and neutralisation assay.  
Four weeks after vaccination, mice were infected with CHIKV A) ELISA of anti-CHIKV 
IgG1 and IgG2c antibody titres (n=3-4 per group, 3 weeks post vaccination).  B)  
Neutralising anti-CHIKV antibody titres (n=3-4 per group, 3 weeks post vaccination).  Titre 
represents the serum dilution giving 100% neutralisation in CHIKV-infected Vero cell 
culture (n=3-4 per group, 3 weeks post infection). C)  Kaplan-Meier plot of survival in 
vaccinated and naive IRF3/7-/- mice (n=4-6 per group). 
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2.3.6 Absence of IRF3 and IRF7 alters type I IFN and pro-inflammatory cytokine 
responses to CHIKV infection. 
 
IRF3 and IRF7 are the key transcription factors for type I IFN production.  To 
examine the extent to which IRF3 and IRF7 affect the expression of type I IFN and pro-
inflammatory mediators, IRF3-/-, IRF7-/- and IRF3/7-/- mice were infected with CHIKV and 
their serum cytokine levels assayed. 
 
Serum bioassay was used to determine the type I IFN levels in mice following 
CHIKV infection.  Consistent with previous reports (Gardner, Anraku et al. 2010), high 
concentrations of type I IFN (peak of ~1000 IU/ml) were detected in WT mice, with levels 
peaking at day 2 post infection.  Type I IFN levels in IRF3-/- mice were similar to WT, 
peaking at ~800 IU/ml on day 2 post infection.  Type I IFN levels in IRF7-/- mice were 
markedly lower than WT mice (~2 IU/ml) and were only detectable on day 2 post infection.  
In IRF3/7-/- mice, type I IFN levels were below the level detectable by serum bioassay (~1 
IU/ml) (Figure 2.6A).  Consistent with protein expression, type I IFN mRNA expression in 
feet at day 2 post infection was highest in WT mice and minimal in IRF3/7-/- mice.  Type I 
IFN mRNA was up-regulated to similar levels in IRF3-/- and IRF7-/- mice (Figure 2.6B)  
Circulating levels of pro-inflammatory cytokines were also measured in mice following 
CHIKV infection (Figure 2.6C).  In IRF3/7-/- mice, peak serum levels of monocyte 
chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), tumour necrosis factor (TNF) and 
IFNγ were significantly elevated compared to WT mice; MCP-1, IL-6 and TNF were ~10 
times higher, and IFNγ was almost 50 times higher in IRF3/7-/- mice compared to WT 
controls in response to CHIKV infection.  MCP-1, IL-6 and IFNγ peaked at day 2 post 
infection, while TNF remained significantly elevated from day 2 until day 6 (time of death).  
Serum levels of these cytokines in IRF3-/- and IRF7-/- mice were not significantly different 
to WT mice. 
 
These results illustrated that mortality in IRF3/7-/- mice, following CHIKV infection, is 
associated with very high levels of IFNγ.   
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Figure 2.6  Cytokine expression during CHIKV infection in WT, IRF3-/- IRF7-/- and 
IRF3/7-/- mice.  Mice were infected with CHIKV.  A)  Serum bioassay of bioactive 
peripheral blood IFN levels at days 1, 2, and 3 post infection (n=3-6 per group).  B)  
Quantitative real-time PCR of IFNα4 and IFNβ1 expression in mouse feet at day 2 post 
infection.  Normalised to RPL13a mRNA (n=4-6 per group).  C)  Peripheral blood cytokine 
levels.  (n=3-6 per group; n.s. not significant, * p<0.05, ** p<0.01; Mann-Whitney U) 
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2.3.7 CHIKV tissue tropism is altered in IRF3/7-/- mice. 
 
The cellular tropism of CHIKV in vivo is not well characterised.  Given the 
differences in replication kinetics, disease and immune responses seen in CHIKV infected 
IRF3/7-/- mice, CHIKV tropism in these mice was examined. In situ hybridisation was used 
to detect CHIKV RNA in the cytoplasm of cells in foot tissues of WT and IRF3/7-/- mice at 
day 3 and day 5 post infection.  Uninfected mouse tissue, RRV anti-sense probes and 
CHIKV sense probes were used as negative controls.   
 
In WT mice at day 3 post infection, staining was observed in endothelial cells 
(Figure 2.7A), skeletal myofibres (B), cells in the periosteum (E) and synovial membranes 
(D).  Sporadic staining of fibroblasts and macrophages was observed within the dermis(C).  
In IRF3/7-/- mice at day 3 post infection, staining was observed in endothelium (F), skeletal 
myofibres (G) and the dermis (H).  However, staining of fibroblasts and 
macrophage/monocytes in the dermis was considerably more apparent in IRF3/7-/- than 
WT mice.  In contrast to WT mice, no staining was seen in the periosteum and synovial 
membranes of IRF3/7-/- mice, but staining was present in chondrocytes (I) of the articular 
cartilage, which was not seen in WT animals. 
 
At day 5.5 post infection, staining was again observed in the endothelium (Figure 
2.7J), fibroblasts and macrophages in the dermis and underlying connective tissues in WT 
mice (L).  Positively stained macrophages could also be seen within the blood vessels (M), 
but staining was no longer present in the muscle (K).  In IRF 3/7-/- mice at day 5.5 post 
infection, CHIKV RNA equivalent to WT mice was seen in the endothelium (O) and 
fibroblasts and macrophages of the dermis and connective tissues (Q,R,S), and also 
remained present in the muscle at day 5.5 post infection (P).  Positive staining was also 
observed in the epidermis, suggesting infection of keratinocytes (S), which had not been 
seen at either time point in WT mice (C, N).  No signal was detected in negative controls at 
any time point (data not shown). 
  
The results here show that while similar to WT, the distribution and tissues targeted 
by CHIKV are distinct in IRF3/7-/- mice, indicating that the cellular tropism of CHIKV is 
altered in the absence of IRF3 and IRF7. 
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Figure 2.7 Virus location by in situ hybridisation in CHIKV-infected IRF3/7-/- and WT 
mice.  CHIKV RNA detection by in situ hybridisation in IRF3/7-/- and WT mice at day 3 and 
day 5.5 post infection.  Staining was observed in both strains at both time points in blood 
vessel walls (A, F, J, M, O), skeletal muscle (B, G, K, P) and skin (C, H, L, S).  Staining 
was also present at day 3 in WT synovial tissue (D) and periosteum (E), IRF3/7-/- articular 
cartilage (I) and at day 5.5 in the dermis (L, Q). RBC: Red blood cells. Images are 
representative of that observed in 3 mice per group 
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2.3.8 Tissue pathology and inflammatory infiltrates were altered in IRF3/7-/- mice 
 
To determine whether the altered tissue tropism observed in IRF3/7-/- mice might 
impact upon tissue pathology, histological analysis was carried out in several tissues, 
excised from IRF3-/-, IRF7-/-, IRF3/7-/- and WT mice at day 5 post infection.   
 
Necrotic lesions, involving keratinocyte karyorrhexis (nuclear blebbing during cell 
death) were observed within the epithelial layer of skin in IRF3/7-/- mice, and were 
associated with bullae (small, fluid filled blisters) formation (Figure 2.8A vs B).  These 
lesions were also present in the skin of IRF7-/- mice, but to a much lesser degree, and 
were not observed in IRF3-/- mice or WT mice (data not shown).  Within the joints of 
IRF3/7-/- mice, evidence of severe exudative arthritis, characterised by the presence of 
fibrin and inflammatory infiltrates, could be observed (Figure 2.8C vs D).  Evidence of 
exudative arthritis could not be seen in IRF3-/-, IRF7-/- or WT mice at day 5 post infection 
(data not shown); however, a similar exudative arthritis has been described previously at 
day 7 post infection in WT mice (Gardner, Anraku et al. 2010).  In the skeletal muscle at 
day 5.5 post infection, a large inflammatory, predominantly macrophage infiltrate was 
present in IRF3-/-, IRF7-/- (Figure 2.7G & H) and WT mice (data not shown).  Myofibre 
necrosis, likely the result of macrophage activity, was also present in these mice.  In 
contrast, the skeletal muscle of IRF3/7-/- mice at day 5.5 post infection was characterised 
by minimal cellular infiltrate and endomysial oedema (Figure 2.8E vs F).  The liver, spleen, 
kidney, gut, lung, lymph nodes and brain of IRF3/7-/- and WT at day 5.5 post infection were 
also examined; with the exception of lung and brain (discussed section 2.3.9), no 
remarkable lesions were observed in these tissues. 
 
These differences in pathology within skin, joint and muscle tissues between 
IRF3/7-/- mice and WT mice thus appear to coincide with the differences with the altered 
tissue tropism (Figure 2.7), and indicate that CHIKV tissue pathology is altered the 
absence of IRF3 and IRF7. 
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Figure 2.8 Histology in CHIKV-infected IRF3/7-/- mouse skin, joint and muscle 
tissues.  A)  Skin necrosis (n) in an IRF3/7-/- mouse at day 5 post CHIKV infection.  
Degenerating leukocytes with pale cytoplasm and karyorrhtic nuclei (arrows) are present. 
B)  Skin of uninfected IRF3/7-/- mice.  C)  Exudative arthritis in joint tissues of IRF3/7-/- 
mice at day 5 post infection with inflammatory infiltrate and fibrin (arrows) present in the 
synovial lining. Synovial space (SS) and articular cartilage (AC) are indicated.  D)  Articular 
cartilage from joint tissues of an uninfected IRF3/7-/- mouse.  E)  Skeletal muscle from an 
uninfected IRF3/7-/- mouse.  F)  Skeletal muscle from an IRF3/7 mouse at day 5 post 
infection.  G)  Skeletal muscle from an IRF7-/- mouse at day 5 post infection.  H)  Skeletal 
muscle from an IRF3-/- mouse at day 5 post infection.  Images are representative of 3 mice 
per group. 
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2.3.9 CHIKV infection in IRF3/7-/- mice induces haemorrhage and oedema 
 
In addition to changes in tissue pathology outlined in section 2.3.8, histological 
analysis revealed evidence of changes to the vasculature and fluid retention in IRF3/7-/- 
mice at day 5 post CHIKV infection. 
 
Severe generalised oedema and multifocal haemorrhage was present within the 
dermis and subcutaneous tissues of feet in IRF3/7-/- mice (Figure 2.9A vs D).  The 
vasculature of IRF3/7-/- mice was seen to contain lesions, which were not present in the 
vasculature of WT mice.  Lesions were characterised by fibrinoid necrosis (accumulation 
of proteinaceous debris in necrotic tissue, resembling fibrin), involving neutrophil 
karyorrhexis indicative of intramural leukocytoclasis (degenerate leukocytes within 
vascular walls) (Figure 2.9B&C).  Perivascular fibrin exudation and extravasated 
erythrocytes surrounding lesions were also observed (Figure 2.9C).  Pulmonary 
consolidation, (fluid in the lungs), as well as perivascular cuffs (leukocytes surrounding the 
vasculature), were present in the lung tissue of IRF3/7-/- mice, and in the brain, mild 
pericapillary oedema was also observed, which was not present in WT mice (data not 
shown).  Oedema and some haemorrhage was also observed in IRF7-/- mice, to a much 
lesser degree, and was not observed in IRF3-/- or WT mice (data not shown). 
 
Thus, mortality in IRF3/7-/- mice following CHIKV infection was associated with 
severe, generalised oedema and multifocal haemorrhage. 
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Figure 2.9 Histological analysis of haemorrhage and oedema in CHIKV-infected 
IRF3/7-/- mice.  Standard H&E staining of IRF 3/7-/- mouse tissues at day 5 post infection 
with uninfected IRF3/7-/- tissues or IRF3-/- and IRF7-/- mice at day 5 post infection for 
comparison.  A)  Subcutaneous foot tissue in IRF 3/7-/- mice day 5 post infection with 
severe, generalised oedema (asterisks) and multi-focal haemorrhage.  B)  Enlarged lower 
portion of panel A, showing oedema and haemorrhage.  C) Vasculitis indicated by fibrinoid 
necrosis (n) and intramural degenerating leukocytes (arrows).  D)  Subcutaneous foot 
tissue in an uninfected IRF3/7-/- mouse.   
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2.3.10 CHIKV induces clinical symptoms of hypovolemic shock in IRF 3/7 -/- mice 
 
 Severe haemorrhage and/or oedema are involved in the development of 
hypovolemic shock, as seen during dengue haemorrhagic fever (DHS) or dengue shock 
syndrome (DSS) (Pang, Cardosa et al. 2007, Huy, Van Giang et al. 2013).  Hypovolemic 
shock is a pathological drop in blood pressure due to blood and fluid loss, resulting in a 
failure to adequately perfuse tissues, and is often an irreversible and fatal condition.  To 
determine whether the oedema and haemorrhage observed in IRF3/7-/- mice were causing 
hypovolemic shock, and ultimately death in these mice, several clinical indicators of 
hypovolemic shock were investigated.  
 
 Thrombocytopenia due to haemorrhage is a criterion used in the diagnosis of 
DSS/DHS (Ranjit, Kissoon et al. 2005, W.H.O 2009).  In humans, a diagnosis of 
thrombocytopenia is given when circulating platelet levels drop by ≥70 %.  In WT mice, 
platelet levels at day 2 were reduced by ~20%, but returned to pre-infection levels by day 
5 post infection.  In IRF3/7-/- mice, platelet levels had dropped to ~55% by day 2, and at 
day 5, were less than 70% of pre-infection levels (Figure 2.10A). 
 
 Hypothermia, due to reduced blood circulation, is also common in hypovolemic 
shock, with a sudden change from fever to hypothermia a clinical indicator of the onset of 
DHS/DSS (W.H.O 2009).  At day 2 post infection, IRF3/7-/- mice developed a fever, before 
a dramatic drop in body temperature at day 3 and day 4 post infection was observed.  In 
WT mice, no significant fever was detected.  There was a very mild drop in body 
temperature at day 3 post infection.  However, body temperature stabilised to pre-infection 
temperatures from day 4 onwards (Figure 2.10B). 
 
 Another measure of hypovolemic shock used in DHS/DSS diagnosis is an increase 
in blood haematocrit levels of >20%, indicative of hemoconcentration following plasma 
leakage into the tissues (W.H.O 2009, Huy, Van Giang et al. 2013). At day 5 post infection, 
haematocrit measurements in IRF3/7-/- mice showed a mean increase of 15.8% (range 7-
24%) from pre-infection measurements, whereas haematocrit levels in infected WT mice at 
day 5 did not differ from pre-infection readings (Figure 2.10D). 
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 Pathologically low blood pressure during hypovolemic shock can also manifest as 
oliguria, or reduced urine output due to poor kidney perfusion (Ranjit, Kissoon et al. 2005, 
W.H.O 2009).  Urine output in WT and IRF3/7-/- mice was not significantly different from 
day 0 to day 3 post infection.  However, urine output on days 4 and 5 was significantly 
lower in IRF3/7-/- mice compared with WT mice, with no urine output seen on day 5 post 
infection in IRF3/7-/- mice (Figure 2.10C). 
 
The severe haemorrhage and generalised oedema observed in histological analysis 
of IRF3/7-/- mice, in conjunction with the clinical parameters observed just prior to death, 
provide compelling evidence that mortality in IFF3/7-/- mice following CHIKV infection was 
due to hypovolemic shock. 
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Figure 2.10  Clinical symptoms of hypovolemic shock in IRF 3/7-/- mice following 
CHIKV infection.  A)  Platelet levels were significantly reduced compared to WT controls 
on days 3, 4 and 5 post infection (p= 0.001, p<0.001 and p, 0.001 respectively; n=8-10 per 
group).  B)  IRF3/7-/- mice temperatures rose significantly from day 0 to day 2 post infection 
(p=0.004) and were higher than WT mice at the same time point (p=0.001).  IRF3/7-/- mice 
temperatures were significantly lower than WT mice on day 4 and day 5 post infection 
(p<0.001; n=4-16 per group).  C)  Urine output from IRF3/7-/- mice was significantly lower 
than WT mice at days 4 and 5 post infection (p<0.001; n= 8-10 per group).  D)  Percentage 
increase of haematocrit levels (from uninfected control levels) in IRF3/7-/- versus WT mice 
at day five post infection (p<0.001; n=10-11 per group).  Data pooled from four individual 
experiments, statistics obtained by Mann-Whitney U test). 
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2.3.11 TRIF, MyD88 and IPS-1 are involved but not critical in viraemia control, foot 
swelling or type I IFN production following CHIKV infection 
 
TRIF, MyD88 and IPS-1 are used by host PRR to relay signals to IRF3 and IRF7 
(Takeuchi and Akira 2010, Jensen and Thomsen 2012).  The endosomal TLRs, with the 
exception of TLR3, transduce their signals through MyD88 (Kawai and Akira 2010); TLR3 
signals exclusively via TRIF (Takeuchi and Akira 2010).  The RLRs, RIG-1 and MDA5, are 
located in the cytoplasm, and signal through IPS-1 (Jensen and Thomsen 2012).  
Haematopoietic cells engage both TLRs and RLRs, while type I IFN production in 
fibroblasts is largely via IPS-1 (Kawai and Akira 2011).  To assess the extent to which 
each adaptor molecules is used, and gain insight into the PRR signalling pathways used in 
CHIKV infection, MyD88-/-, TRIF-/-, and IPS1-/- mice were infected and monitored for viral 
replication, foot swelling and serum type I IFN. 
 
CHIKV infection in MyD88-/-, TRIF-/-, and IPS1-/- mice was not fatal, but caused 
increased foot swelling and viraemia and lower serum type I IFNs compared to WT mice.  
Viraemia was highest in TRIF-/- mice, with titres ~ 2.5 and ~4 log higher than WT at day 3 
(peak) and day 4, respectively.  Peak viraemia in MyD88-/- and IPS-1-/- mice was earlier 
(day 2) and was not significantly different to WT.  At day 4, viraemia in all strains was 
higher than WT mice.  Viraemia in IPS-1-/- mice was slow to clear and remained ~2 log 
higher than WT on day 5 post infection (Figure 2.11A).  Consistent with the prolonged viral 
clearance, foot swelling in IPS-1-/- mice peaked higher and later than all other strains.  
Swelling was also higher than WT mice in TRIF-/- mice (days 2-6 and 8) and in IPS-1 mice 
(days 2-8) following infection.  Foot swelling in WT and MyD88-/- mice did not differ 
significantly (Figure 2.11B).  Serum type I IFN was significantly lower in MyD88-/-, TRIF-/- 
and IPS-1-/- mice compared to WT mice at days 1 and 2 post infection; however in MyD88-
/- mice, type I IFN was ≈100 fold higher than TRIF-/- and IPS-1-/- at day 1 post infection.  By 
day 2 post infection, serum levels in both TRIF-/- and MyD88-/- mice were similar.  Type I 
IFN production in IPS1-/- mice was minimal at all time points measured (Figure 2.11C). 
 
These results demonstrate that TRIF, MyD88 and IPS-1 are involved, but not critical 
for protection against CHIKV infection.  Consistent with results in sections 2.3.1 and 2.3.2, 
type I IFN production was associated with effective viraemia control and the degree of foot 
swelling, with IPS-1 playing the most significant role in type I IFN signalling in response to 
CHIKV infection. 
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Figure 2.11  CHIKV infection in WT, TRIF-/-, MyD88-/- and IPS1-/- mice.  A)  Serum virus 
titres in MyD88-/- (n=8), TRIF-/- mice (n=11) and IPS1-/- mice (n=3) compared to WT mice 
(n=21) Statistics by Mann-Whitney U, day 5, Kolmogrov-Smirnov test.  B)  Percentage 
increase in foot swelling in MyD88-/- (n=8-22), TRIF-/- mice (n=10-32) and IPS1-/- mice 
(n=3), compared to WT mice (n=14-28), statistics by Mann-whitney U test, day 4 and day 
5, Kolmogrov-Smirnov test.  Data derived from multiple experiments. C)  Serum Type I IFN 
levels in MyD88-/- mice (n=5), TRIF-/- (n=5) mice and IPS1-/- (n=3) mice compared to WT 
mice (n=7-11). Mann-Whitney U test. (* p ≤0.05, ** p ≤0.01, n.s. not significant).  
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2.3.12 CHIKV infection of IFNAR-/- mice results in rapid, lethal hypovolemic shock. 
 
Mice deficient in the primary type I IFN transcription factors, IRF3 and IRF7, were to 
shown to have impaired type I IFN production and were more susceptible to CHIKV 
infection, with IRF3/7-/- mice experiencing a fatal hypovolemic shock (Figure 2.10).  Mice 
deficient in the adaptor molecules upstream of IRF3 and IRF7 - TRIF, MyD88 and IPS-1 
were also seen to have impaired type I IFN production that was associated with increased 
disease severity (Figure 2.11).  To confirm the association between increased morbidity 
following CHIKV infection and defective type I IFN responses, IFNAR1-/- mice, which are 
incapable of type I IFN signalling, were challenged with CHIKV.  
 
CHIKV infection of IFNAR1-/- mice resulted in a severe and fatal disease phenotype, 
reminiscent of that seen in CHIKV infection of IRF3/7-/- mice.  Mortality was rapid, with all 
IFNAR-/- mice experiencing extreme foot swelling (Figure 2.12B) and requiring euthanasia 
within 3 days of infection (Figure 2.12A).  Investigations of the clinical indicators of 
hypovolemic shock in IFNAR-/- mice clearly demonstrated that IFNAR-/- mice were 
experiencing a rapid, pathological loss of blood volume prior to death.  Circulating platelet 
levels dropped by ~90%, indicative of severe thrombocytopenia (a drop of ≥ 70%) and 
blood loss (Figure 2.12C).  The mice also displayed a fever at day 2 post infection, prior to 
a rapid decrease in body temperature, and by day 3 post infection (Figure 2.12D), urine 
output was absent, indicative of dehydration and inadequate blood pressure to maintain 
perfusion of the tissues (Figure 2.12E).  Haematocrit readings displayed a mean ~27% 
increase from pre-infection levels, where an increase of 20% is considered a clinical 
indicator of hypovolemic shock (Figure 2.12F).  No other unusual symptoms, such as 
neurological involvement, skin conditions etc., were observed (data not shown). 
 
These findings clearly indicate that mortality in IFNAR1-/- mice following infection 
with CHIKV is the result of hypovolemic shock.  Together with the findings in mice deficient 
in both IRF3 and IRF7, these results further substantiate the association between impaired 
type I IFN responses and increased susceptibility to CHIKV-induced hypovolemic shock. 
 65 
 
Figure 2.12  Survival, foot swelling and clinical parameters in IFNAR-/- mice following 
CHIKV infection.  A)  Kaplan-Meier survival plot of IFNAR-/- mice and WT mice.  Data 
were recorded when an animal was euthanased in accordance with animal ethics guidlines 
(n=6 per group).  B)  Foot swelling in IFNAR-/- mice (n=6) compared to WT mice (n=8-22).  
The mean percentage increase in metatarsal area is presented (n=6). C)  Platelet counts 
in IFNAR-/- mice at day 0 versus day 3 post CHIKV infection (n=6; p=0.009, t-test).  D)  
Body temperature in IFNAR-/- mice following CHIKV infection (n=6; p=0.04, t-test).  E)  
Urine output in IFNAR-/- mice (n=6; p=0.002, Kolmogrov-Smirnov test).  F)  Haematocrit 
levels in IFNAR-/- mice at day 0 and day 3 post infection (n=6; p<0.001; Mann-Whitney U). 
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2.4 Discussion 
Results herein demonstrate a critical role for IRF3 and IRF7 during CHIKV infection.  
Deficiency of either IRF3 or IRF7 in mice following CHIKV infection resulted in a more 
severe disease phenotype, particularly in the case of IRF7; however, a deficiency in both 
transcription factors resulted in mortality.  CHIKV infected IRF3/7-/- mice displayed 
increased viral titres and serum pro-inflammatory cytokine levels, severe arthritic disease, 
altered tissue pathology and signs of fatal hypovolemic shock.  Antibody responses were 
largely unaltered in IRF3/7-/- mice, with vaccination able to protect mice against CHIKV 
disease.  However, prophylactic IFNα treatment only delayed death in IRF3/7-/- mice.  
Infection of IFNAR-/- mice resulted in the same lethal symptoms as those observed in 
IRF3/7-/- mice, confirming the protective role of IRF3 and IRF7 in CHIKV is via regulation of 
type I IFN responses. Infection of mice deficient in the adaptor molecules upstream of 
IRF3 and IRF7 demonstrated that CHIKV-induced type I IFN production is primarily via the 
RIG-1/MDA5/IPS-1 and TLR3/TRIFF pathways. 
 The disease manifestations in CHIKV infected mice were consistent with symtoms 
commonly observed in humans.  In situ hybridisation revealed infection of mature 
myofibres, consistent with the myalgia commonly experienced in human disease.  CHIKV 
has been reported to infect human muscle satellite cells (Ozden, Huerre et al. 2007) and 
myofibers in TLR3-/- mice (Her et al. 2014), and RRV is known to infect myofibres (Murphy, 
Taylor et al. 1973, Morrison, Whitmore et al. 2006).  However, infection of mature 
myofibres following CHIKV infection of WT mice has not previously been reported.  
Chondrocytes were also shown to be infected by CHIKV, which has also, not previously 
been reported, although chondritis is commonly reported in human CHIKV (Emilie, Tiong 
et al. 2014) and likely contributes to rheumatic symptoms.  A skin rash is also common in 
human CHIKV disease (Suhrbier, Jaffar-Bandjee et al. 2012), and may be caused by 
infection of keratinocytes (Pakran, George et al. 2011).  In this study, infection of cells in 
the epidermis was only observed in IRF3/7-/- mice.  IRF3/7-/- mice also experienced a fever 
and oedema, which are common in human disease (Suhrbier, Jaffar-Bandjee et al. 2012).  
IRF3/7-/- mice also displayed disease manifestations that have been observed in severe 
human disease (Economopoulou, Dominguez et al. 2009). 
 
CHIKV infection in humans has occasionally been associated with severe, and 
sometimes fatal disease outcomes (Economopoulou, Dominguez et al. 2009).  Severe 
disease manifestations including thrombocytopenia, haemorrhage, and hypovolemic shock 
 67 
are more common in children/neonates (Gérardin, Barau et al. 2008), in whom IRF7 
responses are known to be defective/underdeveloped (Levy 2007, Danis, George et al. 
2008).  Severe symptoms were only observed in IRF7-/-, IRF3/7-/- and IFNAR-/- mice, which 
were deficient type I IFN, suggesting that poor type IFN responses may predispose 
individuals to severe and atypical CHIKV disease manifestations. 
 
The severe symptoms in IRF3/7-/- and IFNAR-/- mice were also analogous to dengue 
shock syndrome (DSS) and dengue haemorrhagic fever (DHF) involving 
haemoconcentration, oliguria, haemorrhage, severe oedema, fever then hypothermia 
(W.H.O 2009, Huy, Van Giang et al. 2013) and elevated levels of the pro-inflammatory 
cytokines IFNγ, IL-6, MCP-1 and TNF (Lee, Liu et al. 2006, Pang, Cardosa et al. 2007).  
IRF7 responses early in infection have been shown to mediate protection against the 
development DSS/DHF (Hoang, Lynn et al. 2010), and microarray analysis has shown that 
DSS patients have reduced levels of type I IFN-induced gene transcripts (Simmons, 
Popper et al. 2007). The paucity of type I IFNs in IRF3/7-/- and IFNAR-/- mice suggests 
insufficient type I IFN responses may be involved in the development of DHS/DSS.   
  
The absence of type I IFN in IRF3/7-/- and IFNAR-/- mice likely contributes to the 
development of hypovolemic shock, not as a result of increased viral burden, but due to a 
lack of regulation of serum pro-inflammatory cytokines.  TNF is a potent vasodilator that is 
produced by macrophages in response to IFNγ (Loppnow, Werdan et al. 2008).  The very 
high levels of these cytokines in CHIKV infected IRF3/7-/- and IFNAR-/- mice are 
presumably the cause of vascular leakage and shock (Lee, Liu et al. 2006, Pang, Cardosa 
et al. 2007).  Production of IFNγ has been shown to be inhibited by type I IFNs during 
Trypanosoma cruzi infection (Chessler, Caradonna et al. 2011), as well as viral infections 
(Nguyen, Cousens et al. 2000).  Type I IFN is also known to down-regulate expression of 
the IFNγ-receptor, thereby suppressing the effects of IFNγ (Rayamajhi, Humann et al. 
2010).  Thus, in the absence of type I IFN in IRF3/7-/- and IFNAR-/- mice, excessive IFNγ 
production and downstream pro-inflammatory mediators cannot be effectively controlled, 
leading to severe vascular leakage and ultimately, hypovolemic shock.  Vascular leakage 
and cytokine dysregulation likely also lead to the extreme foot swelling in the IRF3/7-/- 
mice. 
 
 68 
 Arthritis in WT mice is associated with a considerable monocyte/macrophage 
infiltrate (Gardner, Anraku et al. 2010). In IRF3/7-/- mice, however, there was a notable 
absence of any cellular infiltrates observed, despite a 140% increase in foot swelling 
(versus 50% in WT mice).  Macrophage/monocyte infiltration of the tissues has been 
shown to be largely dependent on chemokine (C-C motif) receptor 2 (CCR2), which is the 
receptor for MCP-1/CCL2 (Poo, Nakaya et al. 2014).  MCP-1/CCL2 was produced at very 
high levels in IRF3/7-/- mice.  However, type I IFN signalling has been shown to be critical 
for migration of Ly6Chi inflammatory monocytes during chronic inflammation (Lee, Li et al. 
2009).  Thus, the absence of type I IFNs in IRF3/7-/- mice may have impeded the capacity 
for monocyte/macrophage extravasation.  Furthermore, CCR2 expression in monocytes 
and dendritic cells have been shown to be down regulated by high levels of IFNγ (Vecchi, 
Massimiliano et al. 1999) and TNF (Weber, Draude et al. 1999), respectively.  Foot 
swelling in the IRF3/7-/- mice thus appears to be the result of severe oedema, rather than 
arthritis. 
 
The generation of intact type I IFN responses was seen to be more dependent on 
IRF7 than IRF3.  In WT mice, IRF7 mRNA levels were up-regulated >100 fold following 
CHIKV infection.  IRF7-/- mice also displayed greater disease severity and reduced serum 
type I IFN levels, while viral burden, foot swelling and type I IFN production in IRF3-/- mice 
was not significantly different to WT.  These findings were consistent with studies that 
have shown that IRF7, but not IRF3, is required for optimal type IFN production in MEFs 
due to the role of IRF7 in induction of IFNαs, which then mediate amplification via a 
positive feedback loop (Marie, Durbin et al. 1998, Sato, Suemori et al. 2000).  Hence in 
IRF3-/- mice, in which IRF7 could be up-regulated, IFNαs induced and the IRF7-mediated 
positive feedback loop engaged, disruption of the type I IFN response was minimal. This 
also implicates plasmacytoid dendritic cells (pDCs) in CHIKV induced type I IFN 
production, as pDCs can be directly stimulated by virus to produce IFNαs without prior 
IFNβ induction and signalling (Ning, Pagano et al. 2011). These results also suggest that 
an important activity of prophylactic IFNα treatment against CHIKV in WT mice is the up-
regulation of IRF7, rather than the induction of antiviral effectors.  Accordingly, prophylactic 
treatments were unable prevent mortality in IRF3/7-/- mice.  
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Given the pathology that was associated with increased IFNγ, observed in the 
IRF3/7-/- mice following CHIKV infection, it is perhaps not surprising that prophylactic IFNγ 
treatment also failed to protect mice against CHIKV.  Adoptive transfer of WT 
CD45+/CD11b+ cells did not promote survival in the IRF3/7-/- mice, an observation 
consistent with the findings of Schilte, Couderc et al. (2010) that non-haematopoietic cells 
are the major source of protective type I IFN during CHIKV infection.  In contrast to our 
findings, Schilte, Buckwalter et al. (2011) showed that adoptive transfer of WT 
haematopoietic cells into IRF3/7-/- mice was able to protect these mice from lethal CHIKV 
infection.  In the second study by Schilte, Buckwalter et al. (2011), the CHIKV strain 
CHIKV-21, derived from cerebrospinal fluid of a neonate with atypical central nervous 
system complications (Sourisseau, Schilte et al. 2007), was used and injected intra-
dermally.  This study also used bone marrow cells for adoptive transfer.  These differences 
in methodology from the study herein, which used sub-cutaneous injection of CHIKV strain 
LR_OPY2006 (derived from an adult with typical CHIKV disease; Parola, Lamballerie et al. 
2006), and adoptive transfer of spleen-derived cells may account for the differences in the 
findings. 
Treatment with an inactivated-CHIKV vaccine, however, was able to protect IRF3-/-, 
IRF7-/- and IRF3/7-/- mice against CHIKV disease and mortality, and induced high antibody 
and neutralising titres, indicating that antibody responses are not reliant on IRF3 and/or 
IRF7.  IRF3/7-/- mice produced higher IgG1 and less IgG2c than WT mice, indicative of a 
slight Th2 bias.  Type I IFNs promote Th1 responses (Bracci, La Sorsa et al. 2008, Farkas 
and Kemény 2011), and have also been shown to suppress Th2 responses in human 
CD4+ T cells (Huber, Ramos et al. 2010).   It follows that in the absence of detectable 
levels of type I IFNs in IRF3/7-/- mice, there may be a shift toward Th2 responses.  While 
WT mice display a predominantly Th1 response to CHIKV (Gardner, Anraku et al. 2010), 
the Th2-biased responses in vaccinated IRF3/7-/- mice were still capable of providing 
complete protection. 
 
Investigation of the adaptor molecules upstream of IRF3 and IRF7 showed that IPS-1 
was the most important for production of type I IFNs.  IPS-1-/- mice developed a more 
protracted viraemia and increased foot swelling.  This is consistent with the finding that 
IPS-1 is important for protection against CHIKV in non-haematopoietic cells (Schilte, 
Buckwalter et al. 2012), and that non-haematopoietic cells are the most critical to 
protective type I IFN responses during CHIKV infection (Schilte, Couderc et al. 2010).  The 
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importance of IPS-1 in CHIKV infection thus implicates the cytoplasmic RLRs, RIG-1 and 
MDA5, as having a major role in the detection of CHIKV.  Detection of alphavirus RNA by 
endosomal TLR3 in haematopoietic cells is well reported (Schulz, Diebold et al. 2005, 
Daffis, Suthar et al. 2009).While TLR3 is heavily expressed in haematopoietic cells, it is 
also expressed/inducible in endothelium, epithelium, fibroblasts and keratinocytes, which 
can all be infected by CHIKV (Schwartz and Albert 2010, Takeuchi and Akira 2010).  TLR3 
signals via TRIF (Takeuchi and Akira 2010), and consistent with the established role of 
TLR3 in detection of alphaviral RNA, CHIKV-infected TRIF mice displayed reduced serum 
type IFNs and increased foot swelling.  Similarly, Her, Teng et al. (2014) have since 
demonstrated increased CHIKV viral replication in TLR3-/- and TRIF-/- MEFs, and CHIKV 
infection of TLR3-/- mice resulted in increased viral titres and more severe inflammation. 
 
TLR7 also detects endosomal viral RNA (Takeuchi and Akira 2010) and is well 
known to recognise ssRNA viruses (Bauer, Pigisch et al. 2008, Blasius and Beutler 2010).  
MyD88 is the adaptor molecule employed by TLR7 for IFN signalling (Takeuchi and Akira 
2010), and MyD88 deficient mice have been seen to experience increased viral burden 
following CHIKV infection (Schilte, Couderc et al. 2010).  Although mice deficient in 
MyD88, did exhibit reduced type I IFN production, in this study viraemia and disease in 
MyD88-/- mice was largely unaltered compared to WT mice.  RRV infected MyD88-/- and 
TRL7-/- mice also display no significant difference in early (up to day 4) viraemia and tissue 
titres (Neighbours, Long et al. 2012).   However, RRV infection in these mice was shown 
to be lethal, possibly due to a germinal centre defect that results in production of low 
affinity antibodies with poor neutralisation capacity (Neighbours, Long et al. 2012).  
Importantly, the study herein was able to demonstrate the relative significance of the 
individual adaptor molecules involved in type I IFN responses to CHIKV.  RLR/IPS-1, 
TLR3/TRIF and TLR7/MyD88 signalling were all shown to be involved in type I IFN 
responses to CHIKV, with IPS-1 having the most significant role and TLR7/MyD88 
signalling relatively less important.  This is consistent with recent findings by Olagnier, 
Scholt et al. (2014) that the antiviral response to CHIKV is dependent on a functioning 
RIG-1/IPS-1/TBK1/IRF3 signalling pathway. 
 
In summary, the results presented herein demonstrate a critical role for IRF3 and 
IRF7 in the generation of effective type I IFN responses against CHIKV infection.  IRF7 
was shown to be critical for its role in priming and generation of the type I IFN positive 
feedback loop.  These studies also reiterate the central role of type I IFNs in protection 
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against CHIKV infection; the absence of type I IFN resulted in a severe disease that was 
reminiscent of DHF/DSS, involving haemorrhagic shock and excessive IFNγ and TNF 
production.  The results suggest that defective type I IFN responses may predispose to 
DHF/DSS and severe CHIKV disease.  Induction of type I IFNs and activation of IRF3 and 
IRF7 by CHIKV was shown to be predominantly via the RIG-1/MDA5/IPS-1 and 
TLR3/TRIF signalling pathways. However, the primary source of type I IFNs remains 
unclear and is the basis of the ensuing chapter.   
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3. Investigation of the source of type I interferons following CHIKV infection. 
3.1 Introduction 
The specific cells and tissues actively engaged in production of type I IFNs following 
CHIKV infection in vivo remain to be fully characterised.  During viral infection, 
haematopoietic cells engage both TLR and RLR mediated type I IFN production, while 
stromal cells such as fibroblasts, endothelium and epithelium, as well as dendritic cells and 
macrophages, generally rely on the RLR system (Akira, Uematsu et al. 2006, Kawai and 
Akira 2011).  Plasmacytoid DCs (pDCs; murine CD11c/B220), often referred to as 
professional type I IFN producing cells, are reported to be the major IFNα producers 
(Siegal, Kadowaki et al. 1999, Ning, Pagano et al. 2011) and produce high levels of IFNαs 
via the TLR7/MyD88 pathway, even in the absence of IFNAR signalling and amplification 
(Kato, Sato et al. 2005, Ning, Pagano et al. 2011).  However, the previous chapter found 
TLR7/MyD88 signalling to be least important for optimal type I IFN responses to CHIKV.  
Instead, IPS-1 was seen to have the greatest role in type I IFN responses to CHIKV, 
thereby implicating RLRs, and the (predominantly) stromal cells that engage RLR 
signalling, in CHIKV-induced type I IFN production. 
 
Various cell types have been implicated in type I IFN production during CHIKV 
infection.  Her, Malleret et al. (2010) found that human peripheral blood monocytes 
(PBMCs) were a major target of CHIKV during the acute phase of infection, and that 
infection of PBMCs resulted in high levels of IFNαs.  In contrast, Sourisseau et al. (2007) 
found that haematopoietic cell cultures, except monocyte-derived macrophages, were 
refractory to CHIKV infection, suggesting haematopoietic cells produce type I IFNs via 
paracrine signalling, rather than PRR signalling.  Additionally, Schilte, Couderc et al. 
(2010) found in vivo type I IFN production by haematopoietic cells was not vital for 
protection against CHIKV, with type I IFN being produced largely by IPS-1-mediated 
signalling in non-haematopoietic cells.  In a zebra fish larvae model of CHIKV infection, 
IPS-1 was again found to be the major IFN signalling pathway involved.  However, 
uninfected cells, namely neutrophils and hepatocytes were found to be the major 
producers of type I IFN (Palha, Guivel-Benhassine et al. 2013). 
 
 Identification of the cells producing type I IFN proteins in vivo can be difficult due to 
the low stability, short half-life and transient production of type I IFN mRNA and protein 
(McKenna, Vergilis et al. 2004). To address this issue, Kumagai, Takeuchi et al. (2007) 
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engineered mice to express enhanced green fluorescent protein (eGFP) under the control 
of the IFNα6 or IFNβ promoter. GFP is widely used as a fluorescent marker due to its 
structural stability, autocatalytic chromophore formation and low toxicity (Jackson, Craggs 
et al. 2006, Chudakov, Matz et al. 2010).  The transgenic mice were generated by 
replacing the entire IFNβ or IFNα6 open reading frame (ORF) with an eGFP ORF and 
neomycin-resistance gene cassette (Dr Y. Kumagai, personal communication)  (Kumagai, 
Takeuchi et al. 2007).  Thus, upon type I IFN stimulation, the transgenic mice should 
produce a stable, non-secreted, fluorescent protein that enables in situ identification of the 
cells that have type I IFN promoter activation (Kumagai, Takeuchi et al. 2007). 
 
 CHIKV infection is lethal in type I IFN deficient mice (see Chapter 2) (Couderc, 
Chrétien et al. 2008, Rudd, Wilson et al. 2012).  Thus, only mice that retained one WT 
allele (and therefore, the capacity to produce type I IFNs), in addition to the inserted eGFP 
transgene were suitable for analysing  type I IFN production in vivo, following CHIKV 
infection.  These mice were generated by mating heterozygous transgenic mice (herein 
referred to as IFNα6-GFP+/- and IFNβ-GFP+/- mice) with WT mice and genotyping the 
offspring.  Heterozygous offspring were infected with CHIKV as before (Gardner, Anraku et 
al. 2010), with the aim of identifying the tissues and cells producing type I IFNs in 
response to CHIKV infection. 
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3.2 Materials and Methods 
3.2.1 Cells 
Vero and C6/36 cell lines were maintained as described in section 2.2.2.   
3.2.1.1 Bone marrow-derived macrophages (BMMs) and DCs (BMDCs) 
BMMs and BMDCs were derived from bone marrow in the femur. Differentiated 
cells were cultured in DMEM containing L-glutamine (Gibco-Invitrogen) and supplemented 
with 25 mM HEPES (Sigma-Aldrich), 1% 2-ME (Gibco-Invitrogen), Pen-Strep antibiotic 
(Gibco-Invitrogen) and 10% (v/v) FCS (Gibco-Invitrogen).  Briefly, the femur was excised 
and the marrow was flushed from the bone with DMEM using a 5 ml syringe with 23 gauge 
needle.  Cells were suspended in 2 ml DMEM by gently passing through the syringe 
needle several times.  Cell suspensions were incubated with 3 ml ammonium-chloride-
potassium (ACK) buffer (Life Technologies) to lyse red blood cells.  After 3 min incubation 
at room temperature, 5 ml DMEM was added to the tube, the tube was centrifuged (200 g 
x 5 min), and the resulting cell pellet was resuspended in DMEM and washed (200 g x 5 
min) three times.  Cells were seeded (~106 cells/well) in a 24 well plate (Nunc) in 300 µl 
DMEM supplemented with 10% FCS and incubated at 37˚C in a 5% CO2 atmosphere for 4 
hours.  Cell monolayers were washed with ~1 ml PBS per well to remove non-adherent 
cells and 300 µl DMEM supplemented with 10% FCS was added to each well.  For 
generation of BMMs, cells were cultured in 30% L929-cell conditioned media (LCCM) cell 
culture media.  DMEM (30% LCCM) supplemented with 10 ng/ml GM-CSF and 103 IU/ml 
IL-4 (added every 2-3 days) was used for generation of BMDCs.  
 
3.2.1.2 Resident peritoneal macrophages (RPMs)  
 RPMs were cultured in RPMI1640 media containing L-glutamine (Gibco-Invitrogen) 
and supplemented with 25 mM HEPES (Sigma-Aldrich), 1% 2-ME (Gibco-Invitrogen), Pen-
Strep antibiotic (Gibco-Invitrogen) and 5% (v/v) FCS (Gibco-Invitrogen).  Briefly, RPMs 
obtained by lavage of the peritoneal cavity using sterile, ice cold PBS, and were 
transferred into a 10 ml tube.  Cells were centrifuged (200 g x 5 min) at 4˚C, then 
resuspended and washed (200 g x 5 min, 4˚C), before being counted a nd seeded (1-2.5 x 
106 cells/well) into a 24 well plate (Nunc) in 300 µl RPMI1640 media supplemented with 
5% FCS and incubated at 37˚C in a 5% CO 2 atmosphere for 3 hours prior to treatment.  
Non-adherent cells were washed from the plate using sterile PBS prior to treatment (only 
macrophages are adhered). 
 
 75 
3.2.1.3 Splenocytes 
Splenocytes were cultured in phenol red-free RPMI1640 media containing L-
glutamine (Gibco-Invitrogen) and supplemented with 25 mM HEPES, 1% 2-ME, Pen-Strep 
antibiotic and 10% (v/v) FCS. Whole spleens were excised and placed in ~ 1 ml cold PBS 
supplemented with 2% FCS in a 1.5 ml plastic tube.  The contents of the tube were passed 
through a sterile, nylon mesh using the plunger of a 5 ml syringe, onto a sterile petrii dish 
on ice.  The resulting cell suspension was, transferred to a 10 ml tube and centrifuged 
(200 g x 5 min, 4˚C).  Cells were resuspended in 3 ml ACK buffer and incubated for 3 mins 
before the addition of 5 ml phenol red-free RPMI1640 supplemented with 5% FCS. Cells 
were then washed three times (200 g x 5 min, 4˚C) using phenol red -free RPMI1640 
supplemented with 5% FCS, counted and seeded (5 x 106 cells/well) in a 6 well plate in 1 
ml phenol red-free RPMI1640 cell culture media. 
 
3.2.2 Transfections 
 Ex vivo BMM cultures (see section 3.2.1.1) were transfected with pEGFP CI 
mammalian expression plasmid (Clontech Laboratories Inc., CA, USA) using 
GeneJammer transfection reagent, as per the manufacturer’s instructions (Stratagene, La 
Jolla, USA).  A transfection mixture was prepared by incubating 3% (v/v) transfection 
agent in serum-free RPMI1640 supplemented with 10%v/v Penstrep antibiotic) for 5 min at 
room temperature, before adding 2 µg pEGFP CI DNA construct, and incubating for a 
further 30 min.  Cell culture medium was aspirated from BMM monolayers and replaced 
with 2 ml/well fresh, serum-free RPMI1640.  A 100 µl volume of the prepared transfection 
mixture containing the pEGFP CI construct was then added to each well.  Control wells 
received transfection reagent only (i.e. no eGFP construct).  Cells and transfection 
mixtures were incubated at 37˚C in a 5% CO 2 humidified atmosphere.  After 5 hrs, the 
transfection mix was replaced with RPMI1640 media supplemented with 5% FCS, and 
cells incubated a further 24 hours prior to use. 
3.2.3  LPS, IFN and SFV stimulation of type I IFNs 
Ex vivo splenocyte cultures (see section 3.2.1.3)  were treated with either 100 ng/ml 
lipopolysaccharide (LPS; E. coli 055B5) (Sigma), or 10 IU/ml IFNαA (Chemicon 
International, #GF023) in a final volume of 2 ml cell culture media per well.  Ex vivo 
splenocyte, BMM, BMDC and RPM cultures (see sections 3.2.1.1-3.2.1.3) were treated 
with 10 IU/ml IFNαA (Chemicon International, #GF023) or 10 IU/ml IFNγ (Chemicon 
International, #IF005) in a final volume of 2 ml cell culture media per well.  Cells for IFN 
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stimulation by SFV were incubated with 400 CCID50/ml SFV in 1 ml RPMI1640 media.  
After 1 hour, media and virus were aspirated and replaced with 2 ml fresh RPMI1640 
supplemented with 5% FCS.  Cells were monitored for eGFP expression using an EVOS® 
FL Cell Imaging System (Life Technologies).  Prior to imaging, cell culture medium was 
aspirated and replaced with 1 ml PBS. 
 
3.2.4 Virus 
The CHIKV isolate used (LR2006-OPY1) and preparation of viral stocks was the 
same as that described in section 2.2.5. 
 
3.2.5 Mice 
IFNα6-GFP+/- and IFNβ-GFP+/- transgenic mice were provided by Prof.  S. Akira of 
Osaka University (Kumagai, Takeuchi et al. 2007).  C57BL/6J mice (Animal Resource 
Centre, Canning Vale, Western Australia) were used as aged matched controls. 
Transgenic mice were genotyped by PCR using DNA isolated from tail tip.  Mice at ≥ 21 
days were anaesthetised using isoflurane (Attane™ Isoflurane, JD Medical Dist. Co. Inc., 
Phoenix, USA).  1 mm of the tail tip was amputated using a sterile scalpel blade and 
placed in individual 1 ml tubes on ice for later DNA isolation (section 3.2.10). 
Mice were housed in individual ventilated cages and allowed to feed ad libitum. 
Experiments were conducted using female mice aged 10-18 weeks.  All animal 
experiments were approved by the QIMR Animal Ethics Committee and were conducted in 
accordance with the Australian code for the care and use of animals for scientific 
purposes. 
 
3.2.6 Mouse infection, inoculation and monitoring 
Mice were infected or mock infected with RPMI and monitored as per section 2.2.6. 
Naive mice were not injected.  Lipopolysaccharide (LPS) (Sigma-Aldrich) was 
administered via intraperitoneal injection at a dose of 100 µg/ml in a 200 µl volume of 
sterile PBS.  At 3 hours post injection, spleens were removed and processed as per 
section 3.2.7. 
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3.2.7 Blood and tissue preparation 
Blood and tissues collected for analysis were prepared and stored as described in 
section 2.2.4. 
 
3.2.8 Viraemia and foot measurements 
Serum was assayed for viral titres as per section 2.2.8.  Foot swelling was 
measured as described in 2.2.10.  
 
3.2.9  RNA analysis 
Extraction of RNA from tissue samples, cDNA synthesis and quantitative real time 
PCR (RT-PCR) was carried as described in sections 2.2.16-18.  Primers used were 
(5’3’), RPL13A gaggtcgggtggaagtacca (forward), tgcatcttggccttttcctt  (reverse); IFNβ-
eGFP cctacggcgtgcagtgcttcagc (forward), ccttcagctcgatgcggttcac (reverse); IFNβ 
ctccagctccaagaaaggacg (forward), gcatcttctccgtcatctcca (reverse);  IFNα6 
tggcaagactgagtgaggacg (forward) atattgctgcagcgtcttggc (reverse). 
 
3.2.10 DNA isolation 
A prepGemTM Tissue DNA isolation kit (Zygem Inc., Hamilton, NZ) was used to 
isolate DNA from mouse tail tips (section 3.2.5) according to the manufacturer’s 
instructions.  Scissors, decontaminated with 10% bleach and rinsed with ethanol between 
samples, were used to macerate each tail tip contained in a 200 µl PCR tube.  prepGemTM 
enzyme, kit lysis buffer and DNA-free water were added to each sample and incubated 
(75˚C, 15 min; 95˚C for 5 min). Samples were centrifuged briefly, the supernatant 
transferred to a fresh tube and stored at 4˚C.  The quality and quantity of the extracted 
DNA was assessed using a NanoDrop 2000 (ThermoFisher Scientific).  A260/280 ratios 
were consistently above 1.8. 
 
3.2.11 Genotyping PCR 
3.2.11.1 Primers 
 Primer sequences were obtained from Dr Y. Kumagai of Osaka University and 
manufactured by GeneWorks (GeneWorks Pty Ltd., Hindmarsh, Australia). Primers 
specific for p107 were used as a positive control.  The primers were: (5’3’) p107 
gtgtatggcctgtcctagtc (forward), gcgacactaatccgagaacag (reverse); IFNα6 
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aggcaactcgaagaacccaatttgagg (forward), cagatgagtcctttgatgtgaagaggg (reverse); IFNβ 
cttcatttctagagtttccgactctgg (forward), gcttatagttgatggagagggctgtgg (reverse); eGFP 
tttacgtcgccgtccagctcg (reverse, for use with either IFNβ or IFNα6 forward primers, Figure 
3.1). 
 
The forward primer for IFNβ was redesigned.  The IFNβ coding sequence was 
obtained using the National Centre for Biotechnology Information (NCBI) Basic Local 
Alignment Tool (BLAST) database.  Oligomers of 24-27 nucleotide base pairs with at least 
50% G/C nucleotide content were selected as potential primers.  The following sequence 
exhibited the most favourable properties and was sent for manufacture (Geneworks Pty. 
Ltd., SA): (5’3’) IFNβ cactcacaacccttcccttcctgg (forward). 
 
 
 
Figure 3.1.  Schematic diagram of primer design and pairing for detection of 
transgenic and/or WT alleles.  For each sample, two primer pairs were used to probe for 
DNA corresponding to the WT allele and the transgenic eGFP allele. (R) = reverse primer, 
(F) = forward primer. 
3.2.11.2 PCR reaction mixture and cycling conditions 
Isolated DNA was amplified by PCR using a protocol kindly provided by Dr Y. 
Kumagai of Osaka University. The reaction was performed in a 50 µl volume containing 5 
µl DNA (50-100 ng/µl), 2 mM each of dATP, dCTP, dGTP and dTTP, 10 µM of each 
primer, 1x Mg2+-free DyNAzyme™ buffer (Finnzymes Oy, Vantaa, Finland), 1 U 
DyNAzyme™ II DNA Polymerase (Finnzymes) 2 mM MgCl2 and deionised water to 50 µl 
final volume.  Cycling conditions were also modified so that the annealing temperatures 
were better matched to the melt temperature of the redesigned IFNβ primer.  Touchdowns 
were introduced to cover a range of annealing temperatures.  The reaction mixture was 
subjected to the temperature cycling conditions in Table 3.1. 1x Orange G loading dye was 
added to the PCR products, which were separated on a 1% agarose gel containing 0.2% 
ethidium bromide and visualised by UV transillumination. 
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Table 3.1 Cycling conditions for genotype of IFNα6-GFP+/- and IFNβ-GFP+/- mice 
 IFNα6-GFP+/- IFNβ-GFP+/-  
Initial Denaturation 94˚C; 2min 94˚C; 2min x1 
Denaturation 94˚C; 30sec 94˚C; 30sec  
Annealing 61˚C; 1 min 62˚C; 1 min (-0.1˚C/cycle)   x35 
Extension 74˚C; 1 min 74˚C; 1 min  
Final Extension 72˚C; 10 min 72˚C; 10 min x1 
  
3.2.12 Histology 
All issues excised for histology were fixed in 10% neutral buffered formalin for 48-72 
hours to kill virus, in accordance with PC3 regulations.  Feet were decalcified in 15 % 
EDTA/0.1% PBS over 14 days at room temperature.   
 
3.2.12.1 Fluorescence imaging 
Tissues for fluorescence imaging were rehydrated with 10-20% sucrose-PBS for 24 
hours before being frozen at -80°C in optimal cutting temperature (OCT) cryoembedding 
media (Sakura Finetek,Tokyo, Japan) for cryosectioning. 7 µm frozen sections were 
affixed to Superfrost Plus adhesive slides (Menzel-Glaser GmBH, Braunschweig, 
Germany) and air dried overnight.  Sections were permeabilised in 0.05% v/v Triton X100 
(Life Technologies) in PBS for 2 mins, then washed (2 x 5 min) in 0.025% v/v Tween 20 in 
PBS (PBST). Slides were blocked with Background Sniper (Biocare Medical, CA, USA) 
supplemented with 1% BSA for 30 min.  Slides were stained with rabbit anti-GFP antibody 
(Abcam, ab290 1 µg/ml or MBL JM-3999-100 50 µg/ml) in Background Sniper (Biocare 
Medical) supplemented with 1% BSA for 1 hour.  Sections were washed in PBS (3 x 10 
min) then incubated with Alexa Fluor® 488 goat anti-rabbit antibody (ab150077, Abcam) 
diluted 1:300 in PBS for 30 min, in the dark.  Sections were washed (3 x 10 min) in PBST, 
then rinsed in PBS before being incubated with 4', 6-diamidino-2-phenylindole (DAPI) 
nuclear counterstain diluted 1: 75 000 in PBS for 10 min.  Sections were washed (3 x 5 
min) in PBS and mounted with ProLong Gold® Antifade mounting media (Life 
Technologies).  Slides were visualised on an Aperio ScanScope FL (Leica Biosystems), 
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and fluorescence was quantitated using ImageScope Positive Pixel Count FL v1 Algorithm 
software (Aperio). 
 
3.2.12.2 Immunohistochemistry 
Tissues for IHC were paraffin embedded and cut to 4 µm sections and affixed to 
Superfrost Plus adhesive slides (Menzel-Glaser GmBH) and air dried overnight.  Paraffin 
sections were dewaxed in xylene and then rehydrated through descending graded alcohol 
to water.  Sections were incubated in Biocare Medical Diva antigen retrieval buffer for 1 
hour at 37˚ C, washed (3 x 5 min) in water, treated with 0.2% pepsin in 0.1 M HCL for 10 
min at 37˚C, then washed in water (2 x 5 min).  Tissues were permeabilised using 
proteinase K in 0.05 M triphosphate buffered solution (TBS)/calcium chloride pH 8 buffer 
for 10 min, and then washed in water.  Sections were blocked with Background Sniper 
(Biocare Medical) then stained with rabbit anti-GFP antibody (Abcam ab290 10 µg/ml, or 
MBL JM-3999-100 2.5 µg/ml) in Background Sniper (Biocare Medical) supplemented with 
1% BSA for 60 min. Slides were probed with MACH1 mouse probe, then MACH2 anti-
rabbit alkaline phosphatase (Biocare Medical).  Signals were developed in Warp Red ® 
chromogen stain (Biocare Medical).  Sections were counterstained in haematoxylin, and 
mounted using Vectasheild® Hard Set Mounting Media (Vector Labs, CA, USA). 
3.2.13 Western Blot 
Excised tissues were placed in a 2 ml reinforced microcentrifuge tubes that 
contained 4 x 2.8 mm ceramic beads (MoBio Laboratories Inc., Carlsbad, USA) and 1 ml 
radioimmunoprecipitation assay (RIPA) buffer with Complete Protease Inhibitors Cocktail 
(Roche) on dry ice, then stored at -80˚C.  Thawed tissue samples were homogenised (3 x 
30 s, 6800 rpm) using a Precellys 24 Tissue Homogeniser (Bertin Technologies, France).  
Protein concentrations of the homogenates were estimated using a bicinchronic acid 
(BCA) protein assay kit (Pierce, Rockford, USA) according to the manufacturer’s 
instructions.  SDS-PAGE sample buffer was added to the samples, which were then 
denatured by heating (98˚C, 5 min), then separated by electrophoresis on a 12% SDS -
PAGE pre-cast gel (Mini-PROTEAN TGX, BioRad, Hercules, USA).  Electrophoresed 
proteins were transferred (1 hour, 100 volts) at 4˚C onto a nitrocellulose membrane 
(Hybond-C Extra, GE Healthcare, Rydalmere, Australia).  Membranes were blocked for 1 
hour at room temperature using bovine lacto transfer technique optimizer (BLOTTO) (1x 
PBS, 0.1% Tween-20 and 5% skim milk powder) on a rocking platform.  Blocked 
membranes were washed once in 0.1% PBST then incubated with 2 µg/ml purified mouse 
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anti-GFP primary antibody (Invitrogen) in 10 ml BLOTTO overnight at 4˚C on a rocking 
platform.  Membranes were then washed 5 x 10 min in PBST and incubated for 1 hour at 
room temperature on a rocking platform with 0.25 µg/ml HRP-conjugated, pre-adsorbed 
rabbit anti-mouse secondary antibody (Invitrogen)  in 10 ml BLOTTO.  Membranes were 
washed 5 x 10 min in PBST, and HRP detected using Western Lightning 
Chemiluminesence Substrate (Perkin Elmer, Waltham, USA) exposure to x-ray film 
(Fujifilm, Tokyo, Japan) and/or on an ImageQuant LAS 500 scanner (GE Healthcare).  
 
3.2.14 Statistical analysis 
Analyses were performed using IBM SPSS Statistics (version 19).  The t test was 
used if the difference in the variances was <4, skewness was > -2, and kurtosis was < 2.  
Where the data was non-parametric and difference in variances was < 4, the Mann 
Whitney U test was used; if > 4 the Kolmogorov-Smirnov test was used.  
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3.3 Results 
3.3.1  Establishment of an accurate genotyping reaction for identification of IFNα6-GFP+/- 
and IFNβ-GFP+/- mice. 
 
IFNα6-GFP+/- and IFNβ-GFP+/- mice (Kumagai, Takeuchi et al. 2007) were a kind 
gift from Prof. S. Akira (Osaka University).  To generate sufficient mice for experimentation 
these animals were mated with WT mice, with half the offspring expected to be 
heterozygous and therefore able to produce both type I IFNs and eGFP.  All progeny were 
thus genotyped to identify heterozygotes for experimental use. 
 
A lysis buffer protocol provided by Dr Y. Kumagai (Osaka University), a QIAmp 
DNA Mini Kit (QIAGEN) and a QIAmp Blood Mini Kit were used to extract genomic DNA 
from tail tip and/or blood.  However, DNA yields were of low quality and yield (data not 
shown).  Using a prepGemTM Tissue DNA isolation kit (Zygem Inc.) consistently provided 
DNA of adequate yield and quality for use in subsequent RT-PCR reactions (data not 
shown).  The PCR products from the WT IFNα6 and IFNβ alleles were expected to be of a 
similar size (~950 bp) to the transgenic IFNα6-GFP and IFNβ-GFP alleles, respectively, 
and therefore could not be distinguished in the same reaction.  Hence, separate reactions 
for the WT and the transgenic alleles were conducted for each mouse sample.  Primer 
sequences provided by Dr Y Kumagai (Osaka University) were unsuccessful in the 
detection of the IFNβ-GFP allele (data not shown) and were redesigned to have a higher 
annealing temperature.  Using the redesigned primer sets for the WT IFNβ and IFNβ-GFP 
alleles, a PCR product of ≈ 900 bp was produced ( Figure 3.2B).  The WT IFNα6 and 
IFNα6-GFP primer sets both produced a PCR product of ≈ 1000 bp ( Figure 3.2A).  The 
p107 and WT IFN primer sets served as positive controls for DNA isolation and the PCR 
reaction. 
 
Samples in which a PCR product was detected for both a WT allele and a 
transgenic allele were indicative that the mouse was heterozygous (Figure 3.2A, Mouse 1 
& 4; Figure 3.2B, Mouse 1 & 5).  Samples in which no IFN-GFP allele could be detected 
indicated that the mouse was homozygous for the WT allele.  Mice identified as 
heterozygous (IFNα6-GFP+/- and IFNβ-GFP+/- mice) were used in subsequent 
experiments. 
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Figure 3.2  Genotyping of F1 offspring from mating of IFNα6-GFP+/- or IFNβ-GFP+/- 
mice with WT mice.  Genomic DNA isolated from mouse tail tips was amplified by RT-
PCR using primers specific for either A)  WT IFNα6 (α6) and the IFNα6-GFP transgene 
(∆α6) or, B)  IFNβ (β) and the IFNβ-GFP transgene (∆β), in individual reactions.  A mouse 
was deemed to be heterozygous (GFP+/-) when both the WT IFN and GFP PCR products 
were detected.  Mice were considered homozygous for WT IFN (GFP-/-) when only WT 
IFN and p107 PCR products were detected.  Primers for the p107 gene were used as an 
additional control for each sample. 
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3.3.2 CHIKV viral burden and pathogenesis was altered in IFNα6-GFP+/- and IFNβ-GFP+/- 
transgenic mice 
 
To ascertain whether loss of a type I IFN allele by replacement with the eGFP 
reporter would affect CHIKV disease in mice, IFNα6-GFP+/- mice, IFNβ-GFP+/- mice and 
WT mice were infected with CHIKV.  Viraemia, type I IFN production and foot swelling in 
transgenic mice were measured and compared with WT controls.   
 
Viraemia in all mice peaked at similar levels on day 2, and was no longer detectable 
by day 6 post infection.  However, viraemia in IFNβ-GFP+/- mice at day 1 post infection 
was ~1.5 log higher than WT and IFNα6-GFP+/- mice.  At day 3 post infection, viraemia in 
IFNα6-GFP+/- mice was ~1 log higher compared to WT mice (Figure 3.3A).  Type I IFN 
production peaked in all mice at day 2 post infection, and was reduced in both IFNα6-
GFP+/- and IFNβ-GFP+/- mice at day 3 post infection compared to WT mice (Figure 3.3B).  
Foot swelling in IFNα6-GFP+/- and IFNβ-GFP+/- mice was more severe at days 3, 4 and 5 
post infection compared to WT mice, with a greater increase in swelling observed in IFNβ-
GFP+/- mice at days 3 and 5 (Figure 3.3C).  Foot swelling in all mice peaked at comparable 
levels on day 6 post infection and resolved by day 11/12 post infection. 
 
The results here indicate IFNα6-GFP+/- and IFNβ-GFP+/- mice, have a diminished 
type I IFN response, albeit to a small extent, following infection with CHIKV.  
Consequently, viral titres and foot swelling in these mice was also slightly increased.  
However, the overall disease phenotype in these mice was generally comparable to that 
seen in WT mice (Gardner, Anraku et al. 2010) suggesting these mice would be suitable 
for investigating the source(s) of type I IFN production during CHIKV infection.   
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Figure 3.3  CHIKV infection in IFNα6-GFP+/- and IFNβ-GFP+/- mice compared to WT 
mice.  Mice were infected with CHIKV via s.c. injection of the feet and serum was 
collected at the indicated time points via tail vein bleed.  Measurements of the metatarsal 
region were taken before and after infection.  A) Virus titres in the serum of IFNα6-GFP+/- 
and IFNβ-GFP+/- mice (n=7 per group) compared to WT mice (n=17-28).  B)  Serum type I 
IFN levels in IFNα6-GFP+/-, IFNβ-GFP+/- and WT mice (n=4 per group).  C)  Foot swelling 
in IFNα6-GFP+/- and IFNβ-GFP+/- mice (n=7 per group) compared to WT mice (n=6-28).  
Data presented is the mean percentage increase from pre-infection measurements of the 
metatarsal region (* p<0.05, ** p<0.01; all statistics obtained by Mann-Whitney U). 
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3.3.3 eGFP could not be detected in IFNα6-GFP+/- and IFNβ-GFP+/- transgenic mice following 
CHIKV infection mice by histological analysis 
 IFNα6-GFP+/- and IFNβ-GFP+/- mice were infected with CHIKV and their tissues excised 
for examination by histology at day 2 post infection (peak serum type I IFN levels, Chapter 2).  
Fixation of all tissues was required to inactivate CHIKV, a PC3 pathogen, prior to histological 
processing in PC2 facilities. 
Formalin fixation stabilises GFP within tissue, but is also known to enhance 
autofluorescence (Knight and Billinton 2001) and disrupt GFP fluorescence (Swenson, Price et 
al. 2007).  Glycine treatment was used to quench aldehydes that produce autofluorescence.  
However, fixed, glycine treated cryosections of the brain, lymph node, spleen, liver, kidney, 
muscle, feet, gut and lung of IFNα6-GFP+/- and IFNβ-GFP+/- mice at day 2 post infection did 
not produce a fluorescence signal significantly different from the same tissues obtained from 
uninfected WT mice or uninfected IFNα6-GFP+/- and IFNβ-GFP+/- mice using an Aperio 
Scanscope FL immunofluorescent slide scanner (Leica Biosystems) (data not shown).   
An anti-eGFP antibody (detected with an AlexaFluor-labelled secondary antibody) was 
used in formalin-fixed frozen sections to detect eGFP protein, as fluorescence may have been 
disrupted during fixation/processing (Swenson, Price et al. 2007).  Again, no eGFP signal was 
detected above autofluorescence (i) in tissues from WT mice (Figure 3.4A and B), (ii) in 
tissues from mock-infected transgenic mice, or (iii) in tissues from naïve transgenic mice (data 
not shown).  The same results were obtained using an anti-eGFP antibody from a different 
supplier (rabbit anti-GFP, from Abcam rather than MBL), and using both antibodies in paraffin 
sections (data not shown).   
Ethanol and acetone also inactivate viruses and fix tissues, without enhancing 
autofluorescence (Ghendon and Samoilova 1968, Knight and Billinton 2001, Sharma, Gupta et 
al. 2012).  Ethanol, or ethanol and acetone combined, were tested as alternatives to formalin 
fixation.  Using these alternative fixation methods in conjunction with anti-eGFP antibody 
staining (using either anti-body), no eGFP signal above background signal in WT and naïve 
transgenic mouse tissues was detected (data not shown).   
The results described here indicate either a lack of sensitivity in these well established 
assays used for detection of eGFP signals, or a lack of eGFP production by the IFNα6-GFP+/- 
and IFNβ-GFP+/- mice. 
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Figure 3.4  Fluorescence in fixed frozen mouse tissue sections taken from IFNα6-
GFP+/- and IFNβ-GFP+/- transgenic, and WT mice following CHIKV infection.  Mice 
were infected and tissues excised at day 2 post infection. A)  Fluorescence micrographs of 
brain, lymph node and spleen in IFNα6-GFP+/- and IFNβ-GFP+/- mice compared to WT 
mice.  Images presented are representative of each group (n=3).  B)  Ratio of GFP-
positive pixels to DAPI positive pixels per mm2 of mouse brain, lymph node, spleen and 
kidney tissue. 
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3.3.4 eGFP could not be detected by western blot analysis of IFNα6-GFP+/- and IFNβ-
GFP+/- mouse tissues following CHIKV infection. 
Autofluorescence/background signal appeared to impede detection of eGFP 
fluorescence and fluorescent-labelled antibodies (section 3.3.3).   Western blot analysis 
was therefore undertaken as an alternative method to detect eGFP protein expression in 
individual tissues taken from CHIKV-infected IFNα6-GFP+/- and IFNβ-GFP+/- mice.   
Protein was isolated from brain, lymph node, spleen, liver, kidney, muscle, feet, gut 
and lung of CHIKV-infected IFNα6-GFP+/-, IFNβ-GFP+/- and WT mice for analysis by 
western blot using an anti-eGFP antibody.  Serum type I IFNs peak at day 2 in WT mice 
(Chapter2)  (Rudd, Wilson et al. 2012).  In the experiments here, tissues were excised at 
18 hours post infection with the rationale that tissue type I IFN levels are likely to peak 
before serum type I IFN levels, which reflect spill-over of cytokines from the tissues into 
the bloodstream.  Despite maximal exposure of antibody stained blots, no distinct eGFP 
signal was detected in any tissues (Figure 3.5). 
 
Figure 3.5  Western blot of eGFP protein expression in IFNα6-GFP+/- mice compared 
to WT.  Western blot of protein isolated from liver and feet of CHIKV-infected IFNα6-
GFP+/-, CHIKV infected WT and mock infected IFNα6-GFP+/- mouse tissues at 18 hours 
post infection. CHIKV infected IFNα6-GFP+/- tissue (+); mock infected IFNα6-GFP+/- tissue 
(-); CHIKV infected WT tissue (WT); major cross reactive bands (x); marker (M); (C) 
positive control. 
 
The absence of a positive eGFP signal at 18 hours post CHIKV infection, using a 
highly specific and sensitive assay, again suggested low level, or absent, eGFP protein 
production in the IFNα6-GFP+/- and IFNβ-GFP+/- mice. 
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3.3.5 eGFP could not be detected in cultured cells derived from IFNα6-GFP+/- and IFNβ-
GFP+/- transgenic mice following type IFN stimulation. 
Production of eGFP by IFNα6-GFP+/- and IFNβ-GFP+/- mice in response to CHIKV 
could not be detected in tissues by fluorescence microscopy, IHC or western blot (see 
sections 3.3.3 & 3.3.4), suggesting little, or no production of eGFP.  To eliminate 
background signal present in tissues, and establish whether cells isolated from IFNα6-
GFP+/- and IFNβ-GFP+/- mice could produce eGFP, ex vivo cell cultures were stimulated 
with a variety of agonists, and eGFP production monitored over time. 
 
Lipopolysaccharide (LPS) is known to activate type I IFN responses via TLR2/4, 
and rapidly induces type I IFN production in the spleen (Yamamoto, Sato et al. 2002, 
Kawai and Akira 2010).  In erythrocyte-purified splenocytes derived from IFNα6-GFP+/- and 
IFNβ-GFP+/- mice 3 hours post i.v. injection of LPS, no positive signal for eGFP was 
detected by fluorescence microscopy using an EVOS® FL Cell Imaging System (Life 
Technologies) (data not shown).  Type I IFNs themselves induce type I IFN production 
(Levy, Marié et al. 2011).  In ex vivo splenocyte cultures treated with LPS or recombinant 
IFNαA for 1, 3, 6 or 9 hours, no eGFP signal was detected by fluorescence microscopy 
(data not shown).  SFV, an alphavirus closely related to CHIKV, also induces type IFNs 
(Breakwell, Dosenovic et al. 2007).  However, SFV is a PC2 pathogen and could thus be 
used to examine virus-induced type I IFN production in a PC2 laboratory, with no 
requirement for fixation.  No eGFP signal was detected over an 18 hour time period in ex 
vivo splenocyte cultures following infection with SFV.  Similarly, treatment of ex vivo RPM, 
BMM, or BMDC cultures with IFNαA, IFNγ or SFV failed to induce an eGFP signal 
detectable by fluorescent microscopy at 1, 3, 9 or 18 hours post infection/treatment (data 
not shown).  In each experiment, eGFP transfected BMMs were used as positive controls, 
with eGFP fluorescence visible from 9 hours post transfection (data not shown). 
 
Together with the data described in sections 3.3.3 and 3.3.4, these results indicate 
that IFNα6-GFP+/- and IFNβ-GFP+/- mice were incapable of producing detectable levels of 
eGFP protein in response to type I IFN-inducing stimuli. 
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3.3.6  IFNβ mRNA expression is reduced in IFNβ-GFP+/- mice compared to IFNβ mRNA 
expression in WT mice following CHIKV infection. 
 Investigation of eGFP expression by several methods failed to identify the presence 
of eGFP protein in IFNα6-GFP+/- and IFNβ-GFP+/- mouse tissues.  The ability of these 
mice to produce eGFP mRNA was therefore analysed.  Primers targeting mRNA from the 
eGFP allele and primers targeting the IFNβ allele were used in quantitative real time RT-
PCR (RT-PCR) analysis of total RNA isolated from WT and IFNβ-GFP+/- mouse feet at day 
2 post infection.   
 
 mRNA from the IFNβ allele and the eGFP allele were successfully amplified, 
indicating that the transgenic eGFP allele (and the IFNβ allele) were transcriptionally active 
and inducible in IFNβ-GFP+/- mice following CHIKV infection (Figure 3.6A).  Both alleles 
are driven from the same promoter, and as expected, both the IFNβ allele and the eGFP 
allele in IFNβ-GFP+/- mice were induced to a similar degree at day 2 post infection (Figure 
3.6A). 
 
 To determine whether IFNβ mRNA expression levels were different in IFNβ-GFP+/- 
mice compared to WT mice, qRT PCR for IFNβ mRNA in feet from IFNβ-GFP+/- and WT 
mice taken at day 2 post infection was undertaken.  IFNβ mRNA levels in IFNβ-GFP+/- 
mice were shown to be ≈ 6.5 fold lower than IFNβ mRNA levels in WT mice (Figure 3.6B). 
 
 Taken together these results indicate that, despite similar induction of IFNβ and 
eGFP in IFNβ-GFP+/- mice, IFNβ mRNA levels were considerably reduced in IFNβ-GFP+/- 
mice compared with WT mice.  It is possible that the IFNβ promoter was less activated in 
IFNβ-GFP+/- mice than in WT mice, with less than expected mRNA levels transcribed from 
the IFNβ and eGFP alleles as a consequence.  A scarcity of mRNA available for 
translation likely contributed to the absence of detectable levels of eGFP protein in these 
mice.  The reduced IFNβ responses in IFNβ-GFP+/- mice also indicates that this transgenic 
mouse model behaves differently with respect to type I IFN production compared with WT 
mice following CHIK infection and was not appropriate for investigation of CHIKV-induced 
type I IFN expression. 
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Figure 3.6  IFNβ and eGFP mRNA expression by RT-PCR.  Total RNA was isolated 
from the feet of mice at day 2 post infection and analysed by RT-PCR. A)  IFNβ and eGFP 
mRNA induction in the feet of IFNβ-GFP+/- mice (n=3).  Values are normalised to RPL13a 
mRNA levels and are presented relative to mock-infected controls (n=3).  B)  IFNβ mRNA 
expression in the feet of IFNβ-GFP+/- versus WT mice, compared to mock infected animals 
of the respective genotype.  Values presented are normalised to RPL13a mRNA levels 
(n=3 per group).  
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3.3.7 Analysis of IFNα6 and IFNβ mRNA induction in WT mouse tissues following CHIKV 
infection  
 
IFNβ-GFP+/- and IFNα6-GFP+/- mice were found to be unsuitable for analysing IFN 
production following CHIKV infection.  Visualisation of individual cells producing type I IFN 
via eGFP detection could therefore not be realised using this system.  However, using 
samples from CHIKV-infected WT mice that have intact type I IFN responses, RT-PCR 
could be used to investigate the levels of IFNα6 and IFNβ mRNA induction. 
 
IFNα6 and IFNβ mRNA induction was investigated in different tissues from WT 
mice at day 2 post CHIKV infection.  IFNβ and IFNα6 mRNA induction was greatest in 
feet, the site of virus inoculation and arthritic disease, with induction >10 fold higher than in 
the other tissues analysed (Figure 3.7A).  IFNβ mRNA was also substantially induced in 
spleen and lymph nodes, with IFNβ mRNA induction significantly higher than IFNα6 mRNA 
induction in these lymphoid organs (Figure 3.7A). 
 
 Simple linear regression analysis demonstrated a correlation with a high R2 value 
between IFNα6 and IFNβ induction in tissues and the viral tissue titres (see Chapter 2) at 
day 2 post infection (Figure 3.7B); kidney and gut virus titres were not analysed.  The 
relationship between mRNA induction and viral titres was supported by Spearman’s rank 
coefficient analysis (Corder and Foreman 2011) (Figure 3.7C).  The only tissue in which 
mRNA expression did not correspond to viral titres was the brain, in which induction of 
both IFNβ and IFNα6 mRNA was similar to induction in the liver, despite a ~2 log lower 
tissue viraemia. 
 This analysis suggests that type I IFN induction (at least on day 2) correlates with 
virus levels, irrespective of the tissue that is infected, with the exception of brain (see 
discussion), and that type I induction at day 2 post infection is heavily determined by local 
infection, rather than systemic. 
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Figure 3.7.  IFNβ and IFNα6 mRNA induction in WT mice at day 2 post infection 
CHIKV infection.  A)  Total RNA was isolated from the feet of mice at day 2 post infection 
and analysed by RT-PCR using primers targeting IFNβ and IFNα6.  Values are normalised 
to RPL13a mRNA levels and are relative to mock infected controls (n=3 mice per group; * 
= p < 0.05; t-test).  B)  Simple linear regression analysis of IFNβ and IFNα6 induction 
versus viral titres in the tissues at day 2 post infection.  C) Analysis of the relationship 
between IFNβ and IFNα6 mRNA induction versus viral titres in the indicated tissues at day 
2 post infection by Spearman’s rank correlation test.  Spearman’s coefficient of correlation 
(rho) is provided for each tissue. 
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3.4 Discussion. 
Work herein sought to determine, in vivo, the cells and tissues primarily involved in 
CHIKV-induced type IFN production using mice that were heterozygous for expression of 
eGFP under the control of the IFNα6 or IFNβ promoter (IFNα6-GFP+/- and IFNβ-GFP+/- 
mice, respectively).  Serum type I IFN was reduced in the IFNα6-GFP+/- and IFNβ-GFP+/- 
mice compared to WT following CHIKV infection, and low eGFP expression, together with 
high autofluorescence prevented detection of eGFP fluorescence and protein.  
Investigation of mRNA levels showed that IFNβ mRNA was heavily reduced in IFNβ-
GFP+/- mice compared to WT controls.  Ultimately, the results demonstrated that the loss 
of one type I IFN allele by replacement with an eGFP reporter construct resulted in an 
altered type I IFN response, and these mice were not feasible for identification of the 
source of CHIKV-induced type I IFNs.  However, in CHIKV infected WT mouse tissues, 
RT-PCR analysis showed a high level IFNβ and IFNα6 mRNA induction in feet and lymph 
nodes, and a strong, linear correlation between IFNβ and IFNα6 induction and viral tissue 
titres was observed.  
 
A low signal to noise ratio resulted in a failure to detect an eGFP signal.  
Autofluorescence is a common impediment to detection of eGFP signal.  Sources of 
autofluorescence that overlap with the eGFP spectra and were likely present in the tissues 
analysed, include the cofactor NAD(P)H, (Wunder, Brock et al. 2005), lipofuscin pigment 
(Seehafer and Pearce 2006), advanced glycation end-products (Billinton and Knight 2001), 
collagen (Gareau, Bargo et al. 2004), elastin (Gerson, Goldstein et al. 2009), erythrocytes 
(Masilamani, Al-Zhrani et al. 2004) and the ubiquitous cofactors, flavins (Billinton and 
Knight 2001).  Furthermore, heavy formalin fixation (>24hr) required to inactive CHIKV, 
enhances flavin autofluorescence (Billinton and Knight 2001).  Glycine treatment, 
employed to counter formalin-induced autofluorescence, did not improve the signal to 
noise ratio, nor did the use of the alternative fixatives, acetone and ethanol (Zhang, Chen 
et al. 2010).  Formalin fixation can also impede antibody staining of tissues (Werner, Chott 
et al. 2000, Brazelton and Blau 2005), while antigen retrieval and decalcification of hard 
tissues, exposes tissue sections to harsh heat and/or pH conditions that degrade the 
eGFP epitope (Shi, Shi et al. 2011), resulting in low signal.  The poor signal to noise ratio, 
despite methods employed to counter autofluorescence, was suggestive of low eGFP 
protein quantity. 
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A low abundance of eGFP protein was confirmed by protein detection assays that 
negate the problem of autofluorescence.  Splenocytes, macrophages and DCs are all 
capable of producing type I IFNs (Akira, Uematsu et al. 2006, Kawai and Akira 2010), 
while LPS, IFNα and SFV are potent inducers of type I IFN (Yamamoto, Sato et al. 2002, 
Breakwell, Dosenovic et al. 2007, Levy, Marié et al. 2011).  Yet, primary cultures of these 
cells derived from IFNα6-GFP+/- and IFNβ-GFP+/- mice did not produce detectable eGFP 
when exposed to LPS, IFNα, IFNγ and SFV.  Western blot of CHIKV infected IFNα6-
GFP+/- and IFNβ-GFP+/- mouse tissues, also failed to detect eGFP protein.  eGFP protein 
folding is stable and efficient at, or below, room temperature (~20°C) (Tsien 1998).  At 
higher temperatures, (i.e. mouse body temperature of ~36.9°C) (Rudd, Wilson et al. 2012), 
eGFP is prone to misfolding.  Although eGFP is commonly used at 37 °C, any 
impediments to eGFP protein maturation may have been particularly apparent in these 
studies where eGFP protein expression was already low. 
 
The method used to generate the IFNα6-GFP+/- and IFNβ-GFP+/- transgene may 
have hindered eGFP protein translation in these mice.  The inserted eGFP fragment was 
flanked by a 6 bp linker sequence (Y. Kumagai, personal communication), which 
effectively displaced the natural IFN Kozak sequence of the IFNα6 and IFNβ gene.  Kozak 
sequences occur immediately upstream of the translational start codon 
(GCCGCCA/GCCATGG, where A/G can be A or G and ATG is the start codon) in 
eukaryotes, and are involved in ribosomal translation initiation (Kozak 1987, Kozak 1987).  
Displacement or removal of the Kozak sequence heavily impairs the translational 
efficiency of an mRNA (Kozak 1986).  Conversely, insertion of a strong Kozak sequence 
can be used to enhance mRNA translation (Memari, Ramanan et al. 2010).  Thus, 
displacement of the natural Kozak sequence in the IFNα6 and IFNβ 5’ UTR may have 
impaired translation of the IFNα6-GFP+/- and IFNβ-GFP+/- transgene, again contributing to 
low eGFP signal.  
 
 The construction method used to produce IFNβ-GFP+/- mice likely also hindered 
transcription of IFNβ and eGFP driven by the IFNβ promoter. Early, IFNβ transcription is 
monoallelic (transcribed from only one allele) (Hu, Sealfon et al. 2007).  Monoallelic IFNβ 
production up-regulates enhancesome molecules (namely IRF7) that facilitate a switch to 
biallelic expression, paracrine IFNβ signalling and engagement of the positive feedback 
loop (Apostolou and Thanos 2008, Rand, Rinas et al. 2012, Zhao, Zhang et al. 2012).  
Replacement of one IFNβ ORF with the eGFP ORF in this biallelic system would be 
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expected to halve the level of IFNβ mRNA transcribed, and reduce positive feedback 
amplification (since eGFP does not signal through the IFNAR receptor).  However, IFNβ 
mRNA levels in the IFNβ-GFP+/- mice compared to WT mice were up to ≈ 6.5 fold lower, 
possibly due to the stochastic nature of IFNβ expression.  Not all infected cells commit to 
biallelic IFNβ production (Rand, Rinas et al. 2012, Zhao, Zhang et al. 2012) and this is 
influenced by the abundance of signalling molecules available during monoallelic IFNβ 
production (Apostolou and Thanos 2008, Rand, Rinas et al. 2012).  Cells that produce 
early monoallelic eGFP, rather than IFNβ, would not have upregulated the signalling 
molecules required to make the switch to biallelic production, resulting not only in 
diminished type I IFN transcription in cells, but also a lower number of infected cells 
committed to type I IFN production (and therefore eGFP).   
 
 It is important to note that IFNα6-GFP+/- mice have been used to detect IFNα6 
expression (work using mice in which the IFNβ allele was replaced with the eGFP ORF 
has not been published)  (Kumagai, Takeuchi et al. 2007).  Kumagai, Takeuchi et al. 
(2007) found eGFP+ cells were most abundant in the spleen of Newcastle disease virus 
(NDV)-infected IFNα6-GFP+/- mice.  The percentage of eGFP+ splenocytes was ≤ 0.001%, 
however, with even lower levels in the liver, bone marrow and lymph node.  Furthermore, 
these cells were identified by FACS analysis, which was not possible in PC3 facilities.  In 
unfixed cryosections of NDV-infected spleen, eGFP+ cells were visible, albeit very sparse, 
supporting the notion that fixation-enhanced autofluorescence overwhelmed any eGFP 
signals in the studies here.  Lienenklaus, Cornitescu et al. (2009) successfully monitored 
IFNβ expression using a similar model in which the entire IFNβ ORF was replaced with a 
luciferase ORF.  Luciferase does not require light excitation, produces a stronger signal 
than eGFP (Caceres, Zhu et al. 2003, Choy, O Connor et al. 2003) and may therefore 
have negated the low signal to noise ratio encountered here. However, luciferase reporter 
assays require live cell or antemortem analysis (Caceres, Zhu et al. 2003, Choy, O Connor 
et al. 2003) and are not useful for in vivo detection of expression in individual cells 
(Caceres, Zhu et al. 2003), which was the initial aim of this study. 
 
 Investigation of type I IFN induction in WT mouse tissues by RT-PCR showed 
induction of IFNα6 and IFNβ was greatest in the feet, and correlated with viral titres in the 
tissues.  Type I IFN was also heavily induced in the in the spleen and lymph node.  The 
high levels of type I mRNA induction in the lymphoid tissues may reflect the large immune 
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cell population in lymphoid organs.  However, the significant, linear correlation observed 
between type I mRNA induction and viral titres in the tissues, suggested that type I IFN 
induction is influenced by local infection levels, rather than cell/tissue type.  Consistent 
with this, mRNA induction and viral tissue titres appeared to match the proposed route of 
CHIKV spread, with infection starting at the site of inoculation before moving to the 
draining lymph nodes, then entering the circulation (Schwartz and Albert 2010).  An 
exception to the observed correlation was brain tissue.  Defective type I IFN responses are 
known to increase the neurotropism and encephalitic manifestations of several viruses, 
including CHIKV (Abraham, Mudaliar et al. 2013, Sorgeloos, Kreit et al. 2013).  The higher 
type I IFN induction in the brain, relative to viral titres in other tissues, may reflect 
increased protective measures in neural tissue to protect against neuropathology in the 
host. 
 
While the cells primarily involved in type I IFN production following CHIKV infection 
are not well characterised, several studies (Schilte, Couderc et al. 2010, White, Sali et al. 
2011, Palha, Guivel-Benhassine et al. 2013), including the previous chapter, show that 
CHIKV induces type I IFNs largely via RLRs, in particular RIG-1/IPS1.  The IFNα6-GFP+/- 
and IFNβ-GFP+/-  transgenic mice employed in this chapter to determine the cells 
producing findings proved to be unsuitable for study of the type I IFN response.  However, 
analysis of type I IFN induction and viral titres in WT mice, suggested that detection of 
local viral infection, rather than a particular cell type/s, may influence the source/s of type I 
IFN in response to CHIKV infection. 
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4. Quality control and overview of RNA-Seq data from CHIKV infected 
mice 
4.1 Introduction 
 Insights into gene regulation and the transcriptome have improved vastly with the 
development of next generation sequencing technologies.  While microarrays use 
hybridisation technology to examine the transcriptome, they rely on known genome 
sequences and are suboptimal in their detection and quantitation of genome activity 
(Wang, Gerstein et al. 2009, Ozsolak and Milos 2010).  RNA-Seq provides comprehensive 
details of total genome activity via assembly of high throughput cDNA sequences (Ozsolak 
and Milos 2010, McGettigan 2013).  Because, RNA-Seq involves multiple processes from 
library preparation, to computational analysis, all of which can alter the vast quantity of 
data generated (Nekrutenko and Taylor 2012), a high level of quality control and reporting 
is required for interpretation and reproducibility of results. 
 
RNA-Seq uses next generation sequencing technology to perform massively parallel 
sequencing of cDNA generated from isolated RNA.  cDNA is randomly fragmented and 
adapters are ligated to each strand before adsorption to the internal surface of the 
sequencer flow cell via primer-adaptor binding (Mutz, Heilkenbrinker et al. 2013).  
Hybridised fragments are isothermally amplified to generate clusters of approximately one 
thousand copies of the initial cDNA fragment.  Cluster generation enhances signal 
detection during sequencing and enables good sequence coverage of low abundance 
fragments (Mutz, Heilkenbrinker et al. 2013).  Sequencing can be initiated at one end only 
(single-end read) or both ends (paired-end reads) of a bound fragment to produce read 
sequences of 25 – 450 bp, with longer, paired-end protocols allowing greater precision in 
mapping reads that span splice junctions (McGettigan 2013, Mutz, Heilkenbrinker et al. 
2013) 
 
Read mapping and assembly algorithms are used to align the hundreds of millions of 
read sequences generated to a reference genome, assemble the reads into contiguous 
sequences, and estimate the relative abundance of individual gene and isoform transcripts 
(Garber, Grabherr et al. 2011).  Thus, RNA-Seq can provide detailed insight into genome-
wide transcriptional activity, including the abundance of known genes and their individual 
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transcripts/isoforms, as well as non-coding RNAs, and novel/unannotated gene and 
isoform transcripts (Garber, Grabherr et al. 2011, Mutz, Heilkenbrinker et al. 2013). 
 
RNA-Seq of cells/tissues during infection results in amplification and sequencing of 
both host and pathogen RNA.  Using “computational subtraction,” reads are first mapped 
to the host genome, and any unmapped reads are then mapped to the pathogen genome 
or assembled into transcripts by de novo assembly (transcript reconstruction in the 
absence of a reference genome) (Westermann, Gorski et al. 2012).  While RNA-Seq of 
bacterial pathogens is well established (Westermann, Gorski et al. 2012, McClure, 
Balasubramanian et al. 2013), RNA-Seq of small RNA viruses from infected samples can 
be difficult due to the low abundance and high diversity of viral RNA, relative to host RNA 
(Marston, McElhinney et al. 2013). 
 
To examine the transcriptional changes within CHIKV-infected tissues, RNA-Seq 
analysis was undertaken on feet and lymph node tissues - the two tissues with the highest 
type I IFN induction and viral titres (reported in the previous chapters).  The Illumina HiSeq 
platform was used to generate paired-end reads of 100 bp in length, and the Tuxedo 
pipeline of RNA-Seq data analysis algorithms was used to align and assemble reads, and 
estimate the relative abundance and differential expression values.  Data quality at every 
stage of processing was checked against the ENCODE Consortium Standards, guidelines 
and best practice for RNA-Seq v1.0 (ENCODE 2011). 
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4.2 Materials and Methods 
4.2.1 Mice 
Experiments were conducted using female, C57BL/6 mice aged 10-11 weeks old 
(Animal Resource Centre, Canning Vale, Western Australia).  Mice were housed in 
individual ventilated cages and allowed to feed ad libitum.  All animal experiments were 
approved by the QIMR Berghofer Animal Ethics Committee and were conducted in 
accordance with the Australian code for the care and use of animals for scientific 
purposes. 
 
4.2.2 Virus 
The CHIKV isolate (LR2006-OPY1) (Parola, de Lamballerie et al. 2006) and 
preparation of viral stocks was described previously in section 2.2.5. 
 
4.2.3 Mouse infection and tissue preparation 
Twenty four mice received 104 CCID50 CHIKV in 40 µl RPMI1640 media 
supplemented with 2% FCS via subcutaneous injection of the dorsolateral metatarsal 
region of each of the hind limbs, injecting toward the ankle.  Another 12 mice received 40 
µl RPMI1640 supplemented with 2% FCS only, and were used as mock-infected controls.  
Following infection, mice were monitored daily.  The 12 mock-infected mice and 12 of the 
CHIKV-infected mice were euthanased at day 2 post infection.  The remaining 12 CHIKV-
infected mice were euthanased at day 7 post infection.  Euthanasia was performed by CO2 
asphyxiation.  Feet and inguinal lymph nodes were excised.  Feet were cut in half and 
lymph nodes were trimmed of adipose tissue, before being placed in RNAlater (Life 
Technologies) at 4⁰C.  After 24 hours, excised tissues were transferred to a 2 ml screw-top 
microcentrifuge tube containing 4 x 2.8 mm ceramic beads (MO BIO Inc., Carlsbad, USA) 
and TRIzol reagent (Invitrogen) (1 ml per foot/0.5 ml per pair of inguinal lymph nodes) and 
stored at -80⁰C for later RNA isolation. 
 
4.2.4 RNA extraction 
RNA isolation was carried out using TRIzol reagent (Invitrogen) according to the 
manufacturer’s instructions.  Briefly, the samples were homogenised in a Precellys24 
Tissue Homogeniser (Bertin Technologies, Montigny-le-Bretonneux, France) (3 x 30 s, 
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6000 rpm, placed on ice for 1 min between intervals to prevent overheating).  
Homogenates were centrifuged (12,000g x 10 min), supernatant (~ 800 µl feet, 400 µl 
lymph nodes) was transferred to a fresh tube, and chloroform (Sigma-Aldrich) was added 
(200 µl for feet, 100 µl for lymph node).  Tubes were shaken by hand and incubated at 
room temperature for 2 mins, then centrifuged (12,000 x g, 12 min) at 4° C.  A 400-600 µl 
volume of the resulting aqueous phase was transferred to a fresh tube and incubated with 
500 µl isopropanol for 10 min at room temperature before centrifugation (12,000g x 10 
min) at 4˚C.  The resulting supernatant was carefully aspirated and discarded and the 
remaining RNA pellet was washed in 1 ml 75% ethanol, and resuspended in 20 μl 
RNAse/DNAase-free water (Sigma).  The RNA concentration and purity of each sample 
was quantified using a Nanodrop ND 1000 (NanoDrop Technologies Inc.). 
 
4.2.5 Pooling and purification of RNA 
RNA from both inguinal lymph nodes was used, and for each animal, the foot that 
yielded the highest quality RNA was used for DNAase treatment, pooling and RNA-Seq 
analysis.  RNA (5 ng) from each of the 12 foot and lymph node samples were pooled to 
generate three replicates per time point of 20 ng each (i.e. RNA from four mice per 
replicate, three replicates per sample).  The subsequent 20 ng, pooled sample replicates 
of RNA were then treated for DNA contamination and purified using an RNeasy MinElute 
Kit with RNAse-Free DNAse Set (QIAGEN) according to the manufacturer’s instructions.  
Briefly, each 20 µg pooled RNA was incubated with 10 µl RDD buffer and 7.5 Kunitz units 
(2.5 µl) of DNAse 1 and RNAse-free water to final volume 100 µl and incubated at room 
temperature for 10 mins.  DNAse treated replicates were then loaded into columns for 
purification.  RNA was precipitated by adding 700 µl buffer RLT (supplemented with 
0.001% β-mercaptoethanol) and 500 µl 100% ethanol, then bound to the column 
membrane by centrifugation (15 s x 8000 g).  Bound RNA was then washed using 500 µl 
buffer RW1 (15 s x 8000 g), followed by 500 µl 100% ethanol (15 s x 8000 g) then dried (5 
min x 14,000 g).  RNA was then eluted (1 min x 14,000 g) with RNAse/DNAse-free water 
(Sigma) in a 12 µl final volume.  The DNAse treated, purified RNA was stored at -80 ºC. 
4.2.6 High throughput RNA sequencing (RNA-Seq) 
Sequencing of RNA was conducted by the Australian Genome Research Facility 
(AGRF) in Melbourne.  This involved using a TruSeq RNA Sample Prep Kit (v2) (Illumina 
Inc. San Diego, USA) according to the manufacturer’s instructions.  Briefly, poly-A 
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containing RNA was isolated from each 10 µg sample of total RNA using oligo-dt beads, 
then fragmented using divalent cations under heated conditions.  First strand cDNA was 
reverse-transcribed from the fragmented RNA using random primers, before generation of 
double-stranded DNA by second-strand cDNA synthesis.  Blunt-end fragments were 
generated by end-repair processing, before adenylation of the 3’ end of each cDNA 
fragment.  Adenylated fragments were ligated to an adapter (to be used in cluster/library 
generation), and a barcode.  Prepared mRNA libraries were mixed and sequenced from 
both ends in three lanes of an Illumina HiSeq2000 Sequencer (Illumina Inc.).  The 
CASAVA v1.8.2 pipeline was used to separate the bar-coded sequences in each lane into 
their samples and extract 100 bp, paired-end read sequences in FASTQ output format. 
 
4.2.7 Data Analysis using the Tuxedo pipeline 
4.2.7.1 Read mapping and identification of splice junctions 
 Bowtie v2.0.2 (Trapnell, Pachter et al. 2009) was used to align paired end read 
sequences to the UCSC Mus musculus full genome build (mm10, Dec. 2011).  Default 
parameters were used.  Reads that mapped to the genome multiple times (default: ≥10 
times) were considered failed reads mapping to low complexity regions of the genome, 
and were discarded.  Reads that contained few mismatches (default: ≤ 2 mismatches) in 
the high quality 5’ end of the read (default: 5’-most 28 bp) were considered successful.  
Bowtie output is in the form of binary alignment map (.bam) files.  Reads that did not map 
directly to the reference genome using Bowtie were termed initially unmapped reads, while 
successfully mapped reads were termed accepted hits.  Tophat v2.0.6 (Trapnell, Pachter 
et al. 2009, Trapnell, Roberts et al. 2012)  identifies exons and splice junctions in (i) the 
accepted hits and (ii) the initially unmapped read files generated by Bowtie.  Successfully 
aligned reads form ‘coverage islands’ of contiguous sequence, or putative exons.  Tophat 
searches within each coverage island and any surrounding islands for canonical 
intron/exon donor/acceptor (GT-AG) sites for splice junctions.  Sequences (default: 5 bp) 
upstream and downstream of potential junction sites were joined to make ‘seeds.’ Tophat 
searched the initially unmapped read files for sequences that contained seed sequences 
as evidence of a splice junction.  Initially unmapped reads that were found to contain a 
splice junction could then be mapped to the reference genome.  
 
Paired-end reads that did not map to the mouse reference genome using 
Bowtie/Tophat were then mapped to the CHIKV (LR2006-OPY1) genome (Parola, de 
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Lamballerie et al. 2006) using Bowtie.  Because the CHIKV genome does not contain 
intron and exons, Tophat was not used to analyse splice junctions in the Bowtie output.  
Reads aligned to the mouse genome by Tophat were used as input for transcript assembly 
and analysis of differential gene expression between mock and infected samples. 
 
4.2.7.2  Transcript assembly and differential expression analysis 
The Cufflinks v2.1.1 (Trapnell, Williams et al. 2010, Trapnell, Roberts et al. 2012) 
suite was used to assemble transcripts and estimate relative abundance.  Using mapped 
read output from Tophat, the Cufflinks algorithm assembled mapped reads into transcripts 
of genes and estimated their abundance in each sample.  Cufflinks takes into account the 
effect of exon length on the number reads/fragments that will map to a particular region, 
and estimates gene/transcript abundance in fragments per kilobase (of exon) per million 
fragments mapped (FPKM).  Assembled genes and transcripts were assigned an XLOC_ 
(gene) or TCONs (transcript/isoform) number.  Cuffmerge was then used to take transcript 
assemblies for each sample replicate and perform a reference annotation based transcript 
(RABT) assembly with the Genome Research Consortium mouse build 30 (GRCm38).  
RABT assembly merges transcript assemblies with the reference genome to produce a 
single merged annotation file (merged.gtf) that matches cufflinks generated XLOC_ 
identifiers with their location, gene name and accession numbers in the reference genome.  
Cuffdiff was used to run pair wise analyses between each of the samples in the annotated 
Cuffmerge output file.  The fold change and q-value of differential gene and transcript 
expression (including novel/unannotated genes/isoforms), as well as promoter usage, 
coding sequence and splicing differences between each sample was calculated. The q-
value is an adjusted p-value, or threshold below which the false discovery rate (proportion 
of false positives among the rejected null hypotheses) can be considered statistically 
significant (Storey 2002). 
 
4.2.8 Preparation of DEGs lists 
To generate a list of differentially expressed genes (DEGs) and their individual 
transcripts in the different tissues for functional analysis, output files generated in Cuffdiff 
were sorted and filtered using Microsoft Excel.  Each file was filtered to include only the 
gene/isoform transcripts that displayed a statistically significant change in expression from 
mock samples.  Transcripts for which the q-value (false discovery rate adjusted p-value) 
was ≤ 0.01 were selected.  Of these, transcripts with a fold change of ≥ 2 from mock were 
 106 
selected.  FPKM < 1 is a heuristically determined threshold, commonly used to exclude 
ultra-low, (presumably) biologically insignificant changes from analysis (Hart, Komori et al. 
2013, Love, Huber et al. 2014).  Thus, transcripts up-regulated to < 1 FPKM, or down-
regulated from < 1 FPKM were excluded from DEG lists. 
 
4.2.9 Integrated Genome Viewer 
Reads alignments generated by Bowtie and Tophat were visualised in the 
Integrated Genome Viewer (IGV) (Robinson, Thorvaldsdóttir et al. 2011, Thorvaldsdóttir, 
Robinson et al. 2012).  The IGVtools count algorithm was used to compute the average 
density of reads aligned to the reference genome per 25 bp in each sample.  The resulting 
transcriptional data file (.tdf) enabled the transcriptional profile across the entire genome to 
be viewed. 
 
4.2.10 Assessment of data quality 
FASTQC software (Andrews 2010) was used asses the quality of raw FASTQ 
sequences.  SAMtools (Li, Handsaker et al. 2009) was used to convert .bam files 
generated by Bowtie/Tophat to sequence alignment/map (.sam) files.  SAMtools was then 
used to extract read counts and quality scores (MapQ scores) from Bowtie/Tophat for 
assessment of mapping quality.  Only reads with a MapQ ≥ 20 (i.e. uniquely mapped 
reads) were used for downstream analysis.   
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4.3 Results 
4.3.1 Sequence quality assessment 
The quality of base calling by most sequencing platforms commonly reduces as the 
run progresses, resulting in lower quality base calling toward the end of each 
read/sequence (Andrews 2010, Schmieder and Edwards 2011).  FASTQC software was 
used to assess raw sequence data generated using the Illumina HiSeq2000 sequencing 
platform, and determine whether the data required trimming of poor quality bases prior to 
analysis. 
 
Figure 4.1 displays the average quality scores per base along each 100 bp read in 
one replicate.  The quality of base calling falls within the ‘very good’ (green area) quality 
score range of 30-40 (Figure 4.1).  The average sequence quality of all samples was 36.29 
± 1.00 (range: 35.82 - 38.37).  No warnings regarding duplicate sequences, 
overrepresented sequences, GC content or ambiguous base call numbers for any of the 
samples were flagged (data not shown). 
 
FASTQC analysis of raw sequences indicated that all data was of a high quality and 
no reads in any samples required trimming of poor quality sequence prior to read mapping 
using Tophat. 
 
 
Figure 4.1 FastQC assessment of sequence quality scores.  Box and whisker plot of 
average base calling/sequence quality across each read.  Data shown is from the sample 
with the highest number of reads (day 7 foot) and are representative of all samples.  
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4.3.2 Sequence depth and mapping quality 
Sequencing depth can impact on the type of analyses that can be done.  The 
ENCODE Consortium Standards, Guidelines and Best Practices for RNA-Seq 
recommends ~30 million paired-end reads for evaluation of transcriptional profiles.  For 
quantitation of transcripts and identification of novel transcriptional activity, a total depth of 
100-200 million paired end reads ≥ 76 bp in length is recommended (ENCODE 2011). 
Highly expressed transcripts generate more reads, thus the percentage of mapped reads 
is used to indicate the depth of data in RNA-Seq experiments, rather than sequencing 
coverage, with > 80% generally reported for mammalian genomes (Mortazavi, Williams et 
al. 2008, Ruffalo, LaFramboise et al. 2011, Twine, Janitz et al. 2011, Heruth, Gibson et al. 
2012).  SAMtools software is a set of tools for post-processing of read alignment output 
and was used to extract read mapping information from Bowtie/Tophat alignment output 
files. 
   
A total of 486 million, 100 bp paired-end reads were produced from the 18 samples 
sequenced (Foot: 3 x mock, day 2 and day 7; lymph node: 3 x mock, day 2, and day 7).  
Reads were aligned to the UCSC mm10 mouse genome build.  Sequence fragments of 
which neither read mate mapped to the mouse genome were then aligned to the CHIKV 
(LR2006_OPY1 strain) genome.  The number of reads in each sample that mapped to the 
genome with a MapQ ≥ 20 (i.e. the read mapped to only one position in the entire genome) 
are summarised in Table 4.1.  The average percentage of reads that mapped uniquely to 
the mm10 mouse genome ranged from 84.2 – 91.2% per sample (Table 4.1 and Figure 
4.1).  The number of reads mapped to the CHIKV genome was 8.3% in the foot at day 2 
post infection, and substantially less than 1% in all other samples (Table 4.1).  In all 
samples, ~ 5% of reads did not map to either genome with a MapQ ≥ 20, and these reads 
were excluded from further analysis. 
 
 The data here indicated that the sequence depth and quality of reads mapped to 
the mouse genome was sufficient for quantitation of transcripts and investigation of novel 
transcripts.  However, the percentage of total reads that mapped to the CHIKV genome 
was very low.  This was likely due to the smaller size of the CHIKV genome, rather than 
poor quality read mapping. 
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Table 4.1  Summary of RNA-Seq reads mapped to UCSC mm10 mouse genome or 
CHIKV LR2006_OPY1 genome by Bowtie/Tophat. 
Sample 
(mean of 3 
replicates) 
Total reads 
(SD) 
Reads aligned to 
mm10 (% ± SD)a 
Reads aligned to 
CHIKV (% ± SD)b 
Unmapped reads 
(% ± SD) 
Foot Day 2 
55,349,451 
(715,780) 
46,620,761 
(84.231 ± 0.612) 
4,572,386 
(8.260 ± 0.389) 
2,654,892 
(4.796 ± 0.227) 
LN Day 2 
52,331,910 
(2,497,885) 
47,039,395 
(89.881 ± 0.293) 
4,094 
(0.008 ± 0.003) 
2,790,083 
(5.330 ± 0.439) 
Foot Day 7 
57,669,081 
(1,359,085) 
52,598,842 
(91.208 ± 0.078) 
77,219 
(0.134 ± 0.015) 
2,694,124 
(4.674 ± 0.160) 
LN Day 7 
53,248,035 
(1,071,534) 
47,588,454 
(89.373 ± 0.146) 
1,444 
(0.003 ± 0.000) 
2,766,327 
(5.196 ± 0.278) 
Mock Foot 
51,011,141 
(1,550,329) 
46,188,873 
(90.551 ± 0.612) 
n/a 
2,510,208 
(4.919 ±0.175) 
Mock LN 
54,767,209 
(1,789,228) 
49,093,156 
(89.638 ± 0.251) 
n/a 
2,745,703 
(5.018 ± 0.444) 
Data presented is the number of reads and their percentage of the Total reads for each Sample. 
a Both read mates mapped to the mm10 genome, b Neither read mate mapped to the mm10 genome. 
 
 
 
Figure 4.2  Graphical display of the percentage of total reads aligned to the mm10 or 
CHIKV genome.  The mean percentage of high quality reads per sample that mapped 
either the CHIKV of mm10 genome, or did not map to either genome (Ft, Foot, LN: lymph 
node).
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4.3.3 Coverage depth 
 
The total number of reads and the percentage that map to the genome is a 
standard indicator of sequencing depth and quality for RNA-Seq experiments.  However, in 
this experiment, reads were mapped to two genomes of different sizes.  The 
Lander/Waterman general equation (coverage = read length x number of reads / genome 
length) (Lander and Waterman 1988) was thus used to estimate the coverage per lane of 
sequencing over the two different genomes. 
 
The length of the mm10 mouse genome was obtained from the NCBI Assembly 
database and the length of the CHIKV genome was obtained from (Parola, de Lamballerie 
et al. 2006).  The number of total reads aligned was extracted from the Tophat output files 
using SAMtools.  Using the Lander/Waterman equation, each base in the mm10 genome 
and in the CHIKV genome was found to have been sequenced ~11 and ~4.6x106 times, 
respectively, per lane of sequencing (Table4.2) where 10x coverage is considered 
sufficient (Lander and Waterman 1988).  Thus, while only a small percentage of total reads 
mapped the CHIKV genome, this was enough to provide a very high depth of data over the 
length of the CHIKV genome. 
 
 
 Table 4.2  Values used in coverage calculation by Lander/Waterman general equation. 
Genome 
Number of 
reads aligned 
Read length 
(bp) 
Genome length 
(bp) 
Coverage/ lane 
mm10 9.0 x 10
8 
100 2.8 x 109 10.7 
CHIKV 1.4 x 10
7 100 1.2 x 104 4.6 x 10
6 
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4.3.4 Coverage uniformity 
 
 To assess the uniformity of coverage, the average read density was plotted across 
the entire length of each genome.  IGVtools ‘count’ command was used to calculate the 
average read density per 25 bp across the entire CHIKV and mouse genome using read 
mapping information contained in Bowtie/Tophat alignment output files.   
 
 Coverage was consistent across the mm10 genome, with no apparent anomalies 
amongst the different tissues and time points.  Although two regions within chromosomes 
6 and 12 of the lymph nodes showed high peaks of read coverage on day 7 (but not in 
mock or day 2) (Figure 4.3A, red boxes), these were associated with antibody production 
(see Discussion).  There was no indication of sequencing artefacts, such as PCR 
duplicates or incomplete coverage.  In contrast, the transcriptional profile for CHIKV 
displayed a marked difference between each tissue and each time point (Figure 4.3 B).  
Given the quality of sequencing and read mapping (see sections 4.3.1 and 4.3.2) and the 
uniformity of sequence coverage in the mm10 genome, which was sequenced in the same 
run sample as CHIKV, these differences in coverage of the CHIKV genome are likely to 
reflect (i) the different levels of viral RNA in the different samples and (ii) known 
differences in genomic and subgenomic CHIKV RNA ratios, rather than any sequencing 
anomaly.  The very high level of read coverage due to the smaller CHIKV genome 
compared to read coverage of the mouse genome can be also seen (note the difference in 
read depth between the two genomes (Figure 4.3 A & B; bottom right). 
 
Together with sections 4.3.1 - 4.3.3, the results here demonstrate that (i) the total 
number of paired reads produced, (ii) the reads mapped and (iii) the depth of coverage per 
genome, were all well within the parameters outlined in the ENCODE Consortium 
Standards, Guidelines and Best Practices for RNA-Seq v1.0. 
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Figure 4.3  Transcription profile of host and virus gene expression at pre-infection, 
day and day 7 post CHIKV infection.  The average read density per 25 bp interval was 
calculated using IGVtools count algorithm.  A)  Log2 average density of reads per 25 bp 
along the mm10 mouse genome.  (Red circles highlight the peaks in read depth present 
on day 7 & but not day 2 or mock)  B)  Log2 average density of reads per 25 bp along the 
CHIKV (LR2006_OPY1) genome (Ft, Foot, LN: lymph node). 
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4.3.5 Global assessment of mouse gene and transcript regulation during CHIKV infection. 
To assess the transcriptional activity of the host genome, Tophat alignment files 
were analysed using the Cufflinks suite.  Cufflinks assembles aligned reads into transcripts 
and estimates their relative abundance in fragments per kilobase per million (FPKM).  The 
FPKM of all transcripts associated with a gene can then be added to give the FPKM, or 
relative abundance, of that gene.  Cuffdiff was used to generate a list of pair-wise 
comparisons of gene expression in all samples.  The number of genes and transcripts in 
CHIKV infected feet and lymph nodes that were significantly different (q ≤ 0 .01) to mock 
infected controls, and the number of genes and transcripts significantly regulated by ≥ 2 
fold was determined from these lists. 
 
In all samples, the total number of down-regulated genes was higher than the total 
number of up-regulated genes (17.7% vs. 12%, 13.9% vs. 11.1% and 11.4% vs. 7.3% in 
day 7 feet, day 2 and day 7 lymph nodes, respectively), except day 2 feet, in which up- 
and down-regulation differed by < 1%.  However, when considering genes with a ≥ 2 fold 
change, up-regulated genes outnumbered genes down-regulated in the feet at day 2 
(4.6% vs. 1.8%) and day 7 (5.6% vs. 4.1%).  Conversely, in the lymph nodes at day 2 post 
infection, genes down-regulated ≥ 2 fold out-numbered genes up-regulated ≥ 2 fold (3.8% 
vs. 2.3%) and at day 7, there was little difference (2.1% vs. 1.9%; Figure 4.4 A, bright 
red/green).  Transcripts analysis showed up-regulation was more prevalent in day 2 feet 
(2.5% vs. 1.6%) with little difference other samples (2.9% vs. 3.2%, 2.9% vs. 2.2% and 1.4 
vs. 1.5% in day 7 feet, day 2 and day 7 lymph nodes, respectively)(Figure 4.4B).  Similarly, 
the majority of transcripts regulated ≥ 2 fold were up-regulated in day 2 feet (1.6% vs. 
0.5%), with slightly more upregulation in the other samples (1.9% vs. 1.4%, 1.4% vs. 1%, 
0.6% vs. 0.5% in day 7 feet, day 2 and day 7 lymph node, respectively (Figure 4.4 B bright 
red/green). 
   
These results indicate a general trend toward gene down-regulation, perhaps due to 
virus-induced host transcriptional shut-down, cell death and/or dilution effects of infiltrating 
cells (Gardner, Anraku et al. 2010).  A difference in the percentage of genes up- or down-
regulated ≥ 2 fold (i.e. genes most likely to be of biological significance) was also observed 
between feet and lymph nodes.  The trend toward up-regulation of transcripts reflects their 
relative contribution to genes up-regulated ≥ 2 fold. 
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Figure 4.4  Gene and transcript expression in the feet and LN of CHIKV-infected 
mice at day 2 and day 7 post infection.  Each pie chart represents the total number of 
regulated genes in each sample.  Differentially expressed genes, and individual gene 
transcripts were calculated using the Cufflinks suite.  Significantly regulated (q-value ≤ 
0.01) genes/transcripts are shown in green (down-regulated) or red (up-regulated).  
Genes/transcripts regulated by ≥2 fold are shown offset from the pie in bright green (down-
regulated) and bright red (up-regulated). (Ft, Foot, LN: lymph node).
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4.4 Discussion 
 
The analyses presented herein demonstrates that RNA-Seq investigation of CHIKV-
infected, whole mouse foot and lymph node tissues generated data of sufficient quality for 
assessment of both host and pathogen genome activity.  Transcriptional activity across the 
mouse genome was largely uniform, while transcriptional activity across the CHIKV 
genome reflected the known viral RNA replication strategy, whereby the virus spreads 
from the site of infection to the draining lymph nodes and replicates in the joints (Schwartz 
and Albert 2010).  Analysis of differential gene expression showed a high degree of down-
regulation, while differentially expressed transcripts were predominantly up-regulated.   
 
The data produced was shown to be of a standard suitable for analysis of known and 
novel transcriptional activity according to the ENCODE Consortium recommendations 
(ENCODE 2011).  Over 400 million raw sequence reads of high quality were produced.  A 
high percentage (≥ 85%) of reads in all samples mapped uniquely to the host genome, 
with fewer than 5% of reads generated unable to be mapped to either host or viral genome 
after computational subtraction.  At day 2 post infection, read mapping to the host genome 
was lowest, while read mapping to the viral genome was the highest.  In one of the few 
other studies of RNA viruses using high throughput sequencing methods, Marston, 
McElhinney et al. (2013) were able to map a maximum of 5.45% of reads isolated from 
brain tissue, to the genome of the highly neurovirulent rabies virus.  The study used highly 
developed viral RNA isolation protocols and the 454 pyrosequencing platform.  Herein, 
8.3% and 0.13% of the total read sequences in the feet at day 2 and day 7, respectively, 
were seen to be derived from CHIKV (Table 4.1), indicating the utility of the RNA-Seq 
platform for analysing the sequence of tissue-associated viral RNA after the end of the 
viraemic period (Gardner, Anraku et al. 2010, Schwartz and Albert 2010). 
 
Assessment of the mouse transcriptional profiles in each sample showed changes in 
genome scale transcriptional activity in the two tissues and time points.  Two particularly 
apparent increases in the average abundance of transcripts could be seen in the lymph 
nodes at day 7 in chromosomes 12 (~113-116 Mb) and 6 (~68-71 Mb).  These loci within 
the mouse genome encompass the immunoglobulin heavy chain (IgH) complex 
(D'Eustachio, Pravtcheva et al. 1980) and the immunoglobulin κ-light chain (Igk) complex 
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(Swan, D'eustachio et al. 1979), respectively (Pruitt, Tatusova et al. 2009).  These spikes 
in transcriptional activity likely reflect the induction of antibody responses, known to begin 
at day 4 post infection in WT mice (Gardner, Anraku et al. 2010, Rudd, Wilson et al. 2012).  
Chromosome 16, which contains the λ-light chain genes (Pruitt, Tatusova et al. 2009), did 
not display a similar increase in transcript abundance.  However, λ-light chains are 
expressed at a much lower level relative to κ-light chains in C57BL/6 mice (Woloschak and 
Krco 1987, Katzmann, Clark et al. 2002) due to 10-fold fewer λ-light chain genes, order of 
gene expression, and the inactivation of λ-light chain genes by κ-light chain expression 
(Takemori and Rajewsky 1981, Cherayil and Pillai 1991). 
 
The transcriptional profile across the CHIKV genome, and between tissues and time 
points, was highly variable and reflected the replication kinetics of CHIKV.  In all samples, 
sequence coverage of the structural protein ORF was higher than coverage of the non-
structural protein ORF.  During alphavirus replication, genomic RNA, for virion packaging, 
and subgenomic RNA, for production of structural proteins, are transcribed from an 
intermediate negative-strand RNA (Strauss and Strauss 1994).  An increased ratio of 
subgenomic to genomic RNA, ranging from 1.3 – 16.8, is required to facilitate production 
of the 240 copies of E1/E2 envelope proteins that house a single genome copy per mature 
virion (Rümenapf, Strauss et al. 1994, Perri, Driver et al. 2000, Ng, Coppens et al. 2008). 
 
 Investigation of global gene expression revealed a high level of overall down-
regulation, particularly in the foot at day 7.  CHIKV infection is well known to induce host 
transcriptional and translational shutdown as means of delaying apoptosis and facilitating 
viral replication (Sudeep and Parashar 2008, Joubert, Werneke et al. 2012, Fros, Major et 
al. 2014).  Down-regulation of host gene expression in feet at day 7 may also be an 
artefact of CHIKV-induced cell death, or the massive influx of inflammatory infiltrates, 
known to occur at day 6/7 post infection.  Cell death, and/or an influx of cells at day 6/7 
would effectively ‘dilute’ the RNA derived from foot tissues, causing genes expressed in 
mock infected feet to appear down-regulated at day 7.  In support of this notion, a large 
number of down-regulated genes were seen to be down-regulated by < 2 fold.  Despite the 
observed down regulation, the number of genes up-regulated by ≥ 2 fold outweighed  
genes down-regulated by ≥ 2 fold in the feet, and genes regulated by ≥ 2 fold in the lymph 
nodes were roughly equal in numbers.  This indicated that those genes, with what are 
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likely to be the most biologically significant changes (herein referred to as differentially 
expressed genes; DEGs), were largely up-regulated. 
 
 Finally, a major benefit of RNA-Seq over other next generation sequencing 
technologies is the ability to estimate, not only the overall expression of a gene, but also 
the relative abundance of the individual transcripts derived from that gene (Ozsolak and 
Milos 2010, Trapnell, Roberts et al. 2012).  Consistent with the DEGs, there were a greater 
number of up-regulated transcripts compared to down-regulated transcripts, in all samples.  
However, the total number of significantly regulated transcripts was lower than the number 
of significantly regulated genes in all samples.  While more transcripts exist relative to 
genes, changes in individual transcript expression may not reach significance, but 
contribute in summation with other transcripts, to a significant change in expression of the 
whole gene.  Transcripts regulated ≥ 2 fold are likely those genes/isoforms engaged in, or 
actively inhibited, during the response to CHIKV infection, and were used for later analysis 
of differential gene and pathway expression. 
 
 The results presented here demonstrated that the data generated by RNA-Seq of 
CHIKV infected tissues was of a standard of quality suitable for in-depth analysis of 
transcriptional activity.  Global analysis of gene expression showed a high level of 
transcriptional activity in response to CHIKV, which was investigated in further detail in the 
Chapter 6.  
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5. Analysis of host gene expression in response to CHIKV infection using RNA-Seq 
5.1 Introduction 
 Microarray technology has been used to study gene expression in the mouse model 
of CHIKV (Nakaya, Gardner et al. 2012).  However, such technologies allow investigation 
of known/characterised genes only, whereas RNA-Seq technology provides insight into the 
full spectrum of genome regulation during infection, including coding and non-coding gene 
expression, low-level gene expression, novel genes and individual isoform expression 
(Wang, Gerstein et al. 2009, Trapnell, Williams et al. 2010, McGettigan 2013). 
 
 To date, the only study of the mammalian response to an alphavirus using RNA-
Seq, examined salmonoid alphavirus in fish cell lines (Xu, Evensen et al. 2015).  Other 
studies of alphaviruses using RNA-Seq have examined infected invertebrate vectors 
(Morazzani, Wiley et al. 2012, Akbari, Antoshechkin et al. 2013, Poelchau, Huang et al. 
2014, Shrinet, Jain et al. 2014), or viral transcription only (Chen, Kam et al. 2013, Donaszi-
Ivanov, Mohorianu et al. 2013).  Microarray by Nakaya, Gardner et al. (2012) identified a 
significant type I IFN response, with overlap between inflammatory processes in RA and 
acute CHIKV-arthritis.  Atasheva, Akhrymuk et al. (2012) found that a different set of IFN 
regulated genes (IRGs) were expressed during VEEV replication versus viral clearance.  
Ryman, Meier et al. (2005) identified 44 genes induced during SINV infection, five of which 
(ISG20, ISG15, ISG56, viperin/rsad2 and ZAP) were confirmed to inhibit SINV translation 
in mice.  Briolat, Jouneau et al. (2014) also observed a dominant type I IFN response in 
zebrafish larvae responses to CHIKV and this study also demonstrated tissue specific 
differences in IRG production. 
 
 Although all nucleated cells have the capacity to respond to or produce type I IFNs 
(MacMicking 2012), tissue differences in type I IFN and IRG expression exist.  Pulverer, 
Rand et al. (2010), using a luciferase-Myxovirus resistance (Mx) reporter gene as an 
indicator of type I IFN responses, found the responses to IFNβ or Thogoto virus were most 
prominent in the liver, spleen and kidneys.  Zebrafish models of CHIKV found the liver and 
spleen to be major producers of IRG mRNAs (Briolat, Jouneau et al. 2014) and the liver a 
major producer of type I IFN protein (Palha, Guivel-Benhassine et al. 2013).  Results in 
Chapter 3 found that feet, lymph nodes, spleen and liver (ranked highest to lowest) 
produced the highest levels of type I IFN mRNA following CHIKV infection. 
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 What drives these differences and what impact they have on the downstream gene 
expression is still little understood.  Herein, RNA-Seq of CHIKV-infected mouse feet and 
lymph nodes at day 2 and day 7, as well as mock-infected tissues, was used to investigate 
the gene expression profiles in 2 tissues and at 2 time points following CHIKV infection.  
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5.2 Materials and Methods 
5.2.1 High throughput RNA sequencing (RNA-Seq) data 
The RNA-Seq data analysed herein is that described in Chapter 4, and was 
generated as per sections 4.2.1-4.2.9.  Briefly, RNA samples from feet and lymph nodes of 
CHIKV-infected mice at day 2 and day 7 and from mock-infected animals were sequenced 
on an Illumina HiSeq 2000 sequencer.  The 100 bp paired-end read sequences produced 
were aligned to the UCSC mm10 Refseq build mouse genome the Tophat v2.0 read 
mapping software (Trapnell, Pachter et al. 2009).  Tophat output files were analysed using 
the Cufflinks suite (Trapnell, Roberts et al. 2012).  Cufflinks was used to estimate the 
relative abundance of individual gene transcripts in each sample.  Relative abundance is 
measured in fragments per kilobase (of exon) per million fragments mapped (FPKM) and 
is based on the number of reads that align to a particular genomic region.  
Cuffmerge/Cuffdiff were used to run pair wise comparisons of FPKM values for each gene 
in each sample. 
5.2.2 Preparation of DEGs lists  
  To generate a list of differentially expressed genes (DEGs) in the different tissues 
for functional analysis, output files generated in Cuffdiff were sorted and filtered using 
Microsoft Excel.  Each file was filtered to include only the genes with a statistically 
significant change in FPKM from mock values.  FPKM values for which the q-value (p-
value adjusted for false discovery rate) was ≤ 0.01 were selected.  Of these, transcripts 
with a fold change of ≥ 2 difference from mock values were selected.  FPKM < 1 is a 
heuristically determined threshold, commonly used to exclude genes with ultra-low, 
(presumably) biologically insignificant expression from analysis (Hart, Komori et al. 2013, 
Love, Huber et al. 2014).  Thus, transcripts up-regulated to < 1 FPKM, or down-regulated 
from < 1 FPKM were excluded from DEG lists.  
5.2.3 Unannotated DEGs 
Cufflinks assigns every expressed region of the genome an X_LOC (gene) and 
T_CONS (transcript) identifier, which was subsequently linked to, or annotated against the 
UCSC mm10 Refseq reference genome.  Regions of the genome that were expressed but 
were not annotated (i.e. do not exist in the reference genome) appear as ‘-‘in the gene ID 
column of cufflinks output files, but can be tracked by their X_LOC/T_CONS identifiers.  
The genome co-ordinates of each unannotated gene in the top 50 up-regulated DEGs was 
entered into the NCBI Assembly database, and the corresponding nucleotide sequence 
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downloaded in FASTA format from the Genome Reference Consortium mouse build 38 
(GRCm38) C57BL/6J mouse genome assembly. The BLAST algorithm was used to 
search for the unannotated gene mRNA in the NCBI nucleotide database.  Where a match 
was found, the DEGs list was updated.  The remaining unannotated, up-regulated DEGs 
were termed CHIKV induced novel transcripts (CINTs) 
5.2.4 Investigation of the protein coding potential of CHIKV-induced novel transcripts 
  CINTs in each top 50 DEGs list were investigated for their potential to encode a 
protein. 
5.2.4.1  Construction of mRNA sequences 
 The XLOC_ identifier of each CINT was used to find its corresponding transcripts 
(TCONS_) and exon coordinates in the merged.gtf annotation file. Exon sequences were 
extracted from the NCBI Assemblies database using the co-ordinates provided in 
Cufflinks.  Downloaded exon sequences were concatenated to form the full mRNA 
sequence of the individual transcripts/isoforms for each unannotated transcript.  The 
mRNA sequence of each gene isoform was subsequently identified using the 
nomenclature system chikungunya induced novel transcript number.variant number (eg. 
CINT1.1, CINT1.2 etc.). 
5.2.4.2 Assessment of mRNA and amino acid sequences 
 ExPasy Translate tool was used to translate the mRNA sequence of each CINT 
isoform into its amino acid sequence and identify the open reading frames (ORFs) present 
in all six possible frames.  The translated sequences were assessed based on criteria set 
out by the NIH for identification of novel genes with protein coding potential.  Sequences in 
which the longest open reading frame was i) < 30 aa or ii) not in the same strand direction 
reported by Cufflinks (i.e. 5’ 3’, or 3’5’) iii) or had a 5’ UTR < 20 aa or iv) contained 
many (>10) and/or long (> 30 aa) upstream ORFs (uORFs) or v) had upstream start site 
(uAUGs) within 9 bp of the longest ORF start site were excluded from further analysis.  
Remaining CINTs were then assessed for the presence and strength of the Kozak 
sequence in their mRNA sequences.   
5.2.4.3 Assessment of protein homology and presence of conserved domains 
 The mRNA sequences of CINTs that exhibited protein coding gene features were 
investigated for homology to other known proteins.  The BLASTx algorithm was used to 
search for regions of similarity between known proteins in the NCBI protein database and 
amino acid sequences in each of the six possible reading frames that can be translated 
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from a nucleotide sequence.  BLASTx was also used to identify the presence of conserved 
protein domains in translated CUNT isoforms.  CINT sequences found to have 100% 
identity with a protein in the NCBI database were renamed accordingly. 
5.2.5 Interferome v2.01 analysis 
The percentage of differentially expressed genes in each tissue and time point that 
were regulated by type I IFNs was determined using the Interferome v2.01 database of 
interferon regulated genes (Rusinova, Forster et al. 2013).  Parameters were set to identify 
murine genes that are regulated ≥ 2 fold, either in vitro or in vivo, following treatment with 
type I IFNs. 
5.2.6 Ingenuity Pathway Analysis  
Ingenuity Pathway Analysis (IPA) software (QIAGEN) was used to identify the 
canonical signalling pathways and upstream regulators employed in each tissue/time point 
based on the gene expression profile of each data set.  Up- and down-regulated DEGs 
lists were uploaded into IPA and analysis was performed using the “direct and indirect 
relationships” setting.  Upstream regulator analysis was used to predict the 
genes/molecules regulating gene expression seen in each sample.  Upstream regulator 
output was ranked by p-value (significance of overlap with the IPA database) then Z-score 
(extent and direction of up- or down-regulation).   Canonical pathways analysis was used 
to identify the pathways being engaged in each sample based on expression changes in 
each DEGs list.  Canonical pathways output was filtered to exclude “disease specific 
pathways,” and ranked by p-value.   
5.2.7 Sequence alignments and phylogenetic analysis 
 MEGA v6.0 software (Tamura, Dudley et al. 2007) was used to perform multiple 
sequence alignments and phylogenetic analysis of amino acid sequences.  Sequence 
alignments were rendered using consensus–colouring (CHROMA) (Goodstadt and Ponting 
2001).  
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5.3 Results  
5.3.1 Differentially expressed genes (DEGs) 
  
 A global assessment of DEGs was presented in Chapter 4 (section 4.3.5), which 
showed a greater number of genes were down-regulated in tissues post CHIKV infection 
than up-regulated.  Herein, DEGs lists were used to assess the biological processes 
engaged following CHIKV infection.  The 50 most up- and down- regulated genes are 
shown in Tables 1-8.  Down-regulated, unannotated DEGs are indicated by “-” in the gene 
symbol list.  Up-regulated, unannotated DEGs were termed CHIKV induced novel 
transcripts (CINTs) and were further investigated in section 5.3.9. 
 
 There was a 30% overlap in DEGs between day 2 and 7 in the feet, a 32% overlap 
of DEGs at day 2 in feet and lymph node, and 20% of DEGs in the top 50 most up-
regulated were common to day 2 feet, day7 feet and day2 lymph nodes.  The DEG lists 
included several known anti-CHIKV effectors such as Mx proteins (Schoggins, Wilson et 
al. 2011), OAS genes (Bréhin, Casadémont et al. 2009), rsad2/viperin (Teng, Foo et al. 
2012), ISG15 (Werneke, Schilte et al. 2011) and ISG20 (Schoggins, Wilson et al. 2011, 
Karki, Li et al. 2012), as well as the three IFIT genes (Hyde, Gardner et al. 2014).  
Granzymes A and B were heavily induced, particularly in day 7 feet (≈119 and ≈630 fold 
increase, respectively), as were several other inflammatory cell markers and 
chemoattractants.  A broad array of GTPases, in particular the p47 IFN-inducible GTPases 
and the p65 guanylate binding proteins (GBPs) were also up-regulated (see discussion).  
Type I IFNs were induced at day 2, and largely absent on day 7.  Interestingly, IRF7 
remained strongly up-regulated in day 7 feet, despite the lack of type I IFN mRNAs (see 
section 5.3.5).  
 
 DEGs in day 7 lymph node differed from the other samples.  20.7% of all up-
regulated genes, and 60% of the top 50 most up-regulated genes were immunoglobulin 
heavy- and light- chain variable region genes.  To consider non-immunoglobulin mediated 
process, unnamed immunoglobulin genes were removed from DEGs lists; a singular entry 
was retained for immunoglobulin heavy (IgH-V) and light (Igκ-V) chains variable regions 
(Table 5.4).  Day 7 lymph node also revealed a high proportion of CINTs in the top 50 
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(18% versus 10%, 6% and 6% in day 2 lymph node, day 2 and day 7 feet, respectively) 
(see 5.3.9). 
 
 Generally, the top 50 down-regulated genes had lower fold change than up-
regulated genes in the top 50.  16% of down-regulated DEGs were common to all 
samples.  All CD209 isoforms and their homologue CD207 were seen to be down-
regulated in all tissues and time points, as were other lectins/carbohydrate-binding 
molecules.  Keratins, keratin-associated genes, epithelial development genes and genes 
associated with striated muscle function and energy metabolism were also down-regulated 
in the feet.  This may, in part, reflect cell death in infected cells including epithelial cells 
and muscle cells (Nakaya, Gardner et al. 2012, Rudd, Wilson et al. 2012).  A number of 
M2 (anti-inflammatory) markers (Retnla, F13a1 Mrc1, CD163) were also down-regulated in 
each sample.  The most heavily down-regulated gene in lymph nodes at both time points 
was the microRNA, mirlet7h (see Discussion). 
 
 Thus, gene regulation during CHIKV infection shows both tissue and time specific 
difference in regulation.   
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Table 5.1  Up-regulated DEGs in foot tissues at day 2 post CHIKV infection. 
 
Gene 
Symbol Official Gene Name
Mock 
FPKM
Day 2 
FPKM
Log2
(FC)
Ifnb1
CINT6
Ifna4
Gm15056*
Ifna5
Gcg
Ifna6
Ifna2
CINT5
Cxcl10
Gm4841*†
Gm14446*
Cxcl9
Mx1
Gm12185*
CINT7
Iigp1†
Isg15
Rsad2
Ifi44
Ifit1
Oasl1
Gm5431*†
Gm12250*†
Ifit3
Cxcl11
Irf7
Mx2
Prm1
Pydc4
Irg1
Slfn4
Ttll9
Oas1g
Gbp5
Tgtp1†
Ifit2
Apol9b
Gzmb
Ms4a4c
Pydc3
Igtp†
Gbp2
Ccl5
Usp18
Batf2
Apol9a
Cmpk2
Phf11c
Ccl4
Interferon beta 1
Chikungunya induced novel transcript 6
Interferon alpha 4
Beta defensin 52
Interferon alpha 5
Glucagon
Interferon alpha 6
Interferon alpha 2
Chikungunya induced novel transcript 5
Chemokine (C-X-C motif) ligand 10
Interferon gamma-inducible gtpase alpha 3 
Interferon-induced protein with tetratricopeptide repeats 1c
Chemokine (C-X-C motif) ligand 9
Myxovirus (influenza virus) resistance 1
Interferon gamma-inducible gtpase beta 7 
Chikungunya induced novel transcript 7
Interferon inducible gtpase 1
Interferon stimulated gene 15 (ubiquitin-like modifier)
Radical s-adenosyl methionine domain containing 2 (viperin)
Interferon-induced protein 44
Interferon-induced protein with tetratricopeptide repeats 1/ISG56
2',5'-oligoadenylate synthetase-like 1
Interferon gamma-inducible gtpase beta 8
Interferon regulated gtpase 10
Interferon-induced protein with tetratricopeptide repeats 3/ISG60
Chemokine (C-X-C motif) ligand 11
Interferon regulatory factor 7
Myxovirus (influenza virus) resistance 2
Protamine 1
Pyrin domain containing 4
Immunoresponsive 1 homolog 
Schlafen 4
Tubulin tyrosine ligase-like family, member 9
2'-5' oligoadenylate synthetase 1g
Guanylate binding protein 5
T-cell specific gtpase 1
Interferon-induced protein with tetratricopeptide repeats 2
Apolipoprotein L 9b
Granzyme B
Membrane-spanning 4-domains, subfamily A, member 4C
Pyrin domain containing 3
Interferon gamma induced gtpase
Guanylate binding protein 2, interferon-inducible
Chemokine (C-C motif) ligand 5
Ubiquitin specific peptidase 18
Basic leucine zipper transcription factor, atf-like 2
Apolipoprotein L 9a
Cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
PHD finger protein 11C
Chemokine (C-C motif) ligand 4
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.69
0.44
0.29
0.56
1.32
0.08
0.03
0.54
5.34
1.52
0.51
2.24
0.88
0.02
0.33
8.59
0.12
8.43
0.86
0.02
0.32
0.36
2.42
0.01
0.24
1.60
1.62
3.66
0.79
0.16
1.67
0.45
7.95
9.01
5.12
3.25
0.41
0.86
2.16
5.28
0.99
6.79
4.65
4.40
3.18
3.04
2.00
1.33
1.15
1.13
1473.04
295.51
151.64
220.40
375.53
20.30
8.48
132.28
1211.61
337.12
110.50
457.72
134.28
2.40
43.34
1075.31
14.46
979.32
95.59
2.19
28.15
31.89
212.88
1.20
18.96
126.27
123.67
276.80
54.05
11.06
110.11
29.69
510.75
572.19
321.80
201.24
25.14
51.00
125.75
299.45
55.89
21.00
21.00
21.00
21.00
21.00
21.00
21.00
21.00
21.00
9.76
9.42
9.04
8.61
8.16
8.07
8.01
7.97
7.83
7.79
7.75
7.68
7.25
7.06
7.03
6.97
6.87
6.86
6.80
6.48
6.48
6.47
6.46
6.36
6.33
6.30
6.25
6.24
6.09
6.08
6.04
6.04
6.00
5.99
5.97
5.95
5.95
5.90
5.86
5.83
5.82
* Gene name/symbol assigned  after manual search of  gene coordinates; bold: Interferome designated IRG; 
italics: literature validated IRG; † p47 IFN inducible GTPase; 
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Table 5.2 Up-regulated DEG in foot tissues at day 7 post CHIKV infection.  
 
Gene 
Symbol Official Gene Name
Mock 
FPKM
Day 7 
FPKM
Log2
(FC)
CINT1
CINT4
Gm15056*
Tcrb*
Gzmb
Gm4841†
Cxcl9
Gbp1
Fcgr4
Cd300e
Cxcl10
Gm12185*†
Gm12250*†
Gzma
Iigp1†
Irg1
Tgtp1†
Gm5431*†
Slamf8
Batf2
Klra2
Ms4a4c
Tigit
Fam26f
Zbp1
Pydc4
CINT2
Gbp2
Gm5150*
Gbp8
Gm14446*
Fcrl5
Cd8b1
Prm1
Il12rb1
Slfn1
Ubd
Ly6c2
Igtp†
Ifi44
Isg15
Gbp5
Klra3
Ccl5
Ms4a4b
Gm4951*†
Irf7
Nos2
Ccl4
Oasl1
CHIKV-induced novel transcript 1
CHIKV-induced novel transcript 4
Beta defensin 52
T cell receptor beta chain
granzyme B
Interferon gamma-inducible GTPase alpha 3
chemokine (C-X-C motif) ligand 9
guanylate binding protein 1, interferon-inducible
Fc receptor, IgG, low affinity IV
CD300e molecule
chemokine (C-X-C motif) ligand 10
interferon gamma inducible GTPase beta 7
interferon-gamma-inducible p47 GTPase
granzyme A
Interferon inducible GTPase 1
immunoresponsive 1 homolog (mouse)
T cell specific GTPase 1
interferon gamma inducible GTPase beta 8
SLAM family member 8
basic leucine zipper transcription factor, ATF-like 2
killer cell lectin-like receptor, subfamily A, member 2
membrane-spanning 4-domains, subfamily A, member 4C
T cell immunoreceptor with Ig and ITIM domains
family with sequence similarity 26, member F
Z-DNA binding protein 1
Pyrin domain containing 4
CHIKV-induced noel transcript 2
guanylate binding protein 2, interferon-inducible
SIRP beta 1 like 1 protein
guanylate binding protein 8, interferon-inducible
Interferon-induced protein with tetratricopeptide repeats 1c
Fc receptor-like 5
CD8b molecule
protamine 1
interleukin 12 receptor, beta 1
Schlafen 1
ubiquitin D
lymphocyte antigen 6 complex, locus C2
interferon gamma induced GTPase
interferon-induced protein 44
Interferon Stimulated Gene 15 ubiquitin-like modifier
guanylate binding protein 5
killer cell lectin-like receptor, subfamily A, member 2
chemokine (C-C motif) ligand 5
membrane-spanning 4-domains, subfamily A, member 4b
Interferon gamma inducible GTPase 2
interferon regulatory factor 7
nitric oxide synthase 2, inducible
chemokine (C-C motif) ligand 4
2',5'-oligoadenylate synthetase-like 1
0.000
0.000
0.000
0.000
0.164
0.443
0.563
0.082
0.801
0.071
1.695
0.075
0.331
0.612
0.542
0.360
1.620
0.018
0.366
0.406
0.353
1.673
0.094
1.104
4.313
0.316
0.079
9.010
0.273
0.690
0.288
0.033
0.161
0.024
0.162
1.217
0.495
10.216
7.955
0.513
5.341
1.597
0.078
5.123
1.153
0.450
8.430
0.220
0.987
0.883
1.044
1.045
11.584
1.080
102.165
143.131
181.529
24.961
174.742
14.610
313.526
13.855
42.716
76.408
59.376
33.923
142.555
1.500
29.947
31.637
25.736
112.111
5.670
65.832
254.285
18.522
4.554
482.328
14.590
36.166
14.614
1.675
8.140
1.227
7.890
57.859
23.193
465.144
361.793
22.977
238.298
70.955
3.348
211.614
45.347
17.659
327.235
8.337
36.929
32.760
21.000
21.000
21.000
21.000
9.284
8.335
8.333
8.248
7.770
7.688
7.531
7.521
7.011
6.963
6.775
6.559
6.460
6.385
6.354
6.283
6.186
6.067
5.919
5.898
5.882
5.872
5.841
5.742
5.741
5.713
5.663
5.658
5.658
5.647
5.605
5.572
5.549
5.509
5.507
5.486
5.479
5.473
5.418
5.368
5.298
5.294
5.279
5.241
5.225
5.214
* Gene name/symbol assigned  after manual search of  gene coordinates; bold: Interferome designated IRG; 
italics: literature validated IRG; † p47 IFN inducible GTPase; 
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Table 5.3 Up-regulated DEGs in lymph nodes at day 2 post CHIKV infection. 
 
Gene 
Symbol Official Gene Name
Mock 
FPKM
Day 2 
FPKM
Log2
(FC)
CINT8
Ifna5
Ifnb1
CINT9
Cxcl11
Sct
Slfn4
Irg1
CINT10
Gbp10
Isg15
Gzmb
Ifit3
Rsad2
Cdkl4
Nts
CINT11
Fgf23
Tuba8
Ttll9
Ifit2
Oasl2
Ifit1
Tmem171
Gm5431*†
Irf7
Nmes1*
Oas2
Oasl1
Mx2
Il1rn
Ifi44
Gm12185*†
Oas1g
Ptgs2
Gpr31
Cxcl10
Gm14446*†
Prm1
Mx1
Isg20
Zbp1
Il6
Usp18
Klra2
Cmpk2
Oas1a
Pira6
CINT22
Perm1
Chikv-upregulated novel transcript 8
Interferon, alpha 5
Interferon, beta 1, fibroblast
Chikv-upregulated novel transcript 9
Chemokine (C-X-C motif) ligand 11
Secretin
Schlafen 4
Immunoresponsive 1 homolog (mouse)
Chikv-upregulated novel transcript 10
Guanylate-binding protein 10
Interferon stimulated gene 15 ubiquitin-like modifier
Granzyme B
Interferon-induced protein with tetratricopeptide repeats 3/ISG60
Radical s-adenosyl methionine domain containing 2 (viperin)
Cyclin-dependent kinase-like 4
Neurotensin
Chikv-upregulated novel transcript 11
Fibroblast growth factor 23
Tubulin, alpha 8
Tubulin tyrosine ligase-like family, member 9
Interferon-induced protein with tetratricopeptide repeats 2/ISG54
2'-5' oligoadenylate synthetase-like 2
Interferon-induced protein with tetratricopeptide repeats 1/ISG56
Transmembrane protein 171
Interferon gamma inducible gtpase beta 8
Interferon regulatory factor 7
Normal mucosa of esophagus-specific gene 1 protein
2'-5' oligoadenylate synthetase 1a
2'-5' oligoadenylate synthetase-like 1
Myxovirus (influenza virus) resistance 2 (mouse)
Interleukin 1 receptor antagonist
interferon-induced protein 44
interferon gamma inducible GTPase beta 7
2'-5' oligoadenylate synthetase 1g
prostaglandin-endoperoxide synthase 2
G protein-coupled receptor 31
chemokine (C-X-C motif) ligand 10
Interferon-induced protein with tetratricopeptide repeats 1c
protamine 1
myxovirus (influenza virus) resistance 1
interferon stimulated exonuclease gene 20kDa
Z-DNA binding protein 1
interleukin 6 (interferon, beta 2)
ubiquitin specific peptidase 18
killer cell lectin-like receptor, subfamily A, member 2
cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
2'-5' oligoadenylate synthetase 1a
paired-Ig-like receptor A6
CHIKV-upregulated novel transcript 22
PGC-1 and ERR-induced regulator in muscle 1
0.000
0.000
0.000
0.116
0.122
0.642
1.982
0.150
0.037
1.252
25.186
2.967
22.617
3.952
0.123
0.658
1.581
0.082
0.095
0.166
10.000
13.828
9.259
0.170
0.864
49.905
0.695
18.265
8.188
3.847
1.968
4.532
1.275
0.851
0.134
0.134
20.777
15.998
0.148
16.661
13.592
36.520
0.113
20.441
1.008
6.825
14.164
0.955
0.372
4.825
1.774
1.136
1.121
24.319
15.319
70.782
116.073
7.693
1.744
58.399
798.073
87.551
646.874
112.745
3.356
16.680
38.183
1.941
2.112
3.670
221.063
304.946
201.926
3.636
17.969
1003.810
13.928
363.633
160.097
74.201
36.516
79.906
21.753
14.413
2.187
2.179
331.740
246.750
2.271
252.306
199.121
529.494
1.626
289.266
13.857
92.285
190.364
12.825
4.988
60.997
21.000
21.000
21.000
7.712
6.968
6.785
5.872
5.677
5.571
5.409
4.986
4.883
4.838
4.834
4.775
4.663
4.594
4.566
4.475
4.469
4.466
4.463
4.447
4.417
4.379
4.330
4.325
4.315
4.289
4.270
4.214
4.140
4.093
4.081
4.032
4.026
3.997
3.947
3.939
3.921
3.873
3.858
3.845
3.823
3.780
3.757
3.748
3.747
3.744
3.660
* Gene name/symbol assigned  after manual search of  gene coordinates; bold: Interferome designated IRG; 
italics: literature validated IRG; † p47 IFN inducible GTPase; 
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Table 5.4 Up-regulated DEGs in lymph nodes at day 7 post CHIKV infection. 
 
Gene 
Symbol Official Gene Name
Mock 
FPKM
Day 7 
FPKM
Log2
(FC)
CINT12
Igh-V*
Gm5535
Igk-V*
Gm6455*
Gnat3
Slpi
Tmed6
Eaf2
CINT13
Ly6B*
Derl3
Aicda
CINT15
Igj
Bhlha15
Oosp1
Nuggc
Arhgef10
Il21
CINT16
CINT17
Mzb1
Cacna1h
CINT18
CINT19
Gzmk
Fkbp11
CINT20
5830418P13Rik
Mybl1
Ankrd55
Cryba4
CINT21
Endou
Tnfrsf17
Rrm2
Creld2
Fam46c
Mir148a
Pif1
Cdc20
Ccnb1
Nek2
Cdc25c
Gzmb
Cdca3
Sapcd2
Ly6c2
Plk1
Chikv-induced novel transcript 12
Immunoglobulin heavy chain variable region
-
Immunoglobulin light chain variable region
EG623849 pseudogene
Guanine nucleotide binding protein, alpha transducing 3
Secretory leukocyte peptidase inhibitor
Transmembrane emp24 protein transport domain containing 6
ELL associated factor 2
Chikv-induced novel transcript 13
Model protein coding gene containing LU domain
Derlin 3
Activation-induced cytidine deaminase
Chikv-induced novel transcript 12
Immunoglobulin J polypeptide
Basic helix-loop-helix family, member a15
Oocyte secreted protein 1
Nuclear gtpase, germinal center associated
Rho guanine nucleotide exchange factor (GEF) 10
Interleukin 21
Chikv-induced novel transcript 16
Chikv-induced novel transcript 17
Marginal zone B and B1 cell-specific protein
Calcium channel, voltage-dependent, T type, alpha 1H subunit
Chikv-induced novel transcript 12
Chikv-induced novel transcript 12
Granzyme K (granzyme 3; tryptase II)
FK506 binding protein 11, 19 kda
Chikv-induced novel transcript 20
Non-coding RNA
V-myb avian myeloblastosis viral oncogene homolog-like 1
Ankyrin repeat domain 55
Crystallin, beta A4
Chikv-induced novel transcript 21
Endonuclease, polyu-specific
Tumor necrosis factor receptor superfamily, member 17
Ribonucleotide reductase M2
Cysteine-rich with egf-like domains 2
Family with sequence similarity 46, member C
Microrna 148a
PIF1 5'-to-3' DNA helicase
Cell division cycle 20
Cyclin B1
Nima-related kinase 2
Cell division cycle 25C
Granzyme B 
Cell division cycle associated 3
Suppressor APC domain containing 2
Lymphocyte antigen 6 complex, locus C2
Polo-like kinase 1
0.000
42.904
0.115
9.687
0.126
0.289
15.915
0.130
2.086
0.066
1.091
4.291
0.784
0.215
115.486
0.940
0.762
0.702
0.145
0.137
0.137
0.121
56.721
0.667
0.170
0.102
0.443
5.103
0.178
0.522
1.153
0.699
0.912
0.184
1.593
2.025
12.413
22.299
8.812
0.299
0.984
7.294
5.214
2.322
1.014
2.967
7.447
0.851
121.659
5.364
1.777
3716.430
8.582
610.436
4.904
9.229
461.330
3.699
46.594
1.400
19.685
76.115
13.470
3.483
1793.620
14.465
10.706
9.831
2.009
1.802
1.686
1.430
613.061
6.977
1.733
1.023
4.352
45.429
1.351
3.923
8.106
4.646
5.410
1.071
9.174
11.607
66.768
118.987
46.654
1.563
5.016
37.152
26.387
11.715
5.071
14.613
36.513
4.148
591.624
25.822
21.000
6.437
6.225
5.978
5.279
4.996
4.857
4.830
4.482
4.396
4.173
4.149
4.103
4.015
3.957
3.943
3.812
3.809
3.792
3.722
3.622
3.558
3.434
3.388
3.348
3.329
3.297
3.154
2.920
2.910
2.814
2.733
2.568
2.539
2.525
2.519
2.427
2.416
2.404
2.388
2.350
2.349
2.339
2.335
2.322
2.300
2.294
2.285
2.282
2.267
Genes in this list are the top 50 most upregulated genes after immunoglobulin variable region genes (Ig-V) have 
been removed.  Ig-V genes represented by a single entry.  *Gene name/symbol assigned after manual search of 
gene coordinates. Bold; Interferome designated IRG; Italics: literature validated IRG; † p47 IFN-inducible GTPase.  
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Table 5.5 Down-regulated DEGs in foot tissues at day 2 post CHIKV infection. 
Gene 
Symbol Official Gene Name
Mock 
FPKM
Day 7 
FPKM
Log2
(FC)
-
Cd209g
-
Cd209f
Mrgprg
Vsig4
Inmt
Gkn3
Vstm2b
Pck1
Gpr34
Cd163
Retnla
Fcrls
Tmem179
Abca9
Ccl24
Abca6
Cd209d
Hepacam2
2610016A17Rik
Islr2
Cd209b
Pkhd1l1
Aldh1a3
Krt6b
Cd209a
Wnt2
Mrc1
Nnat
Nrac*
Siglech
Cd209c
Slc6a7
Cd33
Gpr1
LOC102633590
Gsta1
Tnfrsf17
Gsc
Fcna
Gdf10
Cyp2e1
Stmn4
Cx3cr1
Megf10
F13a1
Ednrb
Odf3l2
-
-
Cluster of differentiation 209g
-
Cluster of differentiation 209f
Mas-related GPR, member G
V-set and immunoglobulin domain containing 4
Indolethylamine n-methyltransferase
Gastrokine 3
V-set and transmembrane domain containing 2B
Phosphoenolpyruvate carboxykinase 1 (soluble)
G protein-coupled receptor 34
CD163 molecule
Resistin like alpha
Fc receptor-like S, scavenger receptor
Transmembrane protein 179
Atp-binding cassette, sub-family A (ABC1), member 9
Chemokine (C-C motif) ligand 24
Atp-binding cassette, sub-family A (ABC1), member 6
Cluster of differentiation 209
HEPACAM family member 2
Ncrna
Immunoglobulin superfamily containing leucine-rich repeat 2
Cluster of differentiation 209b
Polycystic kidney & hepatic disease 1 (autosomal recessive)-like 1
Aldehyde dehydrogenase 1 family, member A3
Keratin 6B
Cluster of differentiation 209a
Wingless-type MMTV integration site family member 2
Mannose receptor, C type 1
Neuronatin
Nutritionally-regulated adipose and cardiac-enriched protein
Sialic acid binding ig-like lectin H
Cluster of differentiation 209c
Solute carrier family 6 (neurotransmitter transporter), member 7
CD33 molecule
G protein-coupled receptor 1
Non-coding RNA
Glutathione s-transferase alpha 1
Tumor necrosis factor receptor superfamily, member 17
Goosecoid homeobox
Ficolin A
Growth differentiation factor 10
Cytochrome P450, family 2, subfamily E, polypeptide 1
Stathmin-like 4
Chemokine (C-X3-C motif) receptor 1
Multiple egf-like-domains 10
Coagulation factor XIII, A1 polypeptide
Endothelin receptor type B
Outer dense fiber of sperm tails 3-like 2
-
1.03
7.97
2.93
17.71
2.74
17.80
51.52
5.66
2.41
7.70
12.82
20.57
145.84
3.47
1.67
19.02
15.23
2.97
28.45
1.61
1.93
3.63
6.29
1.70
10.18
19.57
7.37
3.54
45.39
29.51
2.24
1.62
4.83
3.19
6.05
7.08
3.69
1.17
1.80
1.41
9.39
40.12
24.42
1.18
2.49
1.89
88.71
7.25
9.19
1.31
0.00
0.57
0.30
1.86
0.32
2.37
7.31
0.83
0.36
1.15
1.97
3.35
25.88
0.62
0.30
3.53
2.84
0.59
5.73
0.33
0.41
0.79
1.41
0.39
2.34
4.55
1.73
0.84
10.75
7.08
0.55
0.40
1.20
0.80
1.52
1.79
0.93
0.30
0.46
0.36
2.42
10.34
6.34
0.31
0.65
0.50
24.10
1.98
2.51
0.36
-21.00
-3.81
-3.27
-3.26
-3.09
-2.91
-2.82
-2.77
-2.75
-2.74
-2.71
-2.62
-2.49
-2.49
-2.48
-2.43
-2.43
-2.33
-2.31
-2.28
-2.24
-2.21
-2.16
-2.14
-2.12
-2.10
-2.09
-2.08
-2.08
-2.06
-2.04
-2.02
-2.01
-2.00
-2.00
-1.98
-1.98
-1.98
-1.97
-1.96
-1.96
-1.96
-1.95
-1.93
-1.93
-1.91
-1.88
-1.87
-1.87
-1.86
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Table 5.6 Down-regulated DEGs in foot tissues at day 7 post CHIKV infection. 
Gene 
Symbol
Official gene name Mock 
FPKM
Day 7 
FPKM
Log2
(FC)
Plac9b
-
Egfbp2
Krt6b
Ep1
Smco1
Mir3965
Gm13490
-
Prss55
-
Ccl24
-
Gm4861
-
Mylk4
-
-
Retnla
Agbl1
-
2310065F04Rik
Mss51
Gdap1
Gm4861
Cox7a1
Ckmt2
Cd209b
-
D830013O20Rik
Crnn
Mucl1
Krtap15
Dupd1
-
Mrgprg
Dhrs7c
-
Vsig4
Mpp3
Col9a1
Myoz3
2310050B05Rik
Defb14
Sprr2h
Krt25
Hhatl
Myoz1
Krt27
Phkg1
Placenta specific 9b
-
Epidermal growth factor binding protein type b
Keratin 6B
Epithelial progenitor 1
Single-pass membrane protein with coiled-coil domains 1
Microrna 3965
Predicted gene 13490
-
Protease, serine, 55
-
Chemokine (c-c motif) ligand 24
-
Predicted gene 4861
-
Myosin light chain kinase family, member 4
-
-
Resistin like alpha
ATP/GTP binding protein-like 1
-
-
MSS51 mitochondrial translational activator
Ganglioside induced differentiation associated protein 1
Predicted gene
Cytochrome c oxidase subunit viia polypeptide 1 (muscle)
Creatine kinase, mitochondrial 2 (sarcomeric)
Cluster of differentiation 209a
-
-
Cornulin
Mucin-like 1
Keratin associated protein 15
Dual specificity phosphatase & pro isomerase domain containing 1
-
Mas-related gpr, member g
Dehydrogenase/reductase (SDR family) member 7C
-
V-set and immunoglobulin domain containing 4
Membrane protein, palmitoylated 3 (MAGUK p55 subfamily 3)
Collagen, type IX, alpha 1
Myozenin 3
Ncrna
Defensin beta 14
Small proline-rich protein 2H
Keratin 25
Hedgehog acyltransferase-like
Myozenin 1
Keratin 27
Phosphorylase kinase, gamma 1 (muscle)
5.29
1.27
6.75
19.57
2.91
6.22
1.04
1.39
1.31
4.09
1.81
15.23
1.09
2.29
3.92
11.85
1.15
1.89
145.84
2.64
1.31
3.35
73.10
1.09
1.11
163.38
46.40
6.29
6.89
1.40
1.84
7.75
8.82
1.48
1.12
2.74
17.23
2.93
17.80
4.96
3.32
11.74
27.83
9.74
5.03
31.30
18.52
173.32
14.60
21.28
0.00
0.00
0.63
1.88
0.31
0.73
0.12
0.18
0.17
0.55
0.25
2.13
0.16
0.34
0.64
2.03
0.20
0.33
25.75
0.47
0.23
0.61
13.68
0.21
0.21
31.22
8.87
1.20
1.32
0.28
0.37
1.56
1.78
0.30
0.23
0.56
3.56
0.61
3.71
1.06
0.71
2.56
6.15
2.18
1.13
7.09
4.22
39.55
3.33
4.91
-21
-21
-3.42
-3.38
-3.24
-3.08
-3.07
-2.95
-2.95
-2.91
-2.86
-2.84
-2.76
-2.74
-2.61
-2.54
-2.53
-2.51
-2.50
-2.48
-2.48
-2.46
-2.42
-2.39
-2.39
-2.39
-2.39
-2.39
-2.38
-2.32
-2.32
-2.31
-2.31
-2.29
-2.29
-2.28
-2.27
-2.27
-2.26
-2.23
-2.22
-2.20
-2.18
-2.16
-2.16
-2.14
-2.13
-2.13
-2.13
-2.12
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Table 5.7 Down-regulated DEGs in lymph nodes at day 2 post CHIKV infection. 
Gene Symbol Official gene name Mock FPKM
Day 7 
FPKM
Log2
(FC)
Mirlet7h
Bpifb6
Bpifb3
Bpifb2
Cd207
Cd209e
Igh-V*
Clec4g
Cd209d
Rasd2
Syndig1
Cd209a
-
Rgr
Necab2
Calca
Cd209f
Il22ra2
1300017J02Rik*
Cbr2
Wasf1
Cd209b
Cd209g
Ccl24
Mrc1
F8
Abca9
Sept3
Gcsam
Epor
Inmt
Nxph3
Adra1b
-
Ces2e
Il13ra2
Marco
Hpgd
Stab2
Slc40a1
Ak8
Crisp3
Gchfr
Chp2
Srpx2
Gria3
Fam65c
Mogat1
Slc16a12
A530099J19Rik*
MicroRNAlet7h
BPI fold containing family B, member 6
BPI fold containing family B, member 3
BPI fold containing family B, member 2
CD207 molecule, langerin
Cluster of differentiation 209e
Immunoglobulin heavy chain variable region
C-type lectin domain family 4, member G
Cluster of differentiation 209d
RASD family, member 2
Synapse differentiation inducing 1
Synapse differentiation inducing 1
Retinal g protein coupled receptor
Ral guanine nucleotide dissociation stimulator-like 4
N-terminal ef-hand calcium binding protein 2
Calcitonin-related polypeptide alpha
Interleukin 22 receptor, alpha 2
Inhibitorof carbonic anhydrase
Carbonyl reductase 2
WAS protein family, member 1
Cluster of differentiation 209b
Cluster of differentiation 209g
Chemokine (C-C motif) ligand 24
Mannose receptor, C type 1
Coagulation factor VIII, procoagulant component
Atp-binding cassette, sub-family A (ABC1), member 9
Septin 3
Germinal center-associated, signaling and motility 
Erythropoietin receptor
Indolethylamine n-methyltransferase
Neurexophilin 3
Adrenoceptoralpha 1B
Carboxylesterase 2e
Interleukin 13 receptor, alpha 2
Macrophage receptor with collagenous structure
Hydroxyprostaglandin dehydrogenase 15-(NAD)
Stabilin 2
Solute carrier family 40 (iron-regulated transporter), member 1
Adenylate kinase 8
Cysteine-rich secretory protein 3
GTP cyclohydrolase I feedback regulator
Calcineurin-like ef-hand protein 2
Sushi-repeat containing protein, x-linked 2
Glutamate receptor, ionotropic, AMPA 3
Family with sequence similarity 65, member C
Monoacylglycerol o-acyltransferase 1
Solute carrier family 16, member 12
G protein coupled receptor like 
229.71
1.01
11.84
7.05
2.82
5.49
2.34
3.27
52.93
2.51
3.65
10.19
1.79
1.43
1.01
3.21
13.21
31.05
1.74
34.73
2.68
214.60
4.89
2.19
18.04
11.58
8.62
2.58
3.48
3.50
46.71
1.29
1.22
4.16
3.52
3.94
131.67
20.12
11.84
7.76
2.46
6.39
2.94
8.72
5.13
4.38
7.21
2.98
1.34
5.94
3.45
0.03
0.46
0.29
0.21
0.41
0.23
0.33
6.07
0.29
0.43
1.21
0.23
0.20
0.15
0.49
2.21
5.57
0.32
6.51
0.51
40.46
0.92
0.41
3.43
2.26
1.69
0.52
0.71
0.72
9.77
0.27
0.26
0.89
0.78
0.88
29.43
4.52
2.67
1.76
0.56
1.46
0.68
2.04
1.20
1.03
1.70
0.71
0.32
1.43
-6.06
-5.03
-4.70
-4.59
-3.75
-3.74
-3.34
-3.32
-3.12
-3.12
-3.08
-3.08
-2.98
-2.83
-2.79
-2.71
-2.58
-2.48
-2.43
-2.42
-2.41
-2.41
-2.40
-2.40
-2.40
-2.36
-2.35
-2.30
-2.29
-2.28
-2.26
-2.24
-2.23
-2.23
-2.18
-2.17
-2.16
-2.15
-2.15
-2.14
-2.13
-2.13
-2.11
-2.10
-2.09
-2.09
-2.08
-2.08
-2.07
-2.05
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Table 5.8 Down-regulated DEGs in lymph nodes at day 7 post CHIKV infection. 
 
Gene Symbol Official gene name Mock FPKM
Day 7 
FPKM
Log2
(FC)
Mirlet7h
Calca
Crabp1
Gm2083*
Krt15
Bpifb6
Pck1
Wfdc18
Cd209e
Bpifb2
Cldn8
Nxph3
Muc15
Fcgbp
A530053G22Rik
Mup3
4931408D14Rik
Slc44a4
Pdk4
Tshr
Saa3
Il17b
Wwc1
S100a14
Mmp12
Ccdc129
B3galt2
Tph1
Defb1
Cbr2
Arhgap40
Tfap2b
LOC102638835
Sox10
Mogat1
Ptgds
Alb
Elf5
Mmd2
Plekhb1
Wif1
Col5a3
Col6a5
Ttpa
Orm1
plet1
Spon2
Enpep
Adra1a
Areg
MicroRNA let 7h
Calcitonin-related polypeptide alpha
Cellular retinoic acid binding protein 1
major urinary protein LOC100048885
Keratin 15
BPI fold containing family B, member 6
Phosphoenolpyruvate carboxykinase 1 (soluble)
Wap-fourdisulphide core domain18
Cluster of differntiation 209e
BPI fold containing family B, member 2
Claudin 8
Neurexophilin 3
Mucin 15, cell surface associated
Fc fragment of igg binding protein
Non-coding RNA
Major urinary protein 3
Non-coding RNA
Solute carrier family 44, member 4
Pyruvate dehydrogenase kinase, isozyme 4
Thyroid stimulating hormone receptor
Serum amyloid A3 pseudogene
Interleukin 17B
WW and C2 domain containing 1
S100 calcium binding protein A14, 
Matrix metallopeptidase 12 (macrophage elastase)
Coiled-coil domain containing 129
Udp-gal:betaglcnacbeta 1,3-galactosyltransferase, polypeptide 2
Tryptophan hydroxylase 1
Defensin, beta 1
Carbonyl reductase 2
Rho gtpase activating protein 40
Transcription factor activating enhancer binding protein 2 beta
Non-coding RNA
SRY (sex determining region y)-box 10
Monoacylglycerol o-acyltransferase 1
Prostaglandin D2 synthase 21kda (brain)
Albumin
Fas (TNFRSF6) binding factor 1, e74-like factor 5 (ets domain TF) 
Monocyte to macrophage differentiation-associated 2
Pleckstrin homology domain containing, family B (evectins) 1
WNT inhibitory factor 1
Collagen, type V, alpha 3
Collagen, type VI, alpha 5
Tocopherol (alpha) transfer protein
Orosomucoid 1
Placenta expressed transcript 1
Spondin 2, extracellular matrix protein
Glutamyl aminopeptidase (aminopeptidase A)
Adrenoceptoralpha 1A
Amphiregulin
229.71
3.21
1.66
2.96
3.20
1.01
126.14
16.09
5.49
7.05
1.83
1.29
2.30
3.84
3.32
1.13
2.10
1.72
10.72
2.46
4.05
1.86
1.39
2.23
1.12
1.07
6.17
1.27
4.09
34.73
1.60
2.03
1.61
3.16
2.98
4.94
3.14
2.11
4.46
4.59
1.77
7.63
2.71
1.30
44.29
3.86
3.30
5.84
1.08
17.60
2.52
0.19
0.25
0.54
0.58
0.23
31.26
4.08
1.40
1.89
0.52
0.37
0.66
1.13
0.98
0.34
0.63
0.52
3.26
0.75
1.24
0.57
0.43
0.71
0.36
0.35
1.99
0.41
1.33
11.36
0.52
0.67
0.53
1.06
1.00
1.67
1.07
0.71
1.51
1.56
0.61
2.62
0.95
0.46
15.58
1.36
1.17
2.07
0.38
6.25
-6.51
-4.08
-2.73
-2.46
-2.45
-2.12
-2.01
-1.98
-1.98
-1.90
-1.82
-1.81
-1.80
-1.76
-1.76
-1.73
-1.73
-1.73
-1.72
-1.71
-1.71
-1.70
-1.70
-1.65
-1.65
-1.63
-1.63
-1.63
-1.62
-1.61
-1.61
-1.60
-1.60
-1.57
-1.57
-1.56
-1.56
-1.56
-1.56
-1.55
-1.55
-1.54
-1.51
-1.51
-1.51
-1.51
-1.50
-1.49
-1.49
-1.49
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5.3.2 Ingenuity Pathway Analysis of upstream regulators  
 
 To gain further insight into gene regulation following CHIKV infection, up- and 
down-regulated DEGs were analysed using Ingenuity Pathways Analysis (IPA) of up-
stream regulators. 
 
 IPA up-stream regulator analysis predicts the transcription factors and signalling 
molecules mediating transcription based on gene expression changes within a data set 
(i.e. a DEGs list).  The majority of predicted up-stream regulators at day 2 in both tissues 
and in the feet at day 7 were components of type I IFN signalling (Table 5.9 & Table 5.10, 
bolded entries).  IFNγ and IL-12 were also predicted upstream regulators, consistent with 
CHIKV-induced Th1 responses (Gardner, Anraku et al. 2010) and the up-regulation of 
multiple IRGs (see sections 5.3.4 & 5.3.5).  Consistent with activation of apoptosis during 
CHIKV (Krejbich-Trotot, Denizot et al. 2011), activity down stream of TRIM24 (negative 
regulator of p53-dependant apoptosis) (Allton, Jain et al. 2009) and the microRNA mir-21 
(suppressor of apoptosis in activated T-cells) (Meisgen, Xu et al. 2012) were down-
regulated in samples at day 2 and day 7 feet. 
 
 While STAT 1 and IFNγ were more prominent upstream regulators, STAT3 and IL-
4, involved in anti-inflammatory and wound repair processes, were also predicted 
regulators at day 7 in the feet.  In the lymph node at day 7, predicted upstream regulators 
also reflected the production of humoral immune responses; CSF2, EP400, FOxM1  are 
drivers of cell cycle progression (Costa 2005, Kim, Woo et al. 2010) with, Myc, CD38 and 
IL-5 associated with B cell proliferation and differentiation (Pasqualucci, Neumeister et al. 
2001) (Table 5.10).  Consistent with increased cellular proliferation, the activity of the 
tumour suppressors SMARCB1 (Modena, Lualdi et al. 2005), RB1 and RBL2 (Villanueva 
2014) and pro-apoptosis gene BNIPL3 (Diwan, Koesters et al. 2008) was predicted to be 
inhibited.  The activity of PPARA and PPARG, key regulators of fatty acid metabolism 
(AlSaleh, Sanders et al. 2012) and transcriptional regulation (Salter and Tarling 2007) and 
the T-cell marker, CD3 as well as IRGM, an up-regulated gene in day 2 samples and day 7 
feet, were also predicted to be inhibited in lymph nodes at day 7. 
 
 These analysis have identified a type I IFN mediated pathway that may play a role 
in gene regulation during CHIKV infection. 
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Table 5.9.  The major upstream regulators of gene expression in the feet of CHIKV 
infected mice at day 2 and day 7 post infection. 
 
 
P-value indicates the likelihood of a signalling pathway downstream of the listed upstream regulator is involved.  Z-score indicates the 
degree to which a downstream pathway is activated or inhibited.  Bold: gene has previously been shown to modulate type I IFN 
signalling. 
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Table 5.10.  The major upstream regulators of gene expression in the lymph 
nodes of CHIKV-infected mice at day 2 and day 7 post infection. 
 
 
P-value indicates the likelihood of a signalling pathway downstream of the listed upstream regulator is involved.  Z-score 
indicates the degree to which a downstream pathway is activated or inhibited.  Bold: gene has previously been shown to 
modulate type I IFN signalling. 
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5.3.3 Ingenuity pathways analysis of canonical pathways 
 
 Up- and down-regulated DEGs were also analysed using the IPA canonical 
pathway analysis tool.  Activated pathways were similar between feet at day 2 and 
day 7, and lymph nodes at day 2, with communication, activation, maturation and 
migration of immune cells common to each sample.  The liver X receptor and retinoic 
acid receptor (LxR/RxR) Activation was predicted to be engaged in the lymph nodes 
at day 2 but not at day 7 (Figure 5.1).  LxR/RxR form heterodimers with PPARA and 
PPARG (predicted to be inhibited upstream regulators at day 7 in the lymph nodes; 
Table 5.10), that can regulate gene transcription and chromatin unwinding (Salter 
and Tarling 2007).  Consistent with the absence of type I IFNs and waning viral titres 
at day 7 (Chapter 2), Interferon signalling and Activation of IRF by cytosolic PRRs 
pathways were not activated in the feet, nor lymph node at day 7.  The pathways 
predicted to be engaged in the lymph nodes at day 7 were dominated by cell cycle 
control, DNA damage repair and homologous recombination.  This is indicative of the 
generation of antibody responses that begin as early as day 4 post CHIKV infection 
(Kam, Lum et al. 2012), and is consistent with the predicted upstream regulators 
engaged in B cell proliferation (previous section 5.3.2) and the abundance of 
immunoglobulin variable regions up-regulated in day 7 lymph node (Table 5.4). 
 
 The results here, together with results of section 5.3.2, are consistent with the 
known immunobiology of the host response to CHIKV and are also consistent with 
the previous microarray studies (Nakaya, Gardner et al. 2012). 
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Figure 5.1 IPA canonical pathways engaged in mouse feet and lymph nodes at day 2 and day 7 post CHIKV infection. Up- or 
down- regulated DEGs that are part of an IPA canonical pathway are presented as the percentage of total genes in that pathway.  
Pathways are ranked by p-value. 
 139 
5.3.4 Quantitation of type I IFN regulated genes 
 
Given the critical role of type I IFNs in CHIKV infection (Chapter 2) (Couderc, 
Chrétien et al. 2008), the abundance of type I IFN regulated genes (IRGs) in the DEGs 
lists was assessed using the Interferome v2.01 database (Rusinova, Forster et al. 2013). 
 
In feet at day 2 and day 7, and lymph nodes at day 2, ≥ 65% of the top 50 up -
regulated DEGs identified by Interferome were IRGs (Figure 5.2, grey bars).  In all 
samples, there was a higher percentage of IRGs in the top 50 up-regulated DEGs 
compared to total DEGs.  In both tissues, the percentage of type I IRGs was greatest at 
day 2 (Figure 5.2, black bars), consistent with the peak production of type I IFN at day 2 
post infection seen in Chapter 2.  However, the percentage of type I IRGs remained 
elevated at day 7 in the feet.  In lymph nodes at day 7, the percentage of type I IRGs was 
substantially lower than the other samples. 
 
A number of DEGs, were not recognised by, or listed in Interferome, such as 
predicted genes and the type I IFNs themselves.  A literature search of unrecognised 
genes brought the percentage of IRGs in the top 50 up-regulated DEGs lists to 86%, 82% 
and 72% in the feet at day 2 and day 7 and in the lymph nodes at day 2, respectively 
(Figure 5.2, white bars, Tables 5.1-8, italised text).  No additional type I IRGs were found 
in the top 50 for lymph nodes at day 7 beyond those identified by the Interferome analysis. 
 
These results show that the majority of genes induced following CHIKV infection are 
regulated by the type I IFNs, particularly at day 2, with sustained up-regulation of type I 
IRGs in the feet at day 7. 
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Figure 5.2.  Percentage of type I IRGs in up-regulated DEGs.  The percentage of IRGs 
in the total (black) and the top 50 (grey) up-regulated DEG lists as determined by 
Interferome v2.01.  White bars represent the percentage of type I IRGs in the top 50 up-
regulated DEGs identified by Interferome, plus type I IRGs identified by literature search.  
Antibody variable regions were excluded from day 7 lymph node DEGs lists.  LN: 
lymphnode; Ft: foot.  
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5.3.5 Quantitation of interferon gene expression 
 
The previous section showed continued up-regulation of IRGs in feet at day 7.  
Eighteen known murine type I IFNs exist, including thirteen IFNα subtypes with often 
confounding sequence homology (Fung, Sia et al. 2004, Woelk, Frost et al. 2007).  RNA-
Seq (unlike microarray technologies) enables identification of the individual IFNα subtypes, 
despite their similarity.  To elucidate the individual IFNs involved in gene regulation 
following CHIKV infection, transcript levels of all type I IFN subtypes, as well as type II IFN 
(IFNγ), the two type III IFNs (λ2 & λ3) were examined through out the course of infection. 
 
The type I IFNs had a surprisingly low relative abundance of transcripts (Figure 5.3).  
In both tissues, type I IFNs were highest at day 2, and returned to mock levels by day 7.  
IFNβ was considerably higher in the feet compared to lymph nodes at day 2, as were 
IFNα4 and IFNα5, with a small but significant increase in IFNα1, IFNα2 and IFNα6.  
Conversely, IFNγ was significantly higher in the lymph node compared to feet at day 2.  
However, IFNγ returned to mock infected levels in the lymph nodes at day 7, while in the 
feet, IFNγ expression had increased and was significantly elevated compared to both 
mock and day 2 levels.  Type III IFNs did not differ significantly from mock in any tissues or 
time points.  The type I IFN, IFNε is specific to the female reproductive tract (Fung, 
Mangan et al. 2013) and was not detected in any tissues or time points analysed. 
  
 The results here demonstrate the remarkably low level of type I IFN transcripts 
required to generate the strong type I IFN response induced following CHIKV infection.  
These results also reconfirm the involvement of IFNγ in the immune response to CHIKV 
(Gardner, Anraku et al. 2010), and provide a better understanding of the induction of the 
individual IFNα subtypes. 
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Figure 5.3  Transcript abundance of the IFN subtypes in CHIKV- and mock-infected 
mouse feet and lymph nodes.  FPKM vales of IFN transcripts in the lymph nodes and 
feet of mock infected mice and at day 2 and day 7 post infection, as determined by 
Cufflinks.  Fragments per kilobase (of exon) per million fragments mapped (FPKM) is the 
estimated number of gene transcripts based on the number of reads that align to a 
particular genomic region.  LN: lymphnode.  Statistics obtained by t-test. 
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5.3.6 FPKM and fold changes of IRGs in the top 50 DEG lists  
  
 The previous section showed a distinction between in the expression of type I and 
type II IFNs in the feet and lymph nodes at the two time points.  To assess how IFN 
expression influenced IRG up-regulation, the expression of a set of IRGs common to day 2 
samples and day 7 feet in the top 50 DEGs was investigated. 
 
 In mock infected tissues, transcript FPKM levels of the selected IRGs were 
consistently higher in the lymph nodes than in feet (Figure 5.4).  However, upon infection, 
these genes were up-regulated by an equal or significantly higher fold change in the feet 
compared to lymph nodes.  Interestingly, while many IRGs in the lymph nodes were less 
up-regulated at day 7 than at day 2, at day 7 all IRGs in the feet remained significantly up-
regulated.  Gbp1 and Gzmb were higher at day 7 than day 2 in the feet.  In the lymph node 
at day 7, all IRGs except ISG20 and Gzmb had returned to mock-infected levels. 
 
 These results suggest continued up-regulation of IRGs in the feet of CHIKV infected 
mice on day 7.  These IRGs emerge to be regulated by both type I and type II IFNs 
(Interferome).  The continued presence of IFNγ in day 7 feet is established in this model of 
CHIKV (Gardner, Anraku et al. 2010), likely explains the up-regulation of these IRGs. 
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Figure 5.4 Transcript abundance and differential expression of IRGs in CHIKV- and 
mock-infected mouse feet and lymph nodes.  Mock FPKM values of IRGs in the lymph 
nodes and feet and their Log2 (fold change) at day 2 and day 7 post infection, as 
determined by Cufflinks. Fragments per kilobase (of exon) per million fragments mapped 
(FPKM) is the estimated number of gene transcripts, calculated by Cufflinks based on the 
number of reads that align to a particular genomic region.  LN: lymphnode; Ft: foot.   
Statistics obtained by t-test.   
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5.3.7 Up-regulated IRGs in day 7 feet are primarily regulated by type I IFNs 
 
 The observations in section 5.3.6 suggested that type I IRGs may remain up-
regulated despite the absence of type I RNAs in day 7 feet.  To investigate this 
phenomenon further, all up-regulated genes in the feet at day 7 were analysed using 
Interferome v2.0 to quantify gene induction by the different IFN analysed subtypes.  The 
majority of IRGs in day 7 feet emerged to be regulated by type I IFN, with some overlap 
with IFNγ regulated genes and no apparent type III IFN involvement.  Thus in the feet at 
day 7 feet, type I IRGs were shown to be widely induced, despite the absence of type I IFN 
transcripts. 
 
 
 
 
Figure 5.5   IFN-induced genes in CHIKV infected mouse feet at day 7.   Venn diagram 
of all up-regulated IRGs in the feet at day 7 post infection detailing the number of IRGs 
induced by each IFN subtype. 
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5.3.8 Transcriptional activity of IRF3 and IRF7 during CHIKV infection 
 
 IRF3 and IRF7 are key type I IFN transcription factors.  Chapter 2 demonstrated the 
importance of IRF3 and IRF7 in preventing severe CHIKV disease.  To further understand 
their function during CHIKV infection, the expression of IRF3 and IRF7 alternatively spliced 
isoforms were compared in all samples. 
 
 Whole gene expression (i.e. all transcriptional isoforms) of IRF3 did not differ 
between mock, day 2 and day 7 time points in either tissue (Figure 5.6A).  However, the 
number of IRF3 transcripts was significantly higher in the lymph nodes compared to feet at 
each time point.  The transcript abundance of IRF7 was significantly elevated at day 2 post 
infection in feet and lymph nodes (Figure 5.6 B) consistent with RT PCR data (Chapter 2).  
At day 7, IRF7 gene expression in the feet had reduced from day 2 levels, but was still 
significantly higher than in mock infected feet.  In contrast, in the lymph nodes at day 7, 
IRF7 gene expression had returned to mock infected levels.  
 
 Seven novel IRF3 transcript isoforms were identified by Cufflinks, in addition to the 
two known IRF3 mRNA sequences (Karpova, Ronco et al. 2001) (Figure 5.6C).  Alignment 
of the novel isoforms to the mouse and the human IRF3 amino acid sequences indicated 
that five of the novel isoforms were lacking the activation domain (AD) (Supplementary 
data, Figure S1). There were no significant differences in expression of the IRF3 isoforms 
at the different time points.  Although there was a substantially higher proportion of IRF3 
isoforms lacking the AD in seen in the lymph nodes (Figure 5.6C), this did not reach 
statistical significance.  The three known IRF7 isoforms were also identified.  However, no 
novel isoforms were reported by Cufflinks and there was no change in isoform transcript 
abundance in the different tissues and time points (Figure 5.6D).   
  
 The results here reveal the presence of seven, previously undescribed IRF3 
isoforms that are expressed at different ratios in the feet and lymph nodes.  IRF3 gene and 
isoform expression and IRF7 isoform expression were stable following CHIKV infection.  In 
contrast, IRF7 was substantially up-regulated in both tissues by day 2, and remained 
elevated in the feet at day 7. 
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Figure 5.6  Gene and isoform expression of IRF3 and IRF7 in mock infected and 
CHIKV-infected mouse feet and lymph nodes.   A & B) FPKM values of total gene 
transcripts in mock infected feet and lymph nodes and at day 2 and day 7 post infection.  C 
& D) The proportion of individual isoform transcripts as a percentage of total gene 
transcripts.  IRF3 isoforms that contain the activation domain are coloured green.  v: 
variant/isoform.  LN: lymphnode; Ft: foot.  Statistics obtained by t-test.  
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5.3.9 Assessment of uncharacterised DEGs  
 
 Many DEGS induced following CHIKV infection were unannotated, or 
uncharacterised.  Unannotated/uncharacterised genes in the top 50 up-regulated DEGs 
lists were termed CHIKV-induced novel transcripts (CINTs) and were investigated for their 
validity and protein coding potential (described in material and methods section 5.2.4).  
Three CINTs, from a total of 22, were identified as having the potential to encode a novel 
protein (Table 5.11) (full list in supplementary data, Table S1) and their RNA sequences 
were investigated for the strength of their Kozak sequence.  A Kozak sequence is required 
for ribosomal recognition of the translational start site and was considered strong if the 
RNA sequence matched the consensus sequence (Figure 5.7) at position -3, or +4, 
adequate if position -6, -3 or +4 matched, and weak if no nucleotides in the CINT RNA 
sequence matched the Kozak consensus (Kozak 1986).  Only CINT9 was found to have a 
strong Kozak sequence (Supplementary data, Figure S2).  Thus, CINT11.2 and 15.2 were 
considered potential long non-coding RNAs, and were not investigated further for protein 
coding potential. 
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Table 5.11 Up-regulated, unannotated genes with protein coding features 
Protein coding gene 
feature 
CINT 9 CINT 11.2 CINT 15.2 
log2 (FC) 7.71 4.59 3.24 
FPKM 24.34 38.19 3.48 
ORF ≥ 30 aa Y Y Y 
uORF 0 0 0 
uAUG 0 4 2 
In frame stop codon N N N 
5’UTR ≥ 20aa Y Y Y 
Protein homology Ly6-I TRIM30a mCG14456 
Conserved domains LU Domain SPRY HMG box 
Kozak sequence Strong None Very weak 
 
 
 
Figure 5.7.  Kozak consensus sequence with nucleotide position indicated and start 
codon (AUG) indicated in bold, underlined text. 
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5.3.10 Investigation of the protein coding potential of CINT9 
  
 The previous section showed that one CHIKV induced novel transcript (CINT), 
CINT9, identified/predicted by Cufflinks, exhibited protein coding potential.  The possible 
function of the CINT9 gene was investigated further. 
 
 CINT9 was expressed in the lymph nodes at day 2 post infection, and was up-
regulated 208 fold.  Using the BLASTx algorithm to search the NCBI protein database, 
significant homology (e-value = 3 x 10-46) was found between lymphocyte 6 antigen B 
(Ly6B) and CINT9 sequences.  The CINT9 locus was located within the Ly6 antigen 
cluster on chromosome 15, between Ly6C1 and Ly6C2 (Figure 5.8A).  An amino acid 
sequence alignment of all mouse Ly6 antigens confirmed that the ly6/uPA receptor-like 
(LU) protein domain, conserved in all Ly6 antigens, was also present in CINT9 (Figure 
5.8B, full alignment in supplementary data, Figure S3).  Evolutionary analysis based on the 
amino acid sequence alignment of all murine Ly6 antigens further confirmed the 
relatedness of CINT9 with the Ly6 antigen gene family.  However, synteny analysis 
showed that CINT9 does not have a human orthologue (Figure 5.8A) and is located in a 
divergent gene cluster that is not found in humans (Lee, Wang et al. 2013) (Figure 5.8 A 
and C). 
 
 These results indicate the existence of potentially novel protein coding Ly6 antigen 
gene, which is up-regulated in the lymph nodes following CHIKV infection.   
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Figure 5.8  Figure 4. Synteny analysis, sequence homology and phylogenetic 
relationship between CINT9 and the Ly6 antigen family.  A) Diagram of the Ly6 
antigen gene cluster on murine chromosome 15 and corresponding region on human 
chromosome 8.  Orthologous genes are connected by lines.  Adapted from Lee, 
Wang et al. (2013).  B)  Alignment of Ly6 antigen amino acid sequences and the 
predicted protein sequence of CINT9 showing the conserved LU domain, containing 
10 cysteine residues, present in all sequences. Conservation threshold was 60%.  C)  
Phylogenetic analysis of CINT9 and Ly6 antigens in the Ly6 gene cluster conducted 
using MEGA v4.0 (Tamura, Dudley et al. 2007). The percentage of replicate trees in 
which The bootstrap test (500 replicates) percentages are shown next to the 
branches. The evolutionary distances were computed using the p-distance method 
and are in the units of the number of amino acid differences per site. 
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5.4 Discussion 
 The results here represent the first deep sequencing study of the in vivo 
mammalian host response to an alphavirus.  The findings demonstrate the nature of the 
genes expressed in mouse feet and lymph nodes following infection with CHIKV.  Early 
infection (day 2) was dominated by the type I IFN responses, with the exception of gene 
up-regulation in day 7 lymph nodes.  This was despite a relatively low level of type I IFN 
mRNAs.  IRGs remained substantially elevated in the feet at day 7 post infection, despite 
an absence of type I IFN mRNA.  In the lymph nodes, up-regulated genes were dominated 
by immunoglobulin variable region genes on day 7, with IFNγ heavily up-regulated on day 
2 and dropping to mock-infected levels by day 7.  Several uncharacterised genes were up-
regulated, including one potentially novel Ly6 antigen.  Six novel IRF3 isoforms were also 
identified.   
 
 The dominance of type I IFN responses. CHIKV infection induces serum type I IFNs 
by day 2 post infection, and up to 80% of genes in feet and lymph nodes at this time were 
type I IFN-regulated, yet the FPKM of type I IFN mRNA transcripts was very low (≤ 8 for all 
subtypes).  This may have been to the low stability of the type I IFNs are subject to tight 
post-transcriptional control; AU-rich repeats in type I IFN mRNA can be stabilised, but also 
targeted for rapid for degradation and prevention of detrimental inflammatory responses 
(Hao and Baltimore 2009, Anderson 2010).  Type I IFN mRNA, particularly IFNβ mRNA, 
expression was higher in feet compared to lymph nodes, consistent with the notion that 
type I IFNs are predominantly produced by non-haematopoietic cells (Schilte, Couderc et 
al. 2010).  Furthermore, IFNβ mRNA levels were relatively low in the lymph nodes 
whereas IFNγ levels were high.  This is perhaps also consistent with findings that IFNβ 
can, in certain settings, suppress IFNγ (Nguyen, Cousens et al. 2000, Rayamajhi, Humann 
et al. 2010, Chessler, Caradonna et al. 2011). 
 
 IRF7 and IRF7 activities.  All IFN mRNAs had returned to mock-infected levels by 
day 7.  Despite this, IRF7, a key transcription factor for IFNαs (Rudd, Wilson et al. 2012), 
as well as many other IRGs (Ning, Pagano et al. 2011, Bidwell, Slaney et al. 2012) 
remained strongly up-regulated in the feet at day 7.  IRF7 is itself heavily up-regulated by 
type I IFNs, and can also be activated in a type I IFN-independent manner when the IRF7 
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protein binds to the virus activated element (VAF) in the IRF7 promoter (Ning, Huye et al. 
2005).  IRF7 may also be up-regulated by IFNγ (Dölken, Ruzsics et al. 2008, O’Donnell, 
Conway et al. 2012), which remained up-regulated by ≈208 fold  in the feet at day 7.  
However, IRF7 mRNA translation can be inhibited via binding of the 3’UTR by OASL (Lee, 
Kim et al. 2013), which was highly expressed at day 7.  Guanylate binding protein (GBP4), 
which was also heavily up-regulated in the feet at day 7 is known to inhibit IRF7-mediated 
gene induction via interaction with the upstream adaptor molecule, TRAF6 (Hu, Wang et 
al. 2011). 
 
 Persistent up-regulation of IRGs.  With no type I IFN mRNA, continued up-
regulation of many of the top 50 most up-regulated IRGs in the feet at day 7 appeared to 
be associated with elevated IFNγ mRNA expression (in the lymph nodes, IFNγ and IRG 
mRNA expression had largely returned to mock levels by day 7).  IFNγ has been shown to 
work synergistically with BRCA1 to up-regulate the IRGs IFIT2, Mx1 and IRF7 as well as 
apoptotic responses (Andrews, Mullan et al. 2002, Buckley, Hosey et al. 2007).  Maloney, 
Thackray et al. (2012) found IFNγ-regulated IRF1 and STAT1 induction of gene 
expression was required for clearance of viral infection in macrophages, and viperin can 
be induced directly by IFNγ-induced IRF1 (Stirnweiss, Ksienzyk et al. 2010).  However, 
Interferome analysis of all up-regulated genes in feet at day 7 suggests that about 50% of 
IRGs were likely to be regulated by type I exclusively, despite the absence of type I IFN 
transcripts.  Ongoing stimulation of IRGs by viral RNA, independent of type I IFNs, has 
been reported and may involve IRF9 (Pulit-Penaloza, Scherbik et al. 2012), 
unphosphorylated ISGF3 (Cheon, Holvey‐Bates et al. 2013) and/or IRF1 (Stirnweiss, 
Ksienzyk et al. 2010, Harman, Lai et al. 2011).  A concept of viral stress-inducible genes 
has also been proposed where type I IRGs are stimulated directly by stress responses, 
rather than type I IFNs (Sarkar and Sen 2004).  CHIKV RNA is also known to persist for an 
extended period (Poo, Rudd et al. 2014) and may be responsible for type I IFN-
independent stimulation of type I IRGs. 
 
 Granzyme A, B and K.  The up-regulation of these granzymes, predominantly in the 
lymph nodes at day 7, may reflect activation of NK and CD8+ T-cells (Bratke, Klug et al. 
2008, Gardner, Anraku et al. 2010).  However, neither NK cells (Alsharifi, Lobigs et al. 
2006, Poo, Rudd et al. 2014) nor CD8+ T-cells (La Linn, Mateo et al. 1998, Smith-
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Norowitz, Sobel et al. 2000) appear to play important roles in controlling alphaviral 
infections.  Although recently,  CD8+ T cells have recently been seen to contribute to 
control of RRV in muscle cells (Burrack, Montgomery et al. 2015).  Granzymes are 
believed to be involved in inducing apoptosis of infected cells as well as other anti-viral 
activities (Domselaar and Bovenschen 2011).  However, they have recently also been 
shown to regulate pro-inflammatory cytokine responses (Wensink, Hack et al. 2015).  
Their presence in CHIKV infected tissues might play a role in CHIKV immunopathology, 
more so than anti-viral activities.  
 
 GTPases and their roles in viral infection.  The IFNγ-induced p47 immunity 
regulated GTPases and the p65 guanylate binding proteins (GBPs) constituted 20 and 
24% of the top 50 most up-regulated DEGs in the feet at day 2 and 7, respectively.  The 
p47 GTPases and GBPs, induced by IFNγ (and to a lesser extent by type I IFNs) (Taylor, 
Feng et al. 2004), associate with pathogen-containing vacuoles (PVs) to activate the PV’s 
pathogen killing activities (Kim, Shenoy et al. 2011, Haldar, Saka et al. 2013).  The p47 
GTPases disrupt PV membranes to promote autophagy and phagolysosome formation 
(Taylor, Feng et al. 2004, Kim, Shenoy et al. 2011), while GBPs facilitate trafficking of 
antimicrobial substrates, including NADPH oxidase (NOX2) and autophagy effectors into 
PVs (Haldar, Saka et al. 2013).  Up-regulation of GTPases in response to an alphavirus 
has been reported previously (Ryman, White et al. 2002).  While p47 GTPases are known 
to be critical for protection against several bacteria and protozoa (Taylor, Feng et al. 2004, 
Saha, Prasanna et al. 2010), little is known about their role in viral infections .  GBPs may 
have a role in viral infection with over-expression of GBP2 shown to inhibit the single-
stranded RNA viruses vesicular stomatitis virus (VSV) and encephalomyocarditis virus 
(EMCV) in mice (Carter, Gorbacheva et al. 2005), and GBP1 and 3 capable of inhibiting 
influenza, in vitro (Nordmann, Wixler et al. 2012).  CHIKV is known to engage autophagy 
processes to facilitate replication (Krejbich-Trotot, Gay et al. 2011, Joubert, Werneke et al. 
2012).  Thus it is plausible that CHIKV might induce and exploit the GTPases to facilitate 
replication, or that the GTPases represent a class of antiviral effectors not previously 
described for alphaviral infections. 
 
 IRF3 isoforms.  Seve novel IRF3 isoforms were identified.  Two IRF3 isoforms are 
known to exist, with one isoform a non-coding RNA that is targeted for non-sense-
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mediated RNA decay (Zhai, Gao et al. 2008).  While all seven novel isoforms identified 
here encoded the highly conserved DNA binding domain, five isoforms were shown to be 
missing all, or part of the activation domain (Lin, Mamane et al. 1999), indicating that these 
isoforms may act as antagonists of full length IRF3 (Karpova, Ronco et al. 2001, Li, Ma et 
al. 2011).  IRF3 protein is expressed constitutively and only becomes activated following 
TLR stimulation (Jensen and Thomsen 2012).  Accordingly, overall IRF3 expression was 
not seen to differ greatly between different time points.  However, expression of the 
different isoforms was seen to differ between the two tissues.  Further research will be 
required to understand the activities of these isoforms; however, it is possible that isoforms 
without activation domains act as inhibitors of IRF3 transcriptional activities (Karpova, 
Ronco et al. 2001, Zhai, Gao et al. 2008).  
 
 Protein coding potential of CINT9  CINT9 was found to meet the criteria for being a 
protein coding gene according to the Havana Annotation Guidelines (Wilming, Frankish et 
al. 2012) and the NCBI CCDS Curation Guidelines (Pruitt, Harrow et al. 2009).  High 
homology with Ly6B, including the presence of the conserved LU domain and was located 
within the Ly6 antigen locus on mouse chromosome 15. Ly6B and Ly6C2 were up-
regulated in samples at day 2 and in the feet at day 7.  The ly6 antigens are cysteine-rich, 
generally GPI-anchored cell surface proteins , commonly expressed on monocytes, DCs 
and neutrophils (Bamezai 2004, Lee, Wang et al. 2013) and have roles in cytokine 
production, cell migration and differentiation (Leuschner, Dutta et al. 2011, Ji, Liu et al. 
2012).  However, the CINT9 gene is located in a region of the chromosome that is present 
only in mice (Lee, Wang et al. 2013), and is unlikely to have a human orthologue.   
 
 Non coding RNAs.  As understanding of the genome progresses, it is apparent that 
gene expression is not limited to protein coding genes, but also diverse RNA species that 
can modulate gene and protein expression (Rinn and Chang 2012).  Non-coding genes 
are increasingly emerging to have a role in immune regulation, with microRNAs able to 
inhibit transcription or target mRNA for degradation (Heward and Lindsay 2014), long non-
coding RNAs (lncRNA) able to exert epigenetic regulation of gene expression (Lee 2012, 
Rinn and Chang 2012), and recently a class of IFN-regulated lncRNAs has been identified 
(Josset, Tchitchek et al. 2014).  CINT11 was found to have several characteristics of a 
long non-coding RNA: it is >200 bp long, exhibited characteristics of a protein coding 
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gene, was immediately upstream of TRIM30α, a gene with which CINT11 shared 
considerable homology, but was unlikely to be protein coding (Poliseno 2012, Qureshi and 
Mehler 2012, Rinn and Chang 2012).  TRIM30α down-regulates inflammasome activation 
(Hu, Mao et al. 2010) and TLR signalling (Shi, Deng et al. 2008), and was identified as a 
gene involved in viral clearance in later stages of encephalitic alphavirus, Venezuelan 
equine encephalitis virus (Atasheva, Akhrymuk et al. 2012).  LncRNAs are often the 
product of gene duplication and function to block the activity of neighbouring homologues 
(Poliseno 2012, Rinn and Chang 2012).  It is possible that expression of CINT11 at day 2 
following CHIKV had a role in blocking TRIM30α, thus promoting TLR signalling.  
 
 Down-regulation of CD209 isoforms.  All CD209 isoforms and their homologue 
CD207 (Langerhin) were seen to be heavily down-regulated in all tissues and time points, 
as were other lectins/carbohydrate-binding molecules. Down-regulation of these genes 
likely reflects stimulation of antigen presenting cells, which commonly down-regulate cell 
surface receptors, including CD209, once they have taken up an antigen (Relloso, Puig-
Kröger et al. 2002).  The down-regulation of a number of other M2 (anti-inflammatory) 
markers (Retnla, F13a1 Mrc1, CD163) likely reflects active suppression of homeostatic 
processes during an inflammatory response 
 
 The role of the microRNA, mirlet7.  In the lymph nodes, the most heavily down-
regulated gene at both day 2 and day 7 was the microRNA, mirlet7h.  The different mirlet7 
subtypes are known to be involved in a broad range of functions, such as apoptosis cell 
cycle regulation and tumour suppression (Ambros 2004, Rozen-Gagnon, Stapleford et al. 
2014), where they function as negative regulators in post-transcriptional control.  Down-
regulation of mirlet7 is known to occur in stimulated macrophages and results in increased 
production of IL-6 and IL-10 (Liu, Chen et al. 2011, Schulte, Eulalio et al. 2011).  
Consistent with down-regulation of the suppressive role of mirlet7 genes, a number of 
mirlet7 targets involved in apoptosis (Bcl proteins, Casp3) (Shimizu, Takehara et al. 2010, 
Wang, Tang et al. 2011) and cell cycle regulation (cyclin dependant kinases and cell 
division cycle genes, AIM1, E2f and CCNa) (Johnson, Esquela-Kerscher et al. 2007, Lee 
and Dutta 2007, Peter 2009) were up-regulated in the lymph nodes. 
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6. RNA-Seq analysis of CHIKV transcription in mice 
6.1 Introduction 
CHIKV enters the body by mosquito bite and is thought to spread from the site of 
infection to the draining lymph nodes (Schwartz and Albert 2010).  CHIKV causes acute 
and chronic, often debilitating polyarthritis that can last for months, to over a year, after 
viraemia has been cleared (Suhrbier, Jaffar-Bandjee et al. 2012).  In mice, infectious virus 
can be recovered from arthritic feet up to 14 day post infection, while viral RNA can persist 
for up to 100 days post infection (Poo, Rudd et al. 2014).  Viral RNA can also be detected 
in joint tissues for extended periods after the end of the viraemic period in humans 
(Hoarau, Jaffar Bandjee et al. 2010) and monkeys (Labadie, Larcher et al. 2010), with 
persisting viral RNA thought to be responsible for chronic inflammatory disease (Suhrbier 
and Mahalingam 2009).   
  
The alphaviral genome is a ~12kb single-strand, positive sense RNA with two open 
reading frames (ORFs) encoding four non-structural proteins (nsps) and five structural 
proteins (Strauss and Strauss 1994).  The genomic RNA resembles messenger RNA with 
5’ and 3’UTRs that facilitate viral RNA transcription and translation (Hyde, Chen et al. 
2015).  Like all RNA viruses, alphaviruses encode their own RNA polymerase, which is 
believed to have a high error rate (~10-4 errors per base) (Crotty, Cameron et al. 2001, 
Coffey, Beeharry et al. 2011).  Upon infection, the non-structural proteins are translated 
and form replication complexes (Strauss and Strauss 1994).  Replication complexes then 
interact with a conserved sequence element (CSE) in the 3’UTR, which serves as the 
promoter for negative strand RNA synthesis (Kuhn, Hong et al. 1990, Frolov, Hardy et al. 
2001).  Negative strand RNA is used a template for transcription of (i) full length, positive 
strand genomic RNA for virion packaging and translation, and (ii) 26S subgenomic RNA 
(encoding structural proteins), via the subgenomic promoter (Strauss and Strauss 1994, 
Schwartz and Albert 2010).   
Herein, RNA-Seq was used to gain insights into the evolution of CHIKV RNA in 
tissues, given that this viral RNA is likely responsible for acute and chronic disease.  Total 
RNA was isolated from the feet and lymph nodes of CHIKV infected mice (described in 
Chapter 4) and used for RNA-Seq analysis of polyadenylated RNA, which includes both 
positive strand genomic, and subgenomic CHIKV RNA.  
 159 
6.2 Materials and Methods 
 
6.2.1 Alignment of CHIKV sequences 
 The data analysed in this chapter is from the experiments described in Chapter 4.  
Specifically, the data files from which read sequences mapping to the mouse genome had 
been removed (section 4.2.7) were aligned to two CHIKV genomes.  Bowtie v2.0.2 
(Trapnell, Pachter et al. 2009) (default parameters) was used to align non-mouse reads to 
(i) the LR2006_OPY1 CHIKV reference genome (Parola, de Lamballerie et al. 2006) 
(accession: DQ443544.2, described in section 4.2.7), and (ii) a parental/input virus 
genome generated by sequencing of input virion RNA (Poo, Nakaya et al. 2014) and 
further sequencing of the 3’ UTR. 
 
6.2.2 Evaluation of alignments & investigation of the parental genome sequence 
Reads alignments generated by Bowtie were visualised in the Integrated Genome 
Viewer (IGV) (Robinson, Thorvaldsdóttir et al. 2011, Thorvaldsdóttir, Robinson et al. 
2012).  Where only one ‘mate’ in a paired-end read mapped to the CHIKV genome, IGV 
was used to extract the sequence of its unmapped mate.  The unmapped sequences were 
used as queries in homology searches using the basic local alignment search tool 
(BLAST, NCBI).  Unmapped read sequences that aligned to the CHIKV genome were 
used to create a consensus sequence.  The consensus sequence was incorporated into 
the LR2006_OPY1 genome to create a reference genome for the input/parental virus. 
 
6.2.3 Determination of partial CHIKV genome sequence 
The inferred sequence of the parental genome was confirmed by RT-PCR 
amplification of the input virus using the reaction and cycling conditions described in 
Chapter 2 (section 3.3.1) and the following primer sequences (5’3’): 
cgggaagctgagatagaagttg (forward), cataccgaactcttccacgatt (reverse).  The virus was also 
sequenced using BigDye terminator v3.1 (Life Technologies), according to the 
manufacturer’s instructions. 
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6.2.4   Mutational assessment 
SAMtools count algorithm was used to obtain read mapping counts from alignment 
data generated by Bowtie v2.0.2.  The total number of reads mapped to the genome as 
well as the number of reads mapped with a mapQ >20 (i.e. uniquely mapped to the 
genome), which also contained at least 1 mismatched base or insertion/deletion mutation, 
were derived and used to calculated the percentage of mutated reads per sample.  The 
IGV allele frequency threshold parameter was set to 5% such that positions in the genome 
at which 5% or more called nucleotides varied from the reference genome were 
highlighted and available for quantitation of potential mutations.  The Ilumina HiSeq200 
sequencing error rate is 0.4 – 2.0% depending on read length (Glenn 2011, Minoche, 
Dohm et al. 2011, Wall, Tang et al. 2014).  
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6.3 Results 
6.3.1 Read mapping to the LR2006_OPY1 CHIKV genome 
RNA-Seq data described in Chapter 4, with mouse genome sequences removed 
were mapped to the LR2006_OPY1 CHIKV genome and alignment files loaded into IGV.  
The frequency allele threshold was set to 5% (sequencing error rate is estimated to be 0.4 
- 2%), to enable identification of sites in the sequenced virus that differed from the 
LR2006_OPY1 genome in ≥ 5% of the nucleotides mapped to that site. 
 
Deviations of the mouse-derived CHIKV RNA sequences from the LR2006_OPY1 
genome of ≥ 5% are indicated by coloured vertical bars (Figure 6.1A, upper panels).  
Some deviations were present in all samples, with ≥97% frequency at each base position 
(Figure 6.1A, red boxes).  A single nucleotide deletion at position 9952 bp was also 
present in ~7.6% of reads in all samples, except day 7 lymph node (Figure 6.1A, blue 
box).  A region within the 3’UTR of the genome was heavily divergent from the reference 
genome, with few, heavily mismatched (> 5 mismatches) or no reads mapping to the 
region  11695 - 11740 bp (Figure 5.1B).  Perplexingly, a high number of reads that 
mapped uniquely to the genome (mapQ ≥20) either side of this aberrant region had a mate 
pair that could not be mapped to the LR2006_OPY1 genome (Figure 6.1B, red horizontal 
reads), suggesting a deletion 
 
 The presence of unmapped mate-pairs, and consistent deviations from the 
LR2006_OPY1 sequence, present in multiple samples from different mice, indicated that 
the input virus was distinct from LR2006_OPY1, rather than representing genuine 
mutations. Sequencing of the parental input virus was deemed necessary.  
 162 
 
 163 
Figure 6.1 Reads mapping to the CHIKV LR2006_OPY1 genome. A)  Schematic 
diagram of reads aligned to the CHIKV genome.  A bar chart of the log10 transformed read 
coverage (i.e. the number of reads aligned at a position in the genome, upper panels) and 
a condensed image of the individual 100 bp reads mapped to the genome (grey horizontal 
bars, lower panel) are shown.  Coloured, vertical bars in the upper coverage panels 
denote positions in the genome at which a nucleotide differs from the reference genome in 
≥ 5% of quality-weighted aligned reads.  Red boxes indicate positions at which ≥ 97% of 
nucleotides differ from the reference.  Blue boxes indicate an insertion in ~7.6% of reads.  
Base positions with < 20 reads mapped were excluded from analysis.  Images are 
representative of the three replicates for each sample.  B)  Enlarged image of the poorly 
mapped region in the 3’UTR of day 2 foot showing the reads with unmapped mate-pairs 
either side.  Red horizontal bar: read with unmapped mate, purple: single nucleotide 
insertion, black: single nucleotide deletion.  Images representative of 3 replicates.  
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6.3.2 Sequencing of the parental input virion genome 
Section 6.3.1 suggested differences between the input virus used to infect mice and 
the LR2006_OPY1 genome.  The parental virion genome sequence was established by 
Ion Torrent sequencing as described by Poo, Rudd et al. (2014).  However, the 3’ UTR 
was not fully sequenced using this technique. PCR primers were designed that flanked the 
aberrant 3’ UTR region and the region was amplified by RT-PCR.  RT-PCR products were 
then sequenced confirming a deletion in the 3’UTR, which was 44 bp in length, and new 
parental reference CHIKV genome, which incorporated the site changes seen by Poo, 
Rudd et al. (2014), as well as the 44 bp deletion in the 3’UTR, was generated 
 
5.3.3. Alignment to the new parental CHIKV genome 
 When non-mouse reads were re-mapped to the new parental virus genome (5.3.2), 
the site differences and the aberrant 3’ UTR region, observed in Figure 6.1, were no longer 
present (Figure 6.2A & B), and general features of the sequence analysis could now be 
described.   
 
 A reduction of ≈ 10 fold in the number of viral transcripts from day 2 to day 7 post 
infection in both tissues was apparent. This is consistent with the pattern of viral replication 
seen in Chapter 2, with peak tissue titres and serum viraemia seen at day 2 and 
undetectable viraemia at day 7.  The number of transcripts in the feet was significantly 
higher than in lymph nodes at both time points (Mean reads mapped: foot day 2: 
4,572,386 and day 7: 77,219 versus LN day 2: 4097 and day 7: 1444) (Figure 6.2A).  The 
lower number of transcripts in the lymph node compared to feet at each time point reflects 
the lower viral tissue titres seen in the lymph nodes compared to feet, as reported 
previously (Chapter 2)  (Rudd, Wilson et al. 2012).  In all samples, a higher number of 
reads were seen to align to the structural protein ORF (non-structural: structural, foot day 
2: 1:95±14, day 7: 1:57±14; lymph node day 2 1:13±4, day 7 1:18±2), consistent with the 
high ratio of subgenomic to genomic RNA found in alphavirus infected cells (Perri, Driver 
et al. 2000, Ng, Coppens et al. 2008). A feature of the alignments not previously reported 
in CHIKV replication was a high number of viral transcripts seen to map to the 5’UTR and 
Nsp1 at day 7 in the foot.   
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Figure 6.2 Reads mapping to the CHIKV genome. A)  Schematic diagram of reads 
aligned to the CHIKV genome.  A bar chart of the log10 transformed read coverage (i.e. 
number of reads aligned at a position in the genome, upper panels) and a condensed 
image of the individual 100 bp reads mapped to the genome (grey horizontal bars, lower 
panel) are shown.  Coloured, vertical bars in the upper coverage panels denote positions 
in the genome at which a nucleotide differs from the reference genome in ≥ 5% of aligned 
reads.  Base positions with < 20 reads mapped were excluded from analysis.  Images are 
representative of the three replicates for each sample.  B)  Enlarged image of the 3’UTR of 
day 2 foot.  Red horizontal bar: read with unmapped mate, black: single nucleotide 
deletion.  Images representative of 3 replicates.  
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6.3.3 Investigation of mutation accrual in the CHIKV genome 
 
 Having established the sequence of the parental input virus, the accrual of 
mutations could be analysed.  The percentage of mutated, 100 bp reads in each sample, 
and the number of positions in the viral genome at which 5% or more of called bases 
differed from the reference were quantified (Fig. 5.3A and B). 
 
 Figure 6.3A shows the percentage of mapped reads in each sample that mapped 
uniquely to the genome (i.e. MapQ >20), but also contained at least one mismatched base 
and/or insertion/deletion mutation.  In the feet, ~20% of mapped reads contained 1 or 
more mutations at day 2 and day 7.  The percentage of mutated reads was slightly but 
significantly higher in the lymph nodes (~23%) than in feet (~20%) on day 2. Over 40% of 
reads at day 7 in LN were found to contain at least one mutation, which was significantly 
higher than both day 2 LN (23%) and day 7 foot (20%).  The percentage of mutated reads 
in each of the 3 replicate samples was remarkably consistent, as indicated by the very 
small error bars. 
  
 Figure 6.3B presents the percentage of sites within the genome where 5% or more 
of called bases differed from the reference genome.  Only positions in the genome that 
had a coverage level of at least 20 reads were considered (e.g. 1 read in 20 with a 
mutation in a given site would reach the 5% threshold at that site).  The percentage of 
sites mutated increased significantly in both feet and lymph nodes from day 2 to day 7 post 
infection.  Consistent with Figure 5.3A, the percentage of mutated sites was significantly 
higher in lymph nodes at both time points, and was particularly evident on day 7. 
 
The results clearly show that there is an increase in mutations in the CHIKV 
genome over time (from day 2 to day 7).  Furthermore, these results also show that 
mutations are more prevalent in lymph nodes than in feet. 
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Figure 6.3.  Percentage of mutations present in RNA-Seq reads aligned to the CHIKV 
genome.  A)  The number of reads that had a Map Q>20, plus at least one mismatched 
base and/or and insertion/deletion mutation as a percentage of total reads aligned to the 
modified CHIKV genome in each tissue and time point. B)  The number of positions in the 
CHIKV genome at which ≥ 5% of aligned nucleotides differed from the reference genome, 
as a percentage of total base pairs in the modified CHIKV genome. *: p ≤ 0.05, **: p ≤ 
0.01, n.s.: not significant by t-test. n = 3 replicates per sample. 
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6.4 Discussion 
This Chapter represents the first deep sequencing analysis of CHIKV genomes in 
tissues.  The data presented here reflected the known CHIKV replication kinetics, in which 
virus spreads from the site of infection (feet) to the draining lymph nodes, via antigen 
presenting cells (Schwartz and Albert 2010), with viral titres peaking at day 2 and largely 
resolved at day 7 (Chapter 2)  (Rudd, Wilson et al. 2012).  A 44 bp deletion was found to 
be present in the parental input virus.  When mapped to a reference genome that was 
consistent with the input/parental virus, mutations within the CHIKV genome appeared to 
accumulate with time, particularly in the nsp ORF, and in the lymph nodes more so than in 
feet.   
 
The CHIKV genome was seen to accumulate mutations over time and the rate of 
mutation accumulation was higher in lymph nodes than in feet.  The error rate of RNA 
polymerases is estimated to be 10-4 mutations per nucleotide copied and is the likely 
cause of mutation accumulation (Holland, Spindler et al. 1982, Steinhauer and Holland 
1987, Coffey, Beeharry et al. 2011).  The accumulation of errors eventually results in error 
catastrophe and loss of replication capacity (Crotty, Cameron et al. 2001).  This is may 
account for the inability to recover infectious virus from feet of CHIKV infected mice after 
day 14 post infection, despite the presence of CHIKV RNA (Poo, Rudd et al. 2014).  Why 
the mutation rate was higher in the lymph nodes than in feet is unclear.  Viral RNA in the 
lymph nodes may be subject to greater immune pressure, or alternatively, the higher 
temperature of the lymph nodes compared with peripheral limbs (i.e. feet) may increase 
the mutation rate.  This increased rate of mutation accrual may also account for the lack of 
persistent infectious virus and viral RNA in lymphoid organs such as spleen and lymph 
nodes (Poo, Nakaya et al. 2014).  
 
As expected, fewer reads mapped to the nsp ORF than the structural ORF, in all 
samples.  As described in Chapter 4, an increased ratio of subgenomic to genomic RNA, 
driven by the subgenomic promoter, is required during alphavirus replication to facilitate 
production of 240 structural E1/E2 envelope proteins that house a single genome copy per 
mature virion (Rümenapf, Strauss et al. 1994, Perri, Driver et al. 2000, Ng, Coppens et al. 
2008).  The increased number of reads aligned to the genome at day 2 compared to day 7, 
is consistent with previous findings, including those in Chapter 2, in which tissue titres 
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peaked at day 2, and almost resolved by day 7 (Gardner, Anraku et al. 2010, Rudd, Wilson 
et al. 2012).  The increased number of reads aligned to the genome in feet compared to 
lymph nodes is consistent with the higher titres in feet compared to lymph nodes (Chapter 
2)  (Rudd, Wilson et al. 2012).  Feet were also the site of inoculation, and contain 
abundant synovial tissue, where alphaviruses are known to replicate (Strauss and Strauss 
1994, Schwartz and Albert 2010).  Virus in the lymph node had to spread from the site of 
inoculation, so titres might be expected to be lower in this tissue due to delay. 
 
Interestingly, a greater number of reads aligned to the 5’UTR/nsp1 (compared to 
nsps 2 - 4) in feet at day7.  Nsp1 facilitates capping of the 5’UTR (Ahola and Kääriäinen 
1995) and the 5’UTR also forms secondary structures that provide mRNA stability 
(Nickens and Hardy 2008), as well as containing promoter elements required for initiation 
of transcription (Gorchakov, Hardy et al. 2004).  The higher number of reads mapped to 
the 5’UTR/nsp1 in feet at day 7 may reflect increased RNA stability of degradation 
products or aborted transcripts. 
 
A frame shift mutation in the 6K protein involving a T insertion was identified in 
around ~ 7.6% of reads.   With the exception of day 7 lymph node (due to the paucity of 
mapped reads) this frame shift mutation was seen in all samples, and possibly represents 
a subset of viral species in the inoculum.  However, Forrester, Guerbois et al. (2011), in a 
study of intra-host variation of viral genomes, have previously reported repeated deletions 
in the 6K protein of Venezualean Equine Encephalitis virus, resulting defective interfering 
(DI) RNAs.  DI RNAs can antagonise viral proteins, and compete with parent virus for host 
transcription/translation factors, effectively enhancing viral fitness by slowing replication 
(Bangham and Kirkwood 1990, Thompson, Rempala et al. 2009).  DI RNA can also be 
packaged into DI particles which cannot replicate independently, but can still infect host 
cells (Thompson, Rempala et al. 2009, Firth, Atasheva et al. 2011).  DI particles have 
been associated with alphaviral persistence, in vivo (Atkinson, Barrett et al. 1986, Firth, 
Atasheva et al. 2011) and may contribute to the development of chronic arthritis following 
CHIKV infection, despite the absence infectious virus. 
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RNA-Seq of CHIKV RNA in tissues prompted a re-sequencing of RNA from parental 
input virions (Poo, Rudd et al. 2014), which confirmed several deviations from the 
LR2006_OPY1 genome.  The LR2006_OPY1 genome sequence was derived from human 
isolates that were passaged once in mammalian (Vero) cells prior to sequencing (Parola, 
de Lamballerie et al. 2006).  The parental virus used herein was from the same stocks 
sequenced by Parola, de Lamballerie et al. (2006), with two additional rounds of passaging 
in C6/36 mosquito cells (Gardner, Anraku et al. 2010).  RNA-Seq of the tissues also 
revealed a 44 bp deletion in the 3’UTR of the parental virus.  The 3’UTR of CHIKV varies 
widely between different strains due to direct sequence repeats that are duplicated, 
inverted or deleted in different CHIKV strains (Chen, Wang et al. 2013).  These variations 
are thought to facilitate viral fitness in different hosts/vectors (Chen, Wang et al. 2013, 
Hyde, Chen et al. 2015).  The 44 bp deletion detected in the parental virus sequence 
corresponds to part of a direct sequence repeat that occurs twice in the Asian lineage, and 
once in the ECSA lineage, of which LR2006_OPY1 derives (Chen, Wang et al. 2013).  The 
parental virus used herein thus likely acquired the site changes and the deletion in the 
3’UTR during the two passages in C6/36 mosquito cells. 
 
 The results presented here highlight the simple, yet effectual nature of alphavirus 
replication.  CHIKV quickly replicates to high titres, can mutate to evade host immune 
pressures and rapidly adapt to different hosts.  Despite encoding only eight genes in 2 
ORFs, CHIKV operates as a highly refined and effective pathogen. 
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7. General Discussion 
7.1 Summary of major findings 
 Chapter 2: IRF3/7 and adaptor molecules. This chapter demonstrated a critical role 
for IRF3 and IRF7 in effective type I IFN responses and protection against CHIKV infection 
and mortality.  IRF7, which was substantially up-regulated by day 1 of CHIKV infection, 
was essential for the type I IFN positive feedback loop.  IRF3/7 deficient mice developed 
severe disease that was associated with excessive IFNγ and TNF production and 
ultimately resulted in a lethal haemorrhagic shock, reminiscent of dengue haemorrhagic 
shock/dengue shock syndrome (DHS/DSS).  The findings implicated the type I IFN 
response in suppression of pathological levels of IFNγ, and in preventing the development 
of severe CHIKV disease.  Using mice deficient in the adaptor molecules upstream of IRF3 
and IRF7, multiple pathways were able to induce type I IFN production.  However, IPS1 
was found to be the most important for type I IFN production, then TRIF, with MyD88-/- 
mice capable of producing type I IFN, at only slightly reduced levels compared to WT 
mice.  Type I IFN induction following CHIKV infection was thereby shown to be 
predominantly via the RIG-1/MDA5/IPS-1 and TLR3/TRIF signalling pathways. 
 
 Chapter 3: GFP reporter mice.  This chapter sought to identify the cellular source of 
type I IFN production following CHIKV infection.  Initially, reporter mice, t heterozygous for 
expression of eGFP under the control of either the IFNβ or the IFNα6 promoter, were 
infected with CHIKV.  However, these mice emerged not to be informative, as eGFP 
production was too low for detection under all conditions tested. This was presumably due 
to disruption of positive feedback loops required to enhance the intrinsically low activity of 
the type I IFN promoter. 
 Analysis of tissue-specific type I IFN induction by RT-PCR and comparison with 
viral tissue titres in infected WT mice revealed a strong correlation between local type I 
IFN induction and viral tissue titres, with feet and lymph nodes producing the most robust 
type I IFN response.  This suggested that detection of local viral infection directs the 
production of type I IFN in responses to CHIKV infection 
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 Chapter 4: Assessment of RNA-Seq data. Comprehensive analysis of RNA isolated 
from the feet and inguinal lymph nodes of mice following CHIKV infection was undertaken 
using RNA-Seq.  Quality assessment of the RNA-Seq data was undertaken in this chapter, 
which demonstrated that the data was of a standard suitable for analysis of transcriptional 
activity of both the host and virus.  The RNA-Seq approach was sensitive enough to detect 
viral genomes, even at day 7 post infection, 1-2 days after the end of the viraemia period.  
Read depth, coverage and mapping was of high quality, and was also sufficient to enable 
host differential gene expression, reliable quantitation of low level gene transcription and 
identification of novel genes/transcripts, according to the ENCODE Consortium Standards, 
Guidelines and Best Practices for RNA-Seq v1.0 (ENCODE 2011).  Global analysis of host 
gene expression showed a general trend toward down-regulation, with more genes down-
regulated than up-regulated in all samples except day 2 feet.  However genes up-
regulated >2 fold out-numbered genes down-regulated >2 fold in all samples. 
 
 Chapter 5: Analysis of host gene expression following CHIKV infection.  In this 
chapter, induction of host transcriptional activity was shown to be dominated by type I IFN 
immune responses, with the majority of up-regulated genes being IRGs.  Relatively low 
levels of type I IFN mRNA transcripts were sufficient for this potent induction of IRGs at 
day 2.  At day 7 in the feet, IRGs, including IRF7, remained up-regulated despite the return 
of type I IFN mRNA transcripts to basal levels.  This suggested a type I IFN-independent 
mechanism of maintaining IRG expression in the feet, following initial type I IFN 
responses.  An exception to this was day 7 lymph node, where genes associated with B-
cell activation were the major class.  
 RNA-Seq analysis also revealed the specific classes of IRGs induced by CHIKV 
infection, with major up-regulation of granzymes A, B and K and the p47 and p65 
GTPases – two classes of genes that have not previously be assessed for their role in the 
host response to CHIKV infection.  Seven novel IRF3 isoforms and a set of novel RNAs 
were identified. The majority of these novel RNAs were assessed as likely to be non-
coding.  However one of these, CINT9, was determined to potentially encode a novel 
protein with a high degree of similarity to Ly6B. 
 
 Chapter 6:  Analysis of CHIKV RNA in host tissues.  The studies in this chapter 
represent the first deep sequencing analysis of CHIKV RNA in tissues.  RNA-Seq analysis 
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of CHIKV RNA was shown to reflect the known kinetics of CHIKV replication, in which 
virus replicates in the joints (i.e. the feet), and spreads to the draining lymph nodes, with 
viral titres peaking at day 2 and largely cleared by day 7.  More transcripts were produced 
from the structural region of the genome than the non-structural region.  Mutations in the 
CHIKV genomes accumulated with time, and the accrual of mutations was higher in the 
lymph nodes than in the feet.  The observed difference in mutation accrual may have 
implications chronic disease, whereby less mutated viral RNA is able to persist long term 
in the feet, while heavily mutated viral RNA in the lymph nodes accumulates too many 
mutations, and is thus unable to persist. 
 
7.2 Discussion and future directions 
 
 Type I IFN deficiency and DHS/DSS.  Mice deficient in type I IFN responses 
(IRF3/7-/- and IFNAR-/- mice, Chapter 2) developed fatal hypovolemic shock, characterised 
by severe oedema, oliguria, hypothermia and increased haematocrit, as well as 
haemorrhagic manifestations; all criteria defined by WHO for hypovolemic shock (W.H.O 
2009).  This pathology closely resembled the characteristic symptoms of DHF/DSS in 
humans (Rajapakse 2011, Huy, Van Giang et al. 2013), implicating defective type I IFN 
responses in the development DHF/DSS and severe CHIKV disease.  Infants, known to 
have immature IRF7 responses (Levy 2007, Danis, George et al. 2008), are more prone to 
development of DHF/DSS (Guzmán, Kouri et al. 2002), and a study of children and young 
adults, found IRF7 transcriptional activity was associated with protection against 
development of DHS/DSS (Hoang, Lynn et al. 2010).  Furthermore, DHS/DSS patients 
have been found to have reduced type I IFN transcript levels (Simmons, Popper et al. 
2007).  The findings in this thesis provide impetus for investigation of the type I IFNs as a 
potential indicator for risk of developing DHS/DSS, and as therapeutic agent for DHS/DSS, 
which affects up 500,000 people annually and results in up to 22,000 deaths, mainly 
children, each year (W.H.O 2015). 
 
 Regulation of IFNγ by type I IFNs.  Mortality in type I IFN deficient mice was 
associated with excessive IFNγ production, as well as IL-6, MCP-1 and TNF (Chapter 2).  
IFNγ induces production by macrophages of the 3 latter cytokines (Loppnow, Werdan et 
al. 2008), which promote vasodilation and inflammation, and were likely the drivers of 
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vascular leakage leading to hypovolemic shock in the type I IFN deficient mice (Lee, Liu et 
al. 2006, Pang, Cardosa et al. 2007).  Many of the top 50 up-regulated genes at day 7 in 
the feet (peak arthritis) were IFNγ-regulated (Chapter 5, Table 5.2), …and furthermore, 
CHIKV infection of IFNγ-/- mice in our hands does not result in more severe arthritis 
(Nakaya, Gardner et al. 2012; N. Prow, personal communication).  However, it is important 
to note that Lum, Teo et al. (2013) found foot swelling was increased in IFNγ-/- mice 
infected with the Asian SGP11 CHIKV strain, perhaps indicating a difference in the role of 
IFNγ in CHIKV pathobiology between different viral strains.  Type I IFNs can inhibit IFNγ 
responses during infection in other settings (Nguyen, Cousens et al. 2000, Chessler, 
Caradonna et al. 2011), and type I IFNs are also known to down regulate the IFNγ 
receptor (Rayamajhi, Humann et al. 2010).  These findings suggest anti-IFNγ agents may 
have utility in the treatment of both DHF/DSS and CHIKV arthritis.  Anti-IFNγ antibody was 
recently shown by our collaborators to ameliorate disease in a mouse model of the related 
alphavirus, Ross River virus (Mahalingam, 2015, unpublished data, see below).  
 
 
 Identification of the cells producing type I IFNs.  Attempts to identify the cellular 
source of type I IFNs using eGFP reporter mice proved to be unsuccessful (Chapter 3).  
The lack of eGFP produced by these mice was likely the result of low type I IFN promoter 
activity.  This was later illustrated in Chapter 5, with the finding that only very low levels of 
type I IFN transcripts were produced in response to CHIKV infection, even at the time of 
peak serum type I IFN (day 2) in WT mice.  In heterozygous IFNα6-GFP+/- and IFNβ-
GFP+/- mice, the number of eGFP transcripts would likely be even lower.  Despite this, 
these mice were successfully used for detection of IFNα6 production in response to NDV 
using unfixed tissue histology and flow cytometry (Kumagai, Takeuchi et al. 2007).  The 
IFNβ-GFP+/- mice have never been reported in a publication (Y.A. Kumagai, personal 
communication).  Identification of the cell types producing type I IFN in response to CHIKV 
using these mice might be achieved by FACS-based isolation of specific cell types from 
the individual organs followed by RT-PCR and/or RNA-Seq analysis of type I IFN mRNA 
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levels.  However, CHIKV is a PC3 pathogen, and this approach would require access to 
PC3 flow cytometry facilities, of which only two have recently come into existence in 
Australia. 
 
 Continued IRG production.  RNA-Seq analysis of gene expression showed that all 
type I IFN subtypes had returned to mock infected levels at day 7 in both the feet and 
lymph nodes (Chapter 5, Figure 5.3).  However, analysis of DEGs using the Interferome 
database, showed almost a quarter of all differentially up-regulated genes in the feet at 
day 7 post infection are regarded as being regulated by type I IFNs, but not IFNγ or type III 
IFNs.  This suggested a type I IFN-independent mechanism of type I IRG induction. 
Alternatively, the idea that these genes are exclusively regulated by type I interferon 
should be reconsidered. 
 The continued up-regulation of pro-inflammatory IRGs has potential to play a role in 
the chronic inflammatory arthritis caused by CHIKV.  To gain insights into the 
mechanism/s driving gene induction, promoter reporter constructs could be used to test 
the responsiveness of the promoter of these up-regulated IRGs to IFNγ. In addition, 
bioinformatics analysis could be undertaken to identify a common transcription factor 
binding site/s in the promoters of these genes.  Gene silencing and/or knock out mouse 
models of candidate transcription factors could be used to block potential type I-
independent mechanisms of IRG production.  RT-PCR assessment of target IRGs 
downstream of the blocked pathways could be used to confirm the type I IFN-independent 
mechanism of IRG-induction following CHIKV infection.  RNA-Seq analysis during the 
chronic phase of the disease (i.e. day 30 post infection) would be very useful to assess 
which IRGs are persistently up-regulated and potentially involved in maintaining chronic 
disease.  In particular, Li, Ding et al. (2013) have identified an IFNβ-induced protein that 
appears to attenuate the type I IFN response in an IRF3/7 dependant mechanism.  
Silencing of this gene, activating signal co-integrator complex 3 (Acc3), in HeLa cells 
resulted in a 20-fold reduction in CHIKV titres due to reduced ISG expression.  In light of 
the role of IRF3/7 in CHIKV pathobiology and the continued ISG production observed in 
these studies, as well as the persistent nature of CHIKV-induced arthritis/arthralgia, future 
studies of Ascc3 in CHIKV are warranted. 
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 Increasing CHIKV mutation rates as a potential therapy.  Site mutations, identified 
by RNA-Seq, in virus isolated from the tissues accumulated over time and the number of 
mutations was significantly higher in the lymph nodes than in feet (Chapter 6, Figure 6.4).  
Analysis of viral titres in Chapter 2 showed that no cytopathic virus could be detected in 
lymph nodes at day 7 post infection.  In contrast, viral titres in the feet at day 7 were still 
about 5 log10CCID50/ml.  Poo, Rudd et al. (2014) also reported recovery of infectious virus 
from WT mice feet up to day 14 post infection, with viral RNA persisting up to day 100.  
Together, these findings suggested that CHIKV in the feet may persist due to a lower rate 
of mutation accrual compared to virus in the lymph nodes.  Ribavirin is a nucleoside 
inhibitor that induces mutations into RNA during RNA virus replication, and can induce 
lethal mutagenesis, or virus extinction via error catastrophe (Crotty, Cameron et al. 2001, 
Ortega-Prieto, Sheldon et al. 2013).  Persistent viral RNA is thought to contribute to the 
chronic nature of CHIKV disease (Labadie, Larcher et al. 2010, Suhrbier, Jaffar-Bandjee et 
al. 2012), therefore Ribavirin might be suggested as an agent for treatment of chronic 
CHIKV. 
 
 The CHIKV genome.  While RNA-Seq of CHIKV RNA isolated from the tissues was 
useful for identification of single nucleotide mutations, there are some limitations to this 
method of viral genome analysis.  Alphaviruses are prone to production of defective 
interfering (DI) RNA, which contain a range of deletions within the genome (Bangham and 
Kirkwood 1990, White, Thomson et al. 1998, Thompson, Rempala et al. 2009).  RNA 
isolated from tissues for RNA-Seq is fragmented prior to library preparation and cDNA 
synthesis.  Although the mean length of fragments is around 200 bp, a large range of 
fragment lengths is produced.  This makes it difficult to determine whether 100 bp paired-
reads mapping to distant parts of the genome derive from (i) a large cDNA library 
fragment, or (ii) a short cDNA library fragment from a DI RNA genome in which a large 
portion of the genome has been deleted. 
 To investigate deletions in individual CHIKV genomes, and the length of CHIKV 
genomes produced during replication in the tissues, CHIKV RNA genomes could be 
isolated using oligo pull-down technologies, cloned and then sequenced.  A key question 
for the future will be to understand why infectious virus cannot be isolated post day 14, 
despite the continued presence of CHIKV RNA up to day 100 post infection (Poo, Rudd et 
al. 2014). 
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 Novel IRF3 isoforms and CINT9.  RNA-Seq analysis identified several novel RNA 
transcripts up-regulated in response to CHIKV infection, including seven IRF3 isoforms 
and a potential protein-coding gene related to the Ly6 antigens.  Chapter 2 highlighted the 
important role of IRF3 in CHIKV infection, with IRF3-/- mice developing more severe 
disease, and IRF3/7-/- mice succumbing to the virus.  Both human (Li, Ma et al. 2011) and 
mouse IRF3 (Zhai, Gao et al. 2008) genes encode ubiquitously expressed splicing variants 
that inhibit virus-induced, IRF3-mediated type I IFN production.  Five of the seven novel 
variants observed here were also predicted to have an inhibitory effect on IRF3 signalling, 
due to partial deletion of the IRF3 activation domain.  The inhibitory activity of these novel 
IRF-3 isoforms could be tested by cloning them and recombinantly expressing them in 
cells, both in isolation and together with full-length IRF3 in different ratios. The transduced 
cells could then be treated with type I interferon or infected with CHIKV and the induction 
of key IRGs analysed by RT-PCR. 
 CINT9 had significant homology with the Ly6 antigens, in particular Ly6B, which 
was upregulated ≈18 fold in the lymph nodes at day 7 and is expressed on nascent 
inflammatory macrophages (Rosas, Thomas et al. 2010).  CINT9 was located upstream of 
Ly6C2, which was heavily up-regulated at day 7 in the feet and lymph nodes.  
Inflammatory monocyte/macrophages that express high levels of Ly6C, also express high 
levels of CCR2 (Geissmann, Manz et al. 2010), which targets these cells to sites of 
inflammation (Leuschner, Dutta et al. 2011).   
 To validate the existence of full-length CINT9, RT-PCR would need to be 
performed.  The product could be then be cloned, transfected into cells to look for 
biological activity, as for the IRF3 isoforms above.  Recombinant protein could also be 
expressed by bacterial expression systems and used for the production of antibodies.  
Evidence of CINT9 protein production could then be sought by western blotting of CHIKV 
infected tissues. 
 
 Granzymes A, B & K in CHIKV infection.  RNA-Seq analysis in Chapter 5 showed 
considerable induction of granzymes A and B in the feet, and B and K in the lymph nodes 
at day 7 post infection.  Granzymes are typically associated with induction of apoptosis in 
infected cells, and are secreted by CD8+ T-cells and NK cells (Domselaar and 
Bovenschen 2011).  These cell types have not previously been shown to play a major role 
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in alphaviral infection (La Linn, Mateo et al. 1998, Smith-Norowitz, Sobel et al. 2000, 
Alsharifi, Lobigs et al. 2006, Poo, Rudd et al. 2014), thus major up-regulation of 
granzymes was unexpected.  However, CD8+ T-cells have recently been shown to be 
important for control of Ross River virus in mouse muscle (Burrack, Montgomery et al. 
2015), and in humans, strong CD8+ T-cell responses have been reported early in infection 
(Wauquier, Becquart et al. 2011).  Additionally, granzymes have recently been proposed to 
have extracellular, immuno-modulatory roles in inflammation, possibly by induction and 
cleavage of secreted cytokines (Wensink, Hack et al. 2015). 
 Further investigation of granzymes A, B and K in CHIKV infection would first involve 
confirmation of protein up-regulation in serum and/or tissue extracts by ELISA or western 
blot.  Analysis of protein levels in CHIKV-infected human serum samples would also be 
useful to establish the relevance of mouse studies to human disease.  Mice deficient in 
granzymes A, B and K are available, and preliminary data indicate a role for these genes 
in the development of CHIKV-induced arthritic disease. 
 
The p47 and p65 GTPases in CHIKV  p47 and p65 GTPases associate with 
pathogen-containing vacuoles during infection (Shenoy, Kim et al. 2008).  The p47 
GTPases promote autophagy (Shenoy, Kim et al. 2008, Haldar, Saka et al. 2013), which 
CHIKV is thought to exploit to delay apoptosis and facilitate replication (Joubert, Werneke 
et al. 2012).  The p47 GTPases also promote acidification of lysosomes (Tiwari and 
MacMicking 2008), which is required for release of alphavirus genomes from the 
nucleocapsid (Jose, Snyder et al. 2009, Leung, Ng et al. 2011).  Thus p47 GTPases may 
facilitate viral un-coating and replication.  The function of the GBPs is less well understood 
(Shenoy, Kim et al. 2008), but these proteins are also recruited to PVs, possibly via p47 
GTPases (Haldar, Saka et al. 2013), and facilitate delivery of microbicidal peptides (Kim, 
Shenoy et al. 2011). 
While up-regulation of the p65 and p47 GTPases in response to CHIKV has been 
reported in previous microarray studies (Ryman, White et al. 2002, Xu, Evensen et al. 
2015), their function in alphaviral infection has not been investigated.  However, several 
studies have implicated a role for GBPs in viral inhibition in both mice (Carter, Gorbacheva 
et al. 2005) and humans (Anderson, Carton et al. 1999).  In contrast, mice deficient p47 
GTPases genes do not alter in their resistance to MCMV (Collazo, Yap et al. 2001) and 
Ebola viruses (Taylor, Collazo et al. 2000).  However, these studies have only looked at 
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single gene knock outs.  Given several genes in these classes were expressed together it 
may be possible that they do not exert activity in isolation.  To asses the potential role of 
these proteins in CHIKV, their presence at the protein level would first need to be 
confirmed, either by ELISA or western blot.  To assess the function of these GTPases in 
CHIKV infection, mice deficient in relevant proteins could then be examined, with double or 
triple gene knockouts likely required to produce significant phenotypes. 
 
7.3 Concluding remarks 
 The findings presented in this thesis have further elucidated role of the type I IFNs 
in the immunobiology of CHIKV.  The findings have defined the contribution of key 
components of type I IFN signalling pathways for induction of the type I IFN response to 
CHIKV.  It was illustrated that type I IFNs protect against lethal haemorrhagic shock; this 
has implications for our understanding of DHF/DSS.  This was the first deep sequencing 
analysis of the host response to CHIKV infection.  Several genes and gene classes not 
previously associated with CHIKV were identified.  These findings have also provided 
insights into CHIKV genome changes within the host tissues, namely reduced mutational 
rates in the joint tissues, which may contribute to persistence of viral RNA and arthritic 
symptoms.  Thus, this thesis advances our understanding of the inflammatory processes 
induced by CHIKV.  
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Figure S1.  IRF3 amino acid sequence alignment.  Amino acid sequences of the 
human, mouse and novel IRF3 isoforms were aligned using MEGA v6.0 software.    
Conservation threshold was 60%.  Sequence alignments were rendered using consensus–
colouring of multiple alignments (CHROMA).  Red arrows indicate the DNA-binding 
domain (D), the nuclear export signal (NES) and the activation domain (AD). 
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Table S1.  Protein coding features in up-regulated, unannotated genes from top 50 DEG lists.
Foot D7 v Log2 (fold 
change)
Transcript 
length (bp)
Longest 
ORF (aa)
uORFs uAUGs
Top BLASTx 
accession
e value BLASTx description Similarity (%) Other observations
CINT1 v1 Inf 694 78 1 3 XP_001924410.2 5.00E-10
PREDICTED: hypothetical protein 
LOC100156886 [Sus scrofa]
76 ID; 25 Cov 
CINT2 v1 5.84 502 33 0 13 ERE78392.1 1.40E+00
L-lactate dehydrogenase A chain 
[Cricetulus griseus]
64 ID; 4 cov
v2 776 22 5 12 nothing
v3 762 33 1 6 nothing
v4 1006 22 2 8 nothing
v5 1938 107 2 7 nothing
v6 2104 107 5 19 nothing
v7 388 22 1 3 nothing
v8 1389 33 2 8 nothing
v9 1276 46 2 7 nothing
CINT3 v1 Inf 572 53 0 7 EDL16837.1 2.00E-15 mCG147594 [Mus musculus] 100 ID; 19 cov
CINT4 v1 Inf 389 56 0 3
WP_017731516.
1
3.80E+00
hypothetical protein [Nafulsella 
turpanensis]
32 ID; 50 cov
contains stop codons, BLAST hit 
in wrong frame 
Foot D2
CINT5 v1 Inf 586 42 1 2 nothing
CINT6 v1 Inf 319 60 0 0 nothing no 5'UTR
CINT7 v1 8.01 79 2 7 EDL79940.1 9.00E-09 rCG26676 [Rattus norvegicus] 54 ID; 3 cov
CINT8 v1 Inf 2053 89 1 2 XP_003515706.1 5.00E-27
PREDICTED: Hhex-like protein [Cricetulus 
griseus]
87 ID; 10 cov contains 2 stop codons
LND2
CINT9 v1 7.71 737 165 0 0 XP_914999.1 3.00E-46
PREDICTED: uncharacterized protein 
LOC546643 [Mus musculus] 
84 ID, 47 cov  contains LU domain
v2 750 165 0 0 XP_914999.1 5.00E-46
PREDICTED: lymphocyte antigen 6I-like 
[Mus musculus] 
84 ID; 36 cov
CINT10 v1 5.57 4435 108 15 42 EDL87013.1 1.60E+00 rCG63130 [Rattus norvegicus] 42 ID; 5 cov BLAST hit in wrong frame 
v2 2283 138 6 15 XP_673000.1 4.00E-28
hypothetical protein [Plasmodium berghei 
strain ANKA] 
78 ID; 9 cov BLAST hit in wrong frame 
CINT11 v1 4.59 4147 125 3 14 XP_485980.5 1.00E-138
PREDICTED: tripartite motif-containing 
protein 30A [Mus musculus]
100 ID; 15 cov
Contains SPRY superfamily 
domain
v2 2232 224 0 0 XP_485980.5 0.00E+00
PREDICTED: tripartite motif-containing 
protein 30A [Mus musculus]
100 ID; 34 cov
Contains SPRY superfamily 
domain
CINT22 v1 3.74 1867 32 5 9 EDL28658.1 6.00E-40
mCG140494, isoform CRA_a [Mus 
musculus]
100 ID, 13 cov
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Table S1.  Protein coding features in up-regulated, unannotated genes from top 50 DEG lists (cont.) 
LND7 v Log2 (fold 
change)
Transcript 
length (bp)
Longest 
ORF (aa)
uORFs uAUGs
Top BLASTx 
accession
e value BLASTx description Similarity (%) Other observations
CINT12 v1 Inf 336 36 0 0 WP_022020858.
1
5.90E+00 ftsK/SpoIIIE family protein [Bacteroides sp. 
CAG 661] 
29 ID, 88 cov contains stop codons
CINT13 v1 4.40 2163 132 0 0 AAI51696.1 2.00E-139 RPLP0 protein [Bos taurus]   78 ID; 37 cov  BLAST hit in wrong frame
CINT14 v1 4.17 804 134 0 0 XP_914999.1 6.00E-81 PREDICTED: uncharacterized protein 
LOC546643 [Mus musculus]
100 ID, 100 
cov
Contains LU superfamily 
domain
CINT15 v1 1543 93 0 3 EDL05858.1 6.00E-51 mCG144566 [Mus musculus] 64 ID; 35 cov Contains HMG box domain, 
v2 969 93 0 2
v3 2834 69 12 29 EDL08408.1 3.00E-14 mCG147230 [Mus musculus] 80 ID; 4 cov BLAST hit in wrong frame 
v4 1647 85 6 11 AAH31435.1 5.00E-14 Chpt1 protein [Mus musculus] 86 ID; 7 cov BLAST hit in wrong frame 
v5 742 85 0 2 EGW01477.1 4.30E+00
E3 ubiquitin-protein ligase NEDD4 
[Cricetulus griseus]
55 ID; 16 cov
BLAST hit in wrong frame, 
contains stop codons
CINT16 v1 4.01 5751 145 8 28 ERE74287.1 2.00E-07 caltractin-like protein [Cricetulus griseus] 76 ID; 2 cov
BLAST hit in wrong frame, 
contains stop codons, no 5'UTR
CINT17 v1 3.62 3975 105 7 29 nothing
v2 642 35 0 0 nothing
CINT18 v1 3.56 2676 81 0 3 ERE74288.1 5.00E-09 E3 ubiquitin-protein ligase [Cricetulus 63 ID; 3 cov BLAST hit in wrong frame 
v2 867 89 0 3 ERE74288.1 2.00E-09
E3 ubiquitin-protein ligase [Cricetulus 
griseus]
63id, 6 cov BLAST hit in wrong frame 
v3 5501 104 4 18 EDL09413.1 3.00E-26 mCG147326 [Mus musculus] 82 ID; 4 cov BLAST hit in wrong frame 
CINT19 v1 3.35 4776 107 5 12 NP_001041357.1 3.00E-17 uncharacterized protein LOC317165 
[Rattus norvegicus] 
52 ID; 5 cov
CINT20 v1 3.33 2226 168 3 14 EDK97113.1 0.00E+00 mCG145673, isoform CRA_a [Mus 
musculus]
100 ID; 13 cov BLAST hit in wrong frame 
v2 1274 80 2 NP_001257345.1 1.00E-55
>gb|AFJ59921.1| stem loop binding 
protein 2 [Rattus norvegicus]
57 ID;  44 cov
BLAST hit in wrong frame, no 5' 
UTR
CINT21 v1 2.92 887 110 1 1 nothing
V: 
variant/isoforms; LN: lymph node; uORF: upstream open reading frame; uAUG: upstream start codon; CINT: CHIKV-induced novel transcript.
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Figure S3. CINT9 isoform mRNA and protein sequences.  A)  The full mRNA 
sequences of the two CINT9 variants are shown.  The open reading frame is indicated by 
bold, uppercase font.  The presence of the Kozak sequence is indicated by underlined 
text.  B)  The translated amino acid sequence encoded by the two CINT9 mRNA isoforms.  
mRNA sequences were translate using ExPASY Translate Tool. 
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FigureS2. Alignment of full Ly6 antigen amino acid sequences and the full predicted 
protein sequence of CINT9.  The conserved LU domain is indicated (red arrows).  
Alignment constructed using MEGA v6.0 software.  Conservation threshold was 60%. 
Sequence alignments were rendered using consensus–colouring of multiple alignments 
(CHROMA). 
